UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2009
For year ended December 31, 20082009
Commission file number001-16407
ZIMMER HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | | 13-4151777 |
| (State of Incorporation) | | (IRS Employer Identification No.) |
| 345 East Main Street Warsaw, Indiana | | 46580 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(574) 267-6131
Securities registered pursuant to Section 12(b) of the Act:
| | | |
| Title of each class | | Name of each exchange on which registered |
| Common Stock, $.01 par value | | New York Stock Exchange |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 ofRegulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of thisForm 10-K or any amendment to thisForm 10-K. oþ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” inRule 12b-2 of the Exchange Act. (Check one):
| | | | | | | |
Large accelerated filer þ | | Accelerated filer o | | Non-accelerated filer o | | Smaller reporting company o |
| | | | | (Do not check if a smaller reporting company) | | |
Indicate by checkmarkcheck mark whether the registrant is a shell company (as defined Exchange ActRule 12b-2). Yes o No þ
The aggregate market value of shares held by non-affiliates was $15,309,609,246$9,120,369,894 (based on the closing price of these shares on the New York Stock Exchange on June 30, 2008,2009 and assuming solely for the purpose of this calculation that all directors and executive officers of the registrant are “affiliates”). As of February 13, 2009, 222,839,49012, 2010, 202,790,978 shares of the registrant’s $.01 par value common stock were outstanding.
Documents Incorporated by Reference
| | | | | |
Document
| | | Form 10-K
| |
Portions of the Proxy Statement with respect to the 20092010 Annual Meeting of Stockholders | | | Part III | |
| | | | | |
| |
| |
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
This annual report contains certain statements that are forward-looking statements within the meaning of federal securities laws. When used in this report, the words “may,” “will,” “should,” “anticipate,” “estimate,” “expect,” “plan,” “believe,” “predict,” “potential,” “project,” “target,” “forecast,” “intend” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include the important risks and uncertainties that may affect our future operations that we describe in Part I, Item 1A — Risk Factors of this report. We may update that discussion in Part II, Item 1A — Risk Factors in a Quarterly Report onForm 10-Q we file hereafter. Readers of this report are cautioned not to place undue reliance on these forward-looking statements. While we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this report.
2
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
OVERVIEW
We are a global leader in the design, development, manufacture and marketing of orthopaedic andreconstructive implants, dental reconstructive implants, spinal implants, trauma products and related surgical products. We also provide other healthcare related services. In this report, “Zimmer,” “we,” “us,” “our,”“our” and similar words refer collectively to Zimmer Holdings, Inc. and its subsidiaries. Zimmer Holdings refers to the parent company only.
There were several developments in 2008 that had a significant impact on our business.
We continued to meet our obligations under the Deferred Prosecution Agreement (“DPA”) and the Corporate Integrity Agreement (“CIA”) we signed in September 2007. During 2008, we devoted substantial resources to meet our obligations under those agreements and implemented enhancements to our corporate compliance program applicable in most respects to all of our businesses on a global basis.
In the first half of 2008, we initiated voluntary product recalls of certain Orthopaedic Surgical Products (“OSP”) manufactured at our Dover, Ohio facility that we determined did not meet internal quality standards. Additionally, we voluntarily and temporarily suspended production and sales of certain OSP products manufactured at the Dover facility. We expect to have a significant portion of these products back into production by the end of the first quarter of 2009, with most other products coming back into production in the second quarter of 2009.
In July 2008, we suspended marketing and distribution of theDurom®Acetabular Component (DuromCup) in the U.S. to permit us to update product labeling and implement a surgical training program in the U.S. We resumed marketing and distribution of theDuromCup in the U.S. in August 2008. We received claims from a number ofDuromCup patients seeking reimbursement for costs and payments for alleged pain and suffering and we recorded a provision for certain claims of $69.0 million in 2008, which represents management’s estimate of liability to patients undergoing revision surgeries related to theDuromCup. In addition, we expect that our entry into the U.S. hip resurfacing market may be hindered or delayed as theDuromCup has been integral to our plans for entry into that market.
In October 2008, we acquired Abbott Spine, previously a subsidiary of Abbott Laboratories, for approximately $360 million. This investment adds a number of innovative products and helps build toward critical mass in the Spine product category. The acquisition also enhances our research and development capabilities in the Spine product category and strengthens our sales coverage.
Zimmer Holdings was incorporated in Delaware in 2001. Our history dates to 1927, when Zimmer Manufacturing Company, a predecessor, was founded in Warsaw, I ndiana.Indiana. On August 6, 2001, Zimmer Holdings was spun off from its former parent and became an independent public company.
CUSTOMERS, SALES AND MARKETING
Our primary customers include musculoskeletalorthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers and, in their capacity as agents, healthcare purchasing organizations or buying groups. These customers range from large multinational enterprises to independent surgeons.
We have operations in more than 25 countries and market products in more than 100 countries, with corporate headquarters in Warsaw, Indiana, and more than 100 manufacturing, distribution and warehousingand/or office facilities worldwide. We manage our operations through three major geographic segments –— the Americas, which is comprised principally of the United States and includes other North, Central and South American markets; Europe, which is comprised principally of Europe and includes the Middle East and Africa; and Asia Pacific, which is comprised primarily of Japan and Australia and includes other Asian and Pacific markets.
We market and sell products through three principal channels: 1) direct to healthcare institutions, such as hospitals or direct channel accounts,accounts; 2) through stocking distributors and in the Asia Pacific region, healthcare dealers,dealers; and 3) directly to dental practices and dental laboratories. With direct channel accounts, inventory is generally consigned to sales agents or customers. With sales to stocking distributors, healthcare dealers, dental practices and dental laboratories, title to product passes generally upon shipment. Direct channel accounts represented approximately 80 percent of our net sales in 2008.2009. No individual direct channel account, stocking distributor, healthcare dealer, dental practice or dental laboratory accounted for more than 1 percent of our net sales for 2008.2009.
We stock inventory in our warehouse facilities and retain title to consigned inventory in sufficient quantities so that products are available when needed for surgical procedures. Safety stock levels are determined based on a number of factors, including demand, manufacturing lead times and quantities required to maintain service levels. We also carry trade accounts receivable balances based on credit terms that are generally consistent with local market practices.
We utilize a network of sales associates, sales managers and support personnel, most of whom are employed or contracted by independent distributors and sales agencies. We invest a significant amount of time and expense in training sales associates in how to use specific products and how to best inform surgeons of product features and uses. Sales force representatives must have strong technical selling skills and medical education to provide technical support for surgeons.
In response to the different healthcare systems throughout the world, our sales and marketing strategies and
3
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
organizational structures differ by region. We utilize a global approach to sales force training, marketing and medical education to provide consistent, high quality service. Additionally, we keep current with key surgical developments and other issues related to musculoskeletalorthopaedic surgeons, neurosurgeons, dentists and oral surgeons and the medical procedures they perform.
Americas. The Americas is our largest geographic segment, accounting for $2,353.9$2,372.4 million, or 5758 percent, of 20082009 net sales, with the United States accounting for 94 percent of net sales in this region. The United States sales force primarily consists of independent sales agents, most of whom sell products exclusively for Zimmer. Sales agents in the United States receive a commission on product sales and are responsible for many operating decisions and costs. Sales commissions are accrued at the time of sale.
In this region, we contract with group purchasing organizations and managed care accounts and have promoted unit growth by offering volume discounts to customer healthcare institutions within a specified group. Generally, we are designated as one of several preferred purchasing sources for specified products, although members are not obligated to purchase our products. Contracts with group purchasing organizations generally have a term of three years with extensions as warranted.
A majority of hospitals in the United States belong to at least one group purchasing organization. In 2008,2009, individual hospital orders purchased through contractual arrangements with our two largest group purchasing organizations accounted for approximately 3534 percent of our net sales in the United States. Contractual sales were highest through Novation, LLC and Premier Purchasing Partners, L.P. No individual end-user, however, accounted for over 1 percent of our net sales, and the top ten end-users accounted for approximately 4 percent of our aggregate net sales in the United States.
In the Americas, we monitor and rank independent sales agents across a range of performance metrics including the achievement of certain sales targets and maintenance of efficient levels of working capital.
3
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Europe. The European geographic segment accounted for $1,179.1$1,119.2 million, or 2927 percent, of 20082009 net sales, with France, Germany, Italy, Spain, Switzerland and the United Kingdom collectively accounting for over 75 percent of net sales in the region. This segment also includes other key markets, including Benelux, Nordic, Central and Eastern Europe, the Middle East and Africa. Our sales force in this region is comprised of direct sales associates, commissioned agents, independent distributors and sales support personnel. In Europe, we emphasize the advantages of our clinically proven, established designs and innovative solutions, such as minimally invasive surgical procedures and technologies and new and enhanced materials and surfaces.
Asia Pacific.The Asia Pacific geographic segment accounted for $588.1$603.8 million, or 1415 percent, of 20082009 net sales, with Japan being the largest market within this segment, accounting for approximately 5558 percent of the region’s sales. This segment also includes key markets such as Australia, New Zealand, Korea, China, Taiwan, India, Thailand, Singapore, Hong Kong and Malaysia. In Japan and most countries in the Asia Pacific region, we maintain a network of dealers, who act as order agents on behalf of hospitals in the region, and sales associates, who build and maintain relationships with musculoskeletalorthopaedic surgeons, neurosurgeons and dental surgeons in their markets. These sales associates cover over 7,000 hospitals in the region. The knowledge and skills of our sales associates play a critical role in providing service, product information and support to surgeons.
SEASONALITY
Our business is somewhat seasonal in nature, as many of our products are used in elective procedures, which typically decline during the summer months and holiday seasons.
DISTRIBUTION
We operate distribution facilities domestically in Warsaw, Indiana; Dover, Ohio; Statesville, North Carolina; Memphis, Tennessee; Carlsbad, California; and Austin, Texas and internationally, in Australia, Austria, Belgium, Canada, the Czech Republic, China, Finland, France, Germany, Hong Kong, India, Italy, Japan, Korea, Malaysia, the Netherlands, New Zealand, Portugal, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand and the United Kingdom. In 2009, we completed construction of our highly automated,state-of-the-art distribution facility in Eschbach, Germany. This new facility supports direct to customer, country and dealer shipments for the European region and global shipments for products sourced from certain European-based supply chain sites.
We generally ship our orders via expedited courier. Our operations support local language labeling requirements for the European Union member countries, as well as specific Asia Pacific countries. OurWe do not consider our backlog of firm orders is not consideredto be material to an understanding of our business.
PRODUCTS
Our products include orthopaedic andreconstructive implants, dental reconstructive implants, spinal implants, trauma products and related surgical products. Orthopaedic reconstructive implants restore joint function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Dental reconstructive implants restore function and aesthetics in patients who have lost teeth due to trauma or disease. Orthopaedic surgeons and neurosurgeons use spinal implants in the treatment of degenerative diseases, deformities and trauma. Trauma products are used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. Our related surgical products include supplies and instruments designed to aid in orthopaedic surgical procedures and post-operation rehabilitation.
We utilize our exclusiveTrabecular Metaltm Technology across various product categories.Trabecular Metalmaterial is a structural biomaterial whosewith a cellular architecture that resembles bone and approximates its physical and mechanical properties more closely than other prosthetic materials. The highly porous trabecular configuration is conducive to more normal bone formation and bone in-growth.Trabecular Metalimplants are fabricated using elemental tantalum metal and a patented vapor deposition technique that creates a metallic strut configuration resembling cancellous bone with nano-textured surface features.
4
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Orthopaedic Reconstructive Implants
Total knee replacement surgeries typically include a femoral component, a patella (knee cap), a tibial tray and an articular surface (placed on the tibial tray). Knee replacement surgeries include first-time, or primary, joint replacement procedures and revision procedures for the replacement, repair or enhancement of an implant or component from a previous procedure. Knee implants are designed to accommodate different levels of ligament stabilization of the joint. While some knee implant designs, called cruciate retaining (CR) designs, require the retention of the posterior cruciate ligament, other designs, called posterior stabilized (PS) and ultracongruent (UC) designs, provide joint stability without the posterior cruciate ligament. There are also procedures for partial reconstruction of the knee, which treat limited knee degeneration and involve the replacement of only one side, or compartment, of the knee with a unicompartmental knee prosthesis.
Our portfolio ofMinimally Invasive Solutionstm Procedures (“MIS”)(MIS) includes the MIS Mini-Incision Total Knee Procedure. The MIS Mini-Incision Total KneeProcedure utilizes specialized MIS Instruments which feature smaller, ergonomic and highly precise instruments which accommodate and facilitate a smaller incision and less disruption of the surrounding soft tissues.
We offer a wide range of products for specialized knee procedures, including the following:
NexGen® Complete Knee Solution. The number one selling knee brand in the world, theNexGenKnee product line is a comprehensive system for knee replacement surgery which has had significant application across the continuum of care in all things related to primary and revision knee arthroplasty, including CR, PS CR and revision procedures. TheNexGenKnee System offers joint stability, sizing and sizingperformance options that can be tailored to individual patient needs while providing surgeons with a unified system of interchangeable components. TheNexGenKnee System provides surgeons with complete and versatile knee instrument options spanning multiple surgeon and treatment
4
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
philosophies, including soft tissue balancing and measured resection MIS Mini-Incision Instruments, milling and multiple traditional saw blade cutting instrument systems. The breadth and versatility of theNexGenKnee System allows surgeons to changetransition from one type of implant to another during surgery, according to the respective needs of the patient, and to support current surgical philosophies.
TheNexGenCR product line is designed to be used in conjunction with a functioning posterior cruciate ligament. Similar to the posterior stabilized design, theNexGenCR-Flex Fixed Bearing Knee is designed to provide a greater range of motion for patients who require deep bending in their activities of daily living. TheNexGenCR-Flex Femoral Components offer a tissue balancing (flexion balancing) solution which allows the surgeon to adjust component sizing and balance and stabilize the implant without removing additional bone or wasting critical procedure time.
TheNexGenComplete Knee SolutionLegacy®Knee-Posterior Stabilized product line provides stability in the absence of the posterior cruciate ligament. The PS capabilities werecan be augmented throughvia the introductionuse of theaNexGen LegacyPosterior Stabilized Flex Knee (the “LPS-Flex Knee”)(LPS-Flex Knee), a high-flexion implant that has the potential to accommodate knee flexion up to a155-degree155-degrees range of motion in some patients. In late 2007,for patients whose lifestyle and body type demand and can accommodate this performance standard. With the Premarket Approval (PMA) application for2008 rollout of theNexGenLPS-Flex Mobile Knee was approved by the FDA. With the staged rollout of this product in the U.S., we are now one of only two companies that can offer a mobile-bearing total knee treatment option in the U.S.
TheNexGenCR product line is designed to market for surgeons and patients that may be used in conjunction with a functioning posterior cruciate ligament. TheNexGenCR-Flex Fixed Bearing Knee is designed with components to provide a greater range of motionbest suited for patients who require deep bending in their daily activities. TheNexGenCR-Flex Femoral Components allow the surgeon to adjust component sizing without removing additional bone.
TheNexGenRevision Knee product line consists of several different products that are designed to provide clinical solutions to surgeons for various revision situations, including a bone augmentationthis high performance implant system made from ourTrabecular Metal Technology material. These augments are designed to address significant bone loss in revision surgery.design.
NexGenKneeGender Solutionstm femorals represent the first knee implants specifically shaped to offer fit and function optimized for anatomic features that arethe unique anatomical considerations more commonly seen in female patients. Gender implants are an important strategic focus, as more than half of total knee arthroplasty patients are female.Gender Solutionsfemorals are available in bothNexGenCR-Flex and LPS-Flex configurations. The concept of advancing implant design through customization based on anatomy or other patient characteristics has manifested in rapidly expanding gender technologies across the continuum of our products and into other important brands in our growing portfolio.
TheNexGenRevision Knee product line consists of several different products that are designed to provide clinical solutions to surgeons for various revision situations, including multiple constraint levels for ligament and soft tissue inefficiencies and a bone augmentation implant system made from ourTrabecular MetalTechnology material. These augments are designed to address significant bone loss in revision surgery while allowing natural bone to reconstruct within the implant construct.
We offer improved polyethylene performance in theNexGenKnee System with our conventional polyethylene andProlong®Highly Crosslinked Polyethylene, which offers reduced wear and resistance to oxidation, pitting and cracking.ProlongHighly Crosslinked Polyethylene is available in designs compatible with bothNexGenCR-Flex andLPS-Flex femoral components.
TheNatural-Knee®II System. TheNatural-KneeII System consists of a range of interchangeable, anatomically designed implants which include a proprietaryCancellous-Structured Titaniumtm (CSTitm) Porous Coating option for stable fixation in active patients andDurasul® Highly Crosslinked Polyethylene.patients.
Gender Solutions Natural-KneeFlex System. TheGender Solutions Natural-KneeFlex System was fully released in 2008 and adds our unique High Flex andGender Solutionsdesign concepts to theNatural-KneeSystem. TheGender Solutions Natural-KneeFlex System recognizes that two distinct populations exist in total knee arthroplasty (female and male) and offers two distinct implant shapes for enhanced fit. The system is compatible with muscle sparing MIS procedures and accommodates high flexion capacity up to 155 degrees. The system features the proven clinical success of our asymmetric tibial plate,CSTi porous coating,ProlongHighly Crosslinked Polyethylene and the ultracongruent articular surface.
TheInnex®Total Knee System. TheInnexKnee System offers fixed bearing and mobile bearing knee components all designed within the same system philosophy. While theInnexKnee System is best known for its mobile bearing knee offering, the availability of differing levels of articular constraint, and theInnexRevision Knee andInnex Gender Solutionscomponents provide formake this offering a comprehensive mobile and fixed bearing knee system.Gender Solutionsdesign features were added to this comprehensive knee system in late 2008. TheInnexKnee
5
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
System is distributed in Europe and Asia Pacific and is not currently available for commercial distribution in the United States.
ZimmerUnicompartmental Knee Systems. TheZimmer®Unicompartmental Knee System offers a high flexion design for unicompartmental knee surgery. TheThis high flexionflex product was designed specifically for MIS Procedures and Technologies. The system offers the surgeon the ability to conserve bone by replacing only the compartment of the knee that has had degenerative changes. TheAGender SolutionsPatello-Femoral Joint System was fully commercialized in 2008 andis also available which incorporates key gender specific design features and a proprietary guided milling surgical technique for use in patello-femoral joint replacement.
ZimmerPatient Specific Instruments. In late 2009, a 510(k) Application for theZimmerPatient Specific Instruments was approved by the U.S. Food and Drug Administration (FDA). TheZimmerPatient Specific Instruments simplify a total knee procedure and help enhance appropriate placement of the final implant based on a surgeon’s preoperative surgical plan. Based on a patient’s MRI scan, a computer generated, custom guide is produced to conform to a patient’s unique knee anatomy. This guide is then utilized intraoperatively to aid in the surgical correction of the patient’s knee.
5
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Zimmer Segmental System. Adding to our broad portfolio of revision options, theZimmerSegmental System is a comprehensive system designed to address patients with severe bone loss associated with disease, trauma or revision. This important addition realizes our strategic goal of expanding our product solutions across the continuum of care and, with the incorporation ofTrabecular MetalTechnology, expands the possibilities for treatment, short and long term fixation and stability.
Total hip replacement surgeries replace both the head of the femur and the socket portion of the pelvis (acetabulum) of the natural hip. Hip procedures include first time, or primary, joint replacement as well as revision procedures. Approximately 30 percent of hip implant procedures involve the use of bone cement to attach or affix the prosthetic components to the surrounding bone. The remaining are press-fit into bone, which means that they have a surface that bone affixes to through either ongrowth or ingrowth technologies.
Our portfolio of MIS Techniques includes theZimmerMIS Anterior Supine Technique, the MIS Posterior Procedure, theZimmerMIS Anterolateral Technique and MIS2-Incisiontm Hip Replacement Procedure. The MIS Techniques are designed to be less invasive to soft tissues and to shorten recovery time.
Our key hip replacement products include:
ZimmerM/L Taper Hip Prosthesis withKinectiv®Technology. TheZimmerM/L Taper Hip Prosthesis offers a proximally porous-coated wedge-shaped design based on long term clinically proven concepts. The M/L Taper has become widely used in MIS Procedures due to several key design features. TheZimmerM/L Taper Hip Prosthesis withKinectivTechnology is a system of modular stem and neck components designed to help the surgeon restore the natural hip joint center intraoperatively by addressing the key variables of leg length, offset and version independently. The M/L Taper hip product family is our fastest growing hip stem family.
Alloclassic®(Zweymüller®)Hip System. TheAlloclassic (Zweymüller)Hip System has become one of the most used, primary, cementless hip systems in the world. This is one of the few stems available today that is practically unchanged since its introduction in 1979. A new offset design was added in 2004 and offers the surgeon increased capability to restore the patient’s anatomical joint movement.
CLS®Spotorno®Hip System. TheCLS SpotornoStem is one of our largest selling hip prostheses, especially in the European markets. Additions to the product line provide the capability for restoration of the physiological center of rotation. TheCLS SpotornoStem has excellent clinical results, confirmed by the 2006 Swedish Hip Registry.
Fitmore® Hip Stem. TheFitmoreHip Stem was released in 2008 and offers the surgeon a short, bone preserving stem. Maintaining bone stock is particularly important for patients who may undergo a later revision procedure. Its unique shape facilitates MIS procedures, especially the MIS Anterior Supine approach which is gaining in popularity.
VerSys® Hip System. TheVerSysHip System is supported by a common instrumentation set and is an integrated family of hip products with design-specific options to meet varying surgical philosophies and patient needs. A unique offering within theVerSysHip System, theVerSys Epoch® Fullcoat Hip System is the first reduced-stiffness stem specifically designed to address varying patient femoral anatomies and minimize implant-related complications such as thigh pain, bone resorption and leg lengthening. In 2008, we introduced a line extension to this family to enhance the stem fit in osteoporotic patients.
Trabecular MetalContinuumPrimary Hip Prosthesis.tm Acetabular System,Trilogy®IT Acetabular System andAllofit®ITAlloclassic®Acetabular System. These systems were released in 2009 and each acetabular system offers the surgeon a choice of advanced bearing options to meet the clinical and lifestyle needs of each patient. Bearing options includeLongevity®Highly Crosslinked Polyethylene,Metasul®Metal-on-Metal Technology and aBIOLOX®1 deltaceramic-on-ceramic (where Zimmer has regulatory clearances). The acetabular systems also provide surgeons a choice of fixation method that accommodates their surgical philosophy.
Zimmer MMCtm Cup. TheTrabecular MetalZimmer MMCPrimary Hip Prosthesis productCup is an acetabular implant featuringMetasulMetal-on-Metal Technology and a hemispherical design that offers familiar handling for surgeons. This system was our first utilizationreleased in 2009. It is used withMetasulLarge Diameter Heads, which are designed to provide increased range ofTrabecular Metaltechnology on a hip prosthesis. The prosthesis utilizes motion and reduced probability of dislocation, making this implant an innovative proximal design to aggressively lock the prosthesis in the bone and provideoption for an optimized environment for biological ingrowth to occur into the highly porousTrabecular Metalmaterial.active patients.
Trilogy® Acetabular System. TheTrilogyAcetabular System, includingwith its titanium alloy shells, polyethylene liners, screwsshell, fiber metal mesh ingrowth surface and instruments, is our primary acetabular cup system. TheTrilogyfamily of products offers versatile component designs and instrumentation. One option, theLongevity®Highly Crosslinked Polyethylene Liner,Liners, is designed to address the issue of wear and reduce the generation of debris in total hip arthroplasty. Polyethylene debris may cause the degeneration of bone surrounding reconstructive implants, a painful condition called osteolysis.our most widely sold acetabular cup system.
We offer theTrabecular MetalModular Primary Acetabular System, which incorporates design features from theTrilogyfamily of acetabular shells augmented with the advanced fixation surface ofTrabecular Metalmaterial. In addition to theTrabecular MetalAcetabular System, we also offer aTrabecular MetalAcetabular Revision System that provides the surgeon with a variety ofoff-the-shelf options to address a wide range of bone deficiencies encountered during acetabular revisions and to achieve a stable construct – without the need for custom implants or bone graft, which carries with it the potential for resorption and disease transmission.construct.
Alternative Bearing Technology. We have a broad portfolio1 Registered trademark of alternative bearing technologies which includeLongevityandDurasulHighly Crosslinked Polyethylenes,Metasul®Metal-on-Metal Tribological Solution,Cerasul®Ceramic-on-Ceramic Tribological Solutions and theTrilogy AB®Acetabular System. Alternative bearings are designed toCeramTec AG
6
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
minimize wear over time, with the goal of increasing the longevity of the implant.
Our extremity portfolio, primarily shoulder and elbow products, areis designed to treat arthritic conditions, soft tissue injuries and fractures, as well as to enhance the outcome of primary or revision surgery.
Our key products include:
Bigliani/Flatow® Complete Shoulder Solution Family. TheBigliani/Flatowproduct line combined with theTrabecular MetalHumeral Stem gives us a significant presence in the global shoulder implant market.
Trabecular MetalGlenoid. TheTrabecular MetalGlenoid offers surgeons a glenoid component designed to improve fixation.Trabecular Metal’s material properties allow for more normal bone formation and maintenance.
Trabecular MetalReverse Shoulder System. TheTrabecular MetalReverse Shoulder System incorporates advanced materials and design to offer improved biological ingrowth potential through the utilization ofTrabecular Metal technology,Technology, while addressing significant loss of rotator cuff function. The reverse shoulder system is designed to restore function to patients who, because of debilitating rotator cuff tears, are not candidates for traditional shoulder surgery and have exhausted other means of repair.
Anatomical Shouldertm System. TheAnatomical ShoulderSystem can be adjusted to each patient’s individual anatomy. This portfolio of products was further expanded to include theAnatomical ShoulderInverse/Reverse System, designed to address significant loss of rotator cuff function, and theAnatomical ShoulderFracture System. Both the primary and fracture shoulder implants can be converted to a reverse shoulder without removal of the initial implant.
Coonrad/Morrey Total Elbow. The Coonrad/Morrey Total Elbow product line is a family of elbow replacement implant products to address patients with conditions of severe arthritis or trauma. It remains the largest elbow franchise in the world.
Our dental products division manufactures and distributesdistributes: (1) dental reconstructive implants –— for individuals who are totally without teeth or are missing one or more teeth; (2) dental restorative products –— aimed at providing a more natural restoration to mimic the original teeth; and (3) dental regenerative products — for soft tissue and bone rehabilitation.
| |
| | Dental Reconstructive Implants |
Our dental reconstructive implant products and surgical and restorative techniques include:
Tapered Screw-Vent®Implant System. Our highest selling dental product line provides the clinician a tapered geometry which mimics the natural shape of a tooth root. TheTapered Screw-VentSystem, with its two-stage design, was developed to minimize valuable chair time for restorations. Featuring a patentedproprietary internal hex connection, multiple lead threads for reduced insertion time and selective surface coatings, theTapered Screw-VentProduct is a technologically advanced dental implant offering features designed to allow the clinician to meet the needs of patients even in the most demanding circumstances.patients. TheZimmerOne-Piece Implant System, designed to complement the success of theTapered Screw-VentSystem, enhances this product line by offering clinicians a fast, convenient restorative option.
AdVent® Implant System. Utilizing many features of theTapered Screw-VentSystem, theAdVentProduct is a transgingival, one stage design that utilizes the same surgical system as theTapered Screw-VentSystem, allowing the clinician to use both design concepts without incurring the added cost of a second surgical system.
Tapered SwissPlus® Implant System. Designed to meet the needs of clinicians who prefer a transgingival, one stage, dental implant, theTapered SwissPlusSystem incorporates multiple lead threads for faster insertion time and a tapered body to allow it to be placed in tight interdental spaces. TheTapered SwissPlusSystem also incorporates an internal connection.
| |
| | Dental Restorative Products |
We commercialize products for the aesthetic market aimed at providing a more natural restoration. We offer a full line of prosthetic devices for each of the above dental implant systems as well as a custom solution, as follows:
Zimmer Hex-Lock® Contour Abutment and Restorative Products. Designed to be used with ourTapered Screw-Ventand One-Piece Implant Systems, our contour lines are an off-the-shelfa solution for immediately addressing the diversity of patients’ needs. Featuring prepared margins, titanium and ceramic options and snap-on impression caps, our abutments are designed to simplify the restoration process, save time for clinicians and technicians and offer versatility.
During 2009, we released our newHex-LockShort Abutment and Restorative System, an all-inclusive system that promotes posterior restorations, as well as theZimmerContour Angled Zirconia Abutment engineered for use with theTapered Screw-Ventimplants to provide clinicians with a restorative solution for patients’ esthetic needs.
| |
| | Dental Regenerative Products |
We market the following product lines for use in regenerative techniques in oral surgery:
Puros®Allograft Products. ThePurosMaterial is an allograft grafting material which in the case of mineralized bone and dermal tissues utilizes theTutoplast®12 Tissue Processing Technique that provides exceptional bone and soft tissue grafting material for use in oral surgery. Zimmer Dental
2 Registered trademark of RTI Biologics, Inc.
7
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
offers fiveseven distinctPurosAllograft products to use together or separately for various bone and soft tissue grafting needs:PurosCancellous Particulate,PurosCortical Particulate,PurosBlock Allografts,PurosPericardium Membranes,PurosDermis Membranes and, in 2009, we extended ourPurosportfolio by addingPurosDemineralized Bone Matrix (DBM) andPurosDermis Membranes.DBM Putty with Chips. We market thePurosAllograft Products through an agreement with RTI Biologics, Inc.
1 Registered Trademark ofThrough this same agreement with RTI Biologics, Inc.
7
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
During 2008, within our Dental division,, we released our newZimmerInstrument Kit System, which is designed to better enable clinicians to use theTapered Screw-Vent andZimmerOne-Piece implants. We extended our regenerative product portfolio by releasing theprovideCopiOs® Pericardium Membrane in the United States. Sourced from bovine pericardial tissue,CopiOsPericardium Membrane provides the characteristics of natural tissue.tissue and can be used as a direct substitute forPurosPericardium Membranes.
Spine ImplantsIn addition, we extended our regenerative portfolio further in wound management by adding theHemCon®3 Dental Dressing, an advanced wound dressing material that utilizes a propriety chitosan-based technology to effectively seal the wound and minimize pain in various surgical procedures. TheHemConDental Dressing is exclusively distributed by Zimmer Dental. In 2009, we also introduced ourZimmerSinus Lift Balloon, created to simplify the delicate sinus lift procedure under an agreement with Osseous Technologies of America (OTA).
Our spineSpine products division designs, manufactures and distributes medical devices and surgical instruments that provideto deliver comprehensive spine care solutions for patientsthose with back pain,or neck pain caused by degenerative disc conditions, and injuries due to trauma. Zimmer Spine offers orthopaedicdeformities or traumatic injury of the spine. We provide surgeons and neurosurgeons a fullbroad range of devicestechnologies for posterior and anterior applications ofprocedures in the cervical, thoracic and lumbar regions of the spine.
In October 2008, we acquired Abbott Spine. This investment adds a numberZimmer Spine’s portfolio of innovative products and builds critical mass in our Spine products segment. In addition to bringing existing products and a promising pipeline, the Abbott Spine acquisition added to our research and development capabilities in the spinal category and strengthened our sales coverage.
Our spine product offerings include:solutions includes:
Dynesys® Dynamic Stabilization System. TheDynesysSystem is usedfamily of implants was designed to facilitate a more physiologic approach to low back spinal stabilization. The system threads flexible components, instead of traditional rigid titanium rods, through pedicle screws in the treatment of lower back and leg painorder to stabilize affected spinal segments in skeletally mature patients. Developed to bring the lumbar vertebrae into a more natural anatomicalanatomic position while stabilizing the affected segments, theDynesysSystem uses flexible materials threaded through pedicle screws rather than rigid rods.and to alleviate pain. TheDynesysDynamic Stabilization Spinal System is currently indicated for use as an adjunct to fusion in the U.S.
PathFinder® Minimally Invasive Pedicle Screw System. TheA pioneering technology in MIS, thePathfinderPathFinderSystem is a minimally invasive posterior stabilization system used in fusion procedures of the lumbar surgery. Its design accommodatesand thoracic spine. The system easily facilitates single or multilevel constructs and offers advancedmulti-level procedures while featuring reduction, compression and distraction capabilities.
Universal Clamp®Device. Spinal Fixation System. The innovative design of theUniversal ClampDevice is designedimplant allows it to be used alongside traditional hooks, screws and wires to treat scoliotic deformities and correct scoliotic deformity and provides intra-operative flexibility with immediate post-operative stability.complex spinal pathologies.
Sequoia®Pedicle Screw System. TheSequoiaPedicle Screw PlatformSystem was designeddeveloped to treat a variety of conditions of the thoracolumbar spine. Thesimplify surgical flow, reduce implantation time and improve ergonomic tool design. This advanced pedicle screw system offers reproducible fixation required for spinal arthrodesis while minimizing screw bulk and footprint. This allows greater decortication and fusion bed preparation, space for distraction/compression and in situ bending. In addition to a reduced footprint, theSequoiaplatform offers a variety of advanced and proprietary featurescombines ergonomic instrumentation with an effective design that improve strength, reduce cross-threading and minimize head splay.reduces implant metal volume.
TiTLEArdis® 2 Polyaxial SpinalInterbody System. TheTiTLEArdisSystem is designed for both minimally invasiveimplant features a self-distracting nose, convex geometry and open procedures in the thoracic and lumbar spine. Its anti-cross threading cap screw and built-in friction head aid in the placement through small surgical openings. Thewide range of sizes. This versatileNorthStarPEEK-OPTIMA® Cannulated Screw Delivery System allows4 device incorporates a large space for percutaneousgraft placement, ofplus an advanced tooth design to effectively resist migration and expulsion during procedures. Ardis instrumentation was also designed to streamline the screws.surgical procedure and improve surgeon comfort.
Ant-Cer®II Plate. TheAnt-Cer II Plate is a dynamic cervical plate providing the capacity for one way translational settling to maintain natural graft loading.
AtaviTrinica® Atraumatic Spine Surgery System. TheAtavifamily of minimally invasive access products includes theNexPosure® System for cervical applications and theFlexPosure® Products for lumbar applications.
Trinica®Select Anterior Cervical PlatePlating System. TheTrinicaSelect Anterior Cervical Plate System and All-Through-One instrumentation is designed to simplify the surgical procedure while requiring less retraction and reducing the risk of soft-tissue damage. TheTrinicaSelect Self-Drilling Screws are designed to provide the surgeon with the optionSecure-Twist® anti-migration system, which provides visual confirmation of screw capture, as well as a wide variety of screw options to reducecustomize the number of instruments required to implant theTrinicaSelect Plate.construct depending on patient need.
Trabecular MetalBiological Products.Technology. Trabecular MetalTechnology has Zimmer Spine offers a wide rangefull line of orthopaedic applications. In the United States,Trabecular Metalmaterial shapes are utilized for vertebral body replacement procedures as well as bone void fillers.
filler products to accommodate most surgical procedures.Puros®Allograft Products. We continue to sell traditional Demineralized Bone Matrix is available in Putty and specialtyPurosAllograft Bone Products through our exclusive U.S.Putty with Chips formulations, and Canadian distribution agreements with RTI Biologics, Inc.
theCopiOs Bone Void Filler2®. CopiOsBone Void Filler is a collagen-basedfamily of products includes synthetic bone graft material provided in the form of sponges or pastes of various sizes for surgical implantation. It is intended for fillingthat are used to fill bone voids resulting from trauma or created by a surgeon.during spine surgery.
TraumaWallis® Posterior Dynamic Stabilization System (available outside the U.S. only). TheWallis system is an innovative spinal implant that was designed to stabilize the lumbar spine while preserving the anatomy and minimizing the need for bony resection. TheWallissystem combines aPEEK-OPTIMAspacer linked to the vertebrae via a polyester band that permits an even distribution of stresses on bone.
Trauma products include devices used to stabilize damaged or broken bones and their surrounding tissues to support the body’s natural healing processes. Fractures are most often stabilized using internal fixation devices such as plates, screws, nails, wires and pins, but may also be stabilized using external fixation devices. Orthobiologics are used in conjunction with traditional trauma devices which are applied externally to the limb.encourage healing and replace bone lost during an injury. We are focused on providing exceptional options to treat a broad range of traumatic injuries, addressing unmet clinical needs aligning our trauma products with MIS Procedures
3 Registered trademark of HemCon Medical Technologies, Inc.
4 Registered trademark of Victrex PLC Corporation, United Kingdom
8
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
and integrating orthobiologics and otherimplementing next-generation technologies into our portfolio of trauma solutions.
Zimmer Trauma offers a comprehensive line of products, including:
Zimmer Natural Nailtm System. TheZimmer Natural NailSystem includes a series of intramedullary nails designed to address a broad range of long bone fractures. The nails are anatomically shaped and incorporate an innovative feature that allows the screws to be linked to the nails, creating a robust construct even in poor quality bone. Instrumentation for nail placement is designed to make it easy for surgeons to utilize the implants as well as to address growing concerns with obesity and osteoporosis.
NCB®Plating Polyaxial Locking Plate System. The titaniumNCBPolyaxial Locking Plates provide surgeons with the ability to place screws with
2 Manufactured by Kensey Nash Corporation
8
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
polyaxial freedom and utilize both conventional and locking technology in the treatment of complex fractures of the distal femur, proximal humerus and proximal tibia. We continue to invest in additional applications of this exciting technology.
ZimmerPeriarticular Locking Plates.Plate System. TheZimmerPeriarticular Locking Plate System combines advanced, design techniquesanatomic designs with locking screw technology to create constructs for use in comminuted fractures or where deficient bone stock or poor bone quality is encountered. By combining locking screw holes with compression slots, the plates can be used as both locking devices and fracture compression devices.
ZimmerUniversal Locking System. TheZimmerUniversal Locking System is a comprehensive system of mini and small fragment stainless steel plates, screws and instruments for fracture fixation. The Universal Locking System plates resemble standard plates, but have figure-8 shaped holes that will accommodate standard or locking screws on either side ofwhich allow the hole. As a result, the plate canplates to be used depending upon the fracture situation, as a compression plate, aplates, locked internal fixatorfixators or as an internal fixation system combining both techniques.
Zimmer Cable-ReadyIntertrochanteric/Subtrochanteric (I.T.S.T.tm®) Nailing System. TheI.T.S.T.Zimmer Cable-Ready system offersSystem includes a proven methodseries of instruments, cables and other implants that help a surgeon treat several different fracture types, including those that occur around a previously implanted device (periprosthetic). The cables are wrapped around the bone and then secured, either to treat hip fractures that are common in elderly patients. The system allowsthemselves or to plates, to provide fixation for treatment of a variety of hip fractures with a simple, well accepted surgical technique. Instrumentation designed specifically for the system allows surgeons to use a minimally invasive approach.fractured limbs.
Orthopaedic Surgical Products
We develop, manufacture and market surgical products that support our reconstructive, trauma, spine and dental product systemsimplant procedures in the operating roomperi-operative environment, with a focus on Bone Cements, Surgical Wound Site Management and Blood Management. Orthopaedic Surgical Products include:
PALACOS®35 Bone Cement. We have exclusive United States distribution rights for thePALACOSline of bone cement products manufactured by Heraeus Kulzer GmbH. Included in these brands arePALACOSR andPALACOSR+G Bone Cements, as well asPALACOSLV andPALACOSLV+G Bone Cements. ThePALACOSR+G andPALACOSLV+G products are bone cements with the antibiotic gentamiacin pre-mixed in the formulation, andformulation; both are used by orthopaedic surgeons to reduce the risk of postoperative infection. Theinfection in second stage revisions. These products have handling characteristics that make them well-suited for minimally invasive procedures.
Hi-Fatiguetm46 Bone Cement. We have exclusive European and Asian distribution rights for theHi-Fatigueline of bone cement products manufactured by aap Biomaterials GmbH. Included in these brands areHi-FatigueandHi-FatigueG Bone Cements. TheHi-FatigueG bone cement utilizes the antibiotic gentamiacin pre-mixed in the formulation and is used by orthopaedic surgeons to reduce the risk of postoperative infection.
A.T.S.® Automatic Tourniquet Systems. TheA.T.S. Tourniquet Systems Product Line is a family of tourniquet machines and cuffs designed to safely create a bloodless surgical field. The machines includeportfolio includes theA.T.S.3000 Tourniquet System, which utilizes proprietary technology to determine a patient’s proper “Limb Occlusion Pressure” (LOP) based on the patient’s specific physiology. A decrease in LOP may reduce tissue or nerve damage. The range of cuffs which complement the machines provides the flexibility to occlude blood flow safely with convenience and accuracy for limbs of virtually every size and shape.
Pulsavac® Plus,PulsavacPlus AC andPulsavacPlus LP Wound Debridement Systems.System. ThesePulsavacSystems are used for cleaning and debridement of contaminants and foreign matter from wounds using simultaneous irrigation and suction. All threePulsavacSystems are completely disposable to reduce the risk of cross contamination. WhilePulsavacPlus andPulsavacPlus LP Wound Debridement Systems are both battery-powered, thePulsavacPlus AC Wound Debridement System is a disposable system that is powered by a reusable AC power source to address battery disposal concerns.
ZimmerBlood Reinfusion System (ZBRS) andHemovac® Blood Management Systems. These two blood management systems are part of a larger family that supports the clinician in managing patient blood loss after the surgical procedure. The ZBRS product is a closed-loop postoperative system that effectively salvages and filters the patient’s own blood, which can help reduce the dependency on banked bloodand/or preoperative autologous donation.
HEALTHCARE CONSULTING
Our healthcare consulting services subsidiary, Accelero Health Partners, LLC (Accelero), is based in Canonsburg,
5 Registered trademark of Heraeus Kulzer GmbH
6 Registered trademark of aap Biomaterials GmbH & Co. KG
9
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Pennsylvania. Accelero consultants work to design a customized program for each client that promotes the active participation and collaboration of the physicians and the hospital-based departments with the goal of consistently producing a superior outcome in the form of a growing, efficient, and effective care delivery network. Currently, revenue related to Accelero represents less than 1 percent of our total net sales.
ORTHOBIOLOGICS
Our research and development efforts include an Orthobiologics group based in Austin, Texas, with its own full-time staff and dedicated projects centralizing on the development of a variety of biologic technologies for musculoskeletal applications, including the repair and replacement of damaged tendon, ligament, meniscus, articular cartilage, bone and spinal nucleus tissues.applications. This group works on biological solutions to repair and regenerate damaged or degenerated musculoskeletal tissues using biomaterials/cell therapies which offer the possibility of treating damaged joints by biological repair rather than replacing them. A sampling of some of our key projects in the Orthobiologics area is set forth below.
We are collaborating with ISTO Technologies, Inc. (ISTO) to develop chondral (Neocartilage) and osteochondral grafts
3 Registered Trademark of Heraeus Kulzer GmbH
4 Trademark of aap Biomaterials GmbH & Co. KG
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
for cartilage repair. ISTO creates cell-based therapies for cartilage regeneration using cells from juvenile donor cartilage. NeocartilageDeNovo ET Engineered Tissue Graft is a living tissue-engineered cartilage graft under clinical investigation for the restoration of cartilage defects, reestablishment of joint function and relief of pain in the knee. The Phase I/II clinical trial (IND) for NeocartilageDeNovo ET has been completed patientand the data has been supplied to the FDA with a request to allow Zimmer/ISTO to proceed with enrollment with all patients having reached the12-monthfollow-up milestone. We plan to distribute this product asDeNovo® ET Engineered Tissue Graft. pivotal Phase III clinical trial. In addition, we launchedcompleted the full launch of our first cartilage repair product, (DeNovoNT Natural Tissue Graft)Graft, in 2007 and expanded use of the product in 2008.2009. This product provides particulated juvenile cartilage tissue for repair of articular cartilage defects of the knee, ankle, shoulder, hip, elbow and has been implanted in nearly 200toe joints. More than 700 patients duringhave undergone this limited release phase.innovative cartilage repair procedure.
Many musculoskeletal surgical procedures use bone grafts to help regenerate lost or damaged bone. In 2008, ourOur Spine, Dental and Trauma divisions have introduced a technologically advanced all-human demineralized bone matrix,PurosDBM Putty and Putty with bone chips. This bone-derived allograft material is used to fill bone voids or defects. It is placed into the bone void where it is then completely replaced by natural bone during the healing process.
RESEARCH AND DEVELOPMENT
We have extensive research and development activities to develop new surgical techniques, materials, orthobiologics and product designs. The research and development functions work closely with our strategic brand marketing function. The rapid commercialization of innovative new materials, orthobiologics products, implant and instrument designs and surgical techniques remains one of our core strategies and continues to be an important driver of sales growth.
We are broadening our product offerings in each of the product categories and exploring new technologies with possible applications in multiple areas. For the years ended December 31, 2009, 2008 2007 and 2006,2007, we spent $194.0$205.4 million, $209.6$192.3 million and $188.3$182.6 million, respectively, on research and development. The decreased spending on research and development in 2008 reflects delays connected with our operational compliance with the DPA and CIA and implementation of our enhanced compliance and ethics initiatives. We intend to increase spending on product development in 2009. Our primary research and development facility is located in Warsaw, Indiana. We have other research and development personnel based in, among other places, Winterthur, Switzerland; Austin, Texas; Minneapolis, Minnesota; Carlsbad, California; Dover, Ohio; and Parsippany, New Jersey. As of December 31, 2008,2009, we employed more than 800 research and development employees worldwide.
We expect to continue to identify innovative technologies and consider acquiring complementary products or businesses, or establishing technology licensing arrangements or strategic alliances.
GOVERNMENT REGULATION AND COMPLIANCE
We are subject to government regulation in the countries in which we conduct business. In the U.S., numerous laws and regulations govern all the processes by which medical devices are brought to market. These include, among others, the Federal Food, Drug and Cosmetic Act and regulations issued or promulgated thereunder. The U.S. Food and Drug Administration (FDA)FDA has enacted regulations that control all aspects of the development, manufacture, advertising, promotion and postmarket surveillance of medical products, including medical devices. In addition, the FDA controls the access of products to market through processes designed to ensure that only products that are safe and effective are made available to the public.
Most of our new products fall into FDA classifications that require the submission of a Premarket Notification (510(k)) to the FDA. This process requires us to demonstrate that the device to be marketed is at least as safe and effective as, that is, substantially equivalent to, a legally marketed device. We must submit information that supports our substantial equivalency claims. Before we can market the new device, we must receive an order from the FDA finding substantial equivalence and clearing the new device for commercial distribution in the United States. Other devices we develop and market are in a category (class) for which the FDA has implemented stringent clinical investigation and Premarket Approval (PMA) requirements. The PMA process requires us to provide clinical and laboratory data that establishes that the new medical device is safe and effective. The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). All of our devices marketed in the United States have been cleared or approved by the FDA, with the exception of certainpre-amendment devices which were in commercial distribution prior to May 28, 1976. The FDA has grandfathered these devices, so new FDA submissions are not required. Some low risk medical devices (including most instruments) also do not require FDA review and approval or clearance prior to commercial distribution. The FDA has the authority to: halt the distribution of certain medical devices; detain or seize adulterated or
10
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
misbranded medical devices; or order the repair, replacement of or refund of the costs of such devices. There are also certain requirements of state, local and foreign governments that we must comply with in the manufacture and marketing of our products.
In many of the foreign countries in which we market our products, we are subject to local regulations affecting, among other things, design and product standards, packaging requirements and labeling requirements. Many of the regulations applicable to our devices and products in these countries are similar to those of the FDA. The member countries of the European Union have adopted the European Medical Device Directive, which creates a single set of medical device regulations for products marketed in all member countries. Compliance with the Medical Device
10
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Directive and certification to a quality system enable the manufacturer to place a CE mark on its products. To obtain authorization to affix the CE mark to a product, a recognized European Notified Body must assess a manufacturer’s quality systems and the product’s conformity to the requirements of the Medical Device Directive. We are subject to inspection by the Notified Bodies for compliance with these requirements.
Further, we are subject to various federal and state laws concerning healthcare fraud and abuse, including false claims laws and anti-kickback laws. These laws are administered by, among others, the U.S. Department of Justice, the Office of Inspector General of the Department of Health and Human Services and state attorneys general. Many of these agencies have increased their enforcement activities with respect to medical device manufacturers in recent years. Violations of these laws are punishable by criminaland/or civil sanctions, including, in some instances, fines, imprisonment and, within the United States, exclusion from participation in government healthcare programs, including Medicare, Medicaid and Veterans Administration (VA) health programs.
Our operations in foreign countries are subject to the extraterritorial application of the U.S. Foreign Corrupt Practices Act (FCPA). As part of meeting our obligations under the 2007 DPA,global compliance program, we developed and have substantially implemented enhanced compliance initiatives and are applying these enhancements in most respectsseek to all of our businesses on a global basis.address FCPA risks proactively.
Our facilities and operations are also subject to complex federal, state, local and foreign environmental and occupational safety laws and regulations, including those relating to discharges of substances in the air, water and land, the handling, storage and disposal of wastes and theclean-up of properties by pollutants. We do not expect that the ongoing costs of compliance with these environmental requirements will have a material impact on our consolidated earnings, capital expenditures or competitive position.
COMPETITION
The orthopaedics industry is highly competitive. In the global markets for reconstructive implants, trauma and related surgical products, our major competitors include: DePuy Orthopaedics, Inc. (a subsidiary of Johnson & Johnson), Stryker Corporation, Biomet, Inc., Synthes, Inc., Smith & Nephew plc, Wright Medical Group, Inc., Synthes, Inc. and Tornier, Inc.
In the Americas geographic segment, we and DePuy Orthopaedics, Inc., Stryker Corporation, Biomet, Inc., Smith & Nephew, Inc. (a subsidiary of Smith & Nephew plc), Wright Medical Group, Inc. and Synthes, Inc. account for a large majority of the total reconstructive and trauma implant sales.
In the Asia Pacific market for reconstructive implant and trauma products, we compete primarily with DePuy Orthopaedics, Inc., Stryker Corporation, Synthes, Inc. and Smith & Nephew plc, as well as regional companies, including Japan Medical Materials Corporation and Japan Medical Dynamic Marketing, Inc. Factors, such as the dealer system and complex regulatory environments, and the accompanying inability to compete on price, make it difficult for smaller companies, particularly those that are non-regional, to compete effectively with the market leaders in the Asia Pacific region.
The European reconstructive implant and trauma product markets are more fragmented than the Americas or the Asia Pacific segments. The variety of philosophies held by European surgeons regarding hip reconstruction, for example, has fostered the existence of many regional European companies, including MathysAesculap AG and(a subsidiary of B. Braun), Waldemar LINK GmbH & Co., KG and Mathys AG which, in addition to the global competitors, compete with us. Today most hip implants sold in Europe are products developed specifically for the European market, although global products are gaining acceptance. We will continue to develop and produce specially tailored products to meet specific European needs.
In the spinal implant category, we compete globally primarily with Medtronic Sofamor Danek, Inc. (a subsidiarythe spinal and biologic business of Medtronic, Inc.), DePuy Spine (a subsidiary of Johnson & Johnson), Synthes, Inc., Stryker Corporation, and EBI, L.P., now operating as Biomet Trauma and Biomet Spine (a subsidiary(subsidiaries of Biomet, Inc.). and NuVasive, Inc.
In the dental reconstructive implant category, we compete primarily with Nobel Biocare Holding AG, Straumann Holding AG, Astra Tech Dental and Implant Innovations, Inc.Biomet 3i (a subsidiary of Biomet, Inc.).
Competition within the industry is primarily based on technology, innovation, quality, reputation and customer service. A key factor in our continuing success in the future will be our ability to develop new products and improve existing products and technologies.
MANUFACTURING AND RAW MATERIALS
We manufacture substantially all of our products at eightnine sites including Warsaw, Indiana; Winterthur, Switzerland; Ponce, Puerto Rico; Dover, Ohio; Statesville, North Carolina; Carlsbad, California; Parsippany, New Jersey; Shannon, Ireland; and Etupes, France. In February 2008, we announced plans to open a new manufacturing facility in Shannon, Ireland and are scheduled to open the facility in the second half of 2009.
We believe that our manufacturing facilities setare among the best in our industry standards in terms of automation and productivity and have the flexibility to accommodate future growth. The manufacturing operations at these facilities are designed to incorporate the cellular concept for production and to implement tenets of a manufacturing philosophy focused on continuous operational improvement and optimization. Our continuous improvement efforts are driven by Lean and Six Sigma methodologies. In addition, at certain
11
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
of our manufacturing facilities, many of the employees are cross-trained to perform a broad array of operations.
We generally target operating our manufacturing facilities at levels up to 90 percent of total capacity. We continually evaluate the potential to in-source products currently purchased from outside vendors toon-site production.
We have improved our manufacturing processes to protect our profitability and offset the impact of inflationary costs. We have, for example, employed computer-assisted robots and multi-axis grinders to precision polish medical devices; automated certain manufacturing and inspection processes, including on-machine inspection and process controls; purchasedstate-of-the-art equipment; in-sourced
11
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
core products, such as castings and forgings; and negotiated reductions in third party supplier costs.
We use a diverse and broad range of raw materials in the manufacturing of our products. We purchase all of our raw materials and select components used in manufacturing our products from external suppliers. In addition, we purchase some supplies from single sources for reasons of quality assurance, sole source availability, cost effectiveness or constraints resulting from regulatory requirements. We work closely with our suppliers to assure continuity of supply while maintaining high quality and reliability. To date, we have not experienced any significant difficulty in locating and obtaining the materials necessary to fulfill our production schedules.
INTELLECTUAL PROPERTY
Patents and other proprietary rights are important to the continued success of our business. We also rely upon trade secrets, know-how, continuing technological innovation and licensing opportunities to develop and maintain our competitive position. We protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with vendors, employees, consultants and others who may have access to proprietary information. We own or control through licensing arrangements more than 4,000 issued patents and patent applications throughout the world that relate to aspects of the technology incorporated in many of our products.
EMPLOYEES
We employ more than 8,5008,200 employees worldwide, including more than 800 employees dedicated to research and development. Over 5,200Approximately 4,900 employees are located within the United States and approximately 3,300 employees are located outside of the United States, primarily throughout Europe and in Japan. We have over 3,6003,500 employees dedicated to manufacturing our products worldwide. The Warsaw, Indiana production facility employs more than 1,600 employees. Fewer than 200 North American employees are members of a trade union covered by a collective bargaining agreement.
In May 2007, we renewedWe have a collective bargaining agreement with the United Steel, Paper and Forestry, Rubber Manufacturing, Energy, Allied Industrial and Service Workers International Union for and on behalf of Local2737-15 covering employees at the Dover, Ohio facility, which continues in effect until May 15, 2012.
EXECUTIVE OFFICERS
The following table sets forth certain information with respect to our executive officers as of January 31, 2009.February 15, 2010.
| | | | | |
| Name | | Age | | Position |
| |
| David C. Dvorak | | 4546 | | President and Chief Executive Officer |
| Cheryl R. Blanchard, Ph.D. | | 4445 | | Senior Vice President Research and Development and Chief Scientific Officer |
| James T. Crines | | 4950 | | Executive Vice President, Finance and Chief Financial Officer |
| Derek M. Davis | | 3940 | | Vice President, Finance and Corporate Controller and Chief Accounting Officer |
| Jeffery A. McCaulley | | 4344 | | President, Zimmer Reconstructive |
| Bruno A. Melzi | | 6162 | | Chairman, Europe, Middle East and Africa |
| Stephen H.L. Ooi | | 5556 | | President, Asia Pacific |
| Jeffrey B. Paulsen | | 48 | | Group President, Global Businesses |
| Chad F. Phipps | | 3738 | | Senior Vice President, General Counsel and Secretary |
Mark C. Throdahl | | 57 | | Group President, Global Businesses |
|
Mr. Dvorakwas appointed President, Chief Executive Officer and a member of the Board of Directors of Zimmer Holdings on May 1, 2007. From December 2005 to April 2007, Mr. Dvorak served as Group President, Global Businesses and Chief Legal Officer. From October 2003 to December 2005, Mr. Dvorak served as Executive Vice President, Corporate Services, Chief Counsel and Secretary, as well as Chief Compliance Officer. Mr. Dvorak was appointed Corporate Secretary in February 2003. He joined Zimmer Holdings in December 2001 as Senior Vice President, Corporate Affairs and General Counsel.
Dr. Blanchardwas appointed Senior Vice President Research and Development and Chief Scientific Officer of Zimmer Holdings in December 2005. She
12
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
is responsible for Corporate Research, Global Quality and Regulatory Affairs, Global Medical Affairs, Biologics Research and DevelopmentQuality and Regulatory, Medical Education, and Medical Affairs.Biologics Marketing. From October 2003 to December 2005, Dr. Blanchard served as Vice President, Corporate Research and Clinical Affairs and from August 2002 to October 2003, she served as Vice President, Research and Biologics.
Mr. Crineswas appointed Executive Vice President, Finance and Chief Financial Officer of Zimmer Holdings on May 1, 2007. From December 2005 to April 2007, Mr. Crines served as Senior Vice President, Finance, Operations and Corporate Controller and Chief Accounting Officer. From October 2003 to December 2005, Mr. Crines served as Senior Vice President, Finance/Controller and Information Technology and from July 2001 to October 2003, he served as Vice President, Finance/Controller.
Mr. Daviswas appointed Vice President, Finance and Corporate Controller and Chief Accounting Officer of Zimmer Holdings in May 2007. He has responsibility for internal and external reporting, planning and analysis, and corporate and business
12
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
unit accounting. From March 2006 to May 2007, Mr. Davis served as Director, Financial Planning and Accounting. From December 2003 to March 2006, Mr. Davis served as Director, Finance, Operations and Logistics and from April 2003 to December 2003, he served as Associate Director, Finance.
Mr. McCaulleywas appointed President, Zimmer Reconstructive in DecemberNovember 2008. He has overall responsibility for our activities in the reconstructive devices market,Global Reconstructive Business, including direct responsibility for Global Brand Management, Product Development and Medical Training and Education, as well as Americas Marketing and Americas Sales. Prior to joining us, Mr. McCaulleyZimmer, he served as President and Chief Executive Officer of the Health Division of Wolters Kluwer a leading provider of scientific informationfrom 2005 and workflow solutions for healthcare professionals, providers, payors and the pharmaceutical industry, from November 2004 to November 2008. Prior to joining Wolters Kluwer, Mr. McCaulley served as Vice President and General Manager of the Diabetes Division of Medtronic, Inc., a global leader in medical technology, from 2002 to 2004.2002.
Mr. Melziwas appointed Chairman, Europe, Middle East and Africa of Zimmer Holdings in October 2003. He is responsible for the sales, marketing and distribution of products in the European, Middle Eastern and African regions. From March 2000 to October 2003, Mr. Melzi served as President, Europe/MEA.
Mr. Ooiwas appointed President, Asia Pacific of Zimmer Holdings in December 2005. He is responsible for the sales, marketing and distribution of products in the Asia Pacific region, including responsibility for Japan. From September 2003 to December 2005, Mr. Ooi served as President, Australasia, where he was responsible for operations in Asia Pacific, excluding Japan. From September 2002 to September 2003, Mr. Ooi served as President, Asia Pacific region.
Mr. Paulsenwas appointed Group President, Global Businesses of Zimmer Holdings in December 2009. He has responsibility for Zimmer Spine, Zimmer Dental, Zimmer Trauma and Zimmer Orthopaedic Surgical Products. Prior to joining us, Mr. Paulsen served as Chief Operating Officer of MPS Group, Inc., a privately held environmental services and facility management firm, from September 2008 to December 2009. Prior to that, he served as Group President of TriMas Corporation, a specialty manufacturing company, from January 2007 to June 2008. Before joining TriMas Corporation, Mr. Paulsen held a number of increasingly responsible executive roles at Stryker Corporation from 1996 to December 2006, including President, Orthopaedic Reconstructive Division.
Mr. Phippswas appointed Senior Vice President, General Counsel and Secretary of Zimmer Holdings in May 2007. He has global responsibility for our legal affairs and he serves as Secretary to the Board of Directors. Mr. Phipps also oversees our Government Affairs, Corporate CommunicationCommunications and Public Relations activities. From December 2005 to May 2007, Mr. Phipps served as Associate General Counsel and Corporate Secretary and from September 2003 to December 2005, he served as Associate Counsel and Assistant Secretary.
Mr. Throdahlwas appointed Group President, Global Businesses of Zimmer Holdings in May 2008. He is responsible for Zimmer Spine, Zimmer Dental, Zimmer Trauma, Zimmer Orthopaedic Surgical Products, Zimmer Computer Assisted Solutions and Accelero Health Partners. Prior to joining us, Mr. Throdahl served as Chief Executive Officer of Consort Medical plc (formerly Bespak plc), a leader in medical devices for inhaled drug delivery and anesthesia based in Milton Keynes, United Kingdom, from June 2001 to December 2007.
AVAILABLE INFORMATION
Our Internet website address is www.zimmer.com. Our annual reports onForm 10-K, quarterly reports onForm 10-Q, current reports onForm 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available or may be accessed free of charge through the Investor Relations section of our Internet website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our Internet website and the information contained therein or connected thereto are not intended to be incorporated by reference into this Annual Report onForm 10-K.
The following corporate governance and related documents, among others, are available through our website or may be obtained in print form, without charge, by request to our Investor Relations Department:website: Corporate Governance Guidelines, Code of Business Conduct, Code of Ethics for Chief Executive Officer and Senior Financial Officers, Audit Committee Charter, Compensation and Management Development Committee Charter, Corporate Governance Committee Charter and Science and Technology Committee Charter.
We will post on our Internet website any substantive amendment to, or waiver from, our Code of Ethics for Chief Executive Officer and Senior Financial Officers or a provision of our Code of Business Conduct that applies to any of our directors or executive officers.
Risk factors which could cause actual results to differ from our expectations and which could negatively impact our financial condition and results of operations are discussed below and elsewhere in this report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that are currently not believed to be significant to our business may also affect our actual results and could harm our business, financial condition and results of operations. If any of the risks or uncertainties described below or any additional risks and uncertainties actually occur, our business, results of
13
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
operations and financial condition could be materially and adversely affected.
RISKS RELATED TO OUR BUSINESS
If we fail to comply with the terms of the Deferred Prosecution Agreement and Corporate Integrity Agreement we entered into in September 2007, we may be subject to criminal prosecutionand/or exclusion from federal healthcare programs.
As previously reported, in September 2007 we settled an investigation conducted by the United States Attorney’s Office for the District of New Jersey (the “U.S. Attorney”)(U.S. Attorney) into financial relationships between major orthopaedic manufacturers and consulting orthopaedic surgeons. As part of that settlement, we entered into a Deferred Prosecution Agreement (the “DPA”) with the U.S. Attorney and a Corporate Integrity Agreement (the “CIA”)(CIA) with the Office of Inspector General of the Department of Health and Human Services (the “OIG-HHS”)(OIG-HHS). Copies of the DPA and CIA are filed as exhibits to this report and aA copy of the DPACIA is available on our website at www.zimmer.com.
13
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
filed as an exhibit to this report. If we do not comply with the terms of these agreements,the CIA, we could be subject to prosecution for violations of the federal Anti-Kickback Statute that the U.S. Attorney alleges we committed between 2002 and 2006, as well as any new or continuing violations. We could also be subject to exclusion by OIG-HHS from participation in federal healthcare programs, including Medicaid and Medicare.
We could be subject to further governmental investigations or actions by other third parties based on allegations of wrongdoing similar to those made by the U.S. Attorney.
Our settlement with the U.S. government does not preclude other governmental agencies or state authorities from conducting investigations or instituting proceedings based on allegations of wrongdoing similar to those made by the U.S. Attorney. As previously disclosed, we are cooperating with the U.S. Securities and Exchange Commission and the U.S. Department of Justice with regard to an informalongoing investigation into potential violations of the Foreign Corrupt Practices Act in the sale of medical devices in a number of foreign countries by companies in the medical device industry. We are also cooperating with investigative demands made by two state attorneys general. While we believe that the pending state investigations are not likely to have a material adverse effect on our business or financial condition, similar investigations by other states or governmental agencies are possible. In addition, the settlement with the government could increase our exposure to lawsuits by potential whistleblowers under the federal false claims acts, based on new theories or allegations arising from the allegations made by the U.S. Attorney. We intend to review and take appropriate actions with respect to any such investigations or proceedings; however, we cannot assure that the costs of defending or resolving those investigations or proceedings would not have a material adverse effect on our financial condition, results of operations and cash flows.
If we are not able to fulfill or otherwise resolve our existing royalty and other payment obligations to healthcare professional consultants and institutions, our ability to maintain our existing intellectual property rights and obtain future rights may be impaired.
We have reviewed our existing royalty agreements with healthcare professional consultants and institutions in light of the requirements of the DPA. Following our review, we resumed paying royalties with respect to some of the agreements. With respect to others, we made lump-sum payments to resolve our accrued and future royalty obligations and secure rights to the intellectual property. With respect to the remaining agreements, if we do not fulfill our obligations or reach some other resolution acceptable to the affected healthcare professional consultants and institutions, our ability to use the intellectual property covered by those agreements may be adversely affected. In addition, our ability to enter into new agreements with healthcare professional consultants or institutions for the future acquisition of intellectual property rights may be adversely affected.
Our temporary suspension of the U.S. marketing and distribution of one of our hip products has adversely affected sales growth, resulted in claims and may adversely affect our ability to compete in the growing hip resurfacing market in the U.S.
In July 2008,As previously reported, we temporarily suspended the marketing and distribution of ourDuromAcetabular Component (DuromCup) in the U.S. We believe this action adversely affected our hip product sales in the U.S. in the last half ofJuly 2008. Although we resumed U.S. marketing and distribution in August 2008, we expectbelieve the effects of this action willhad a negative impact on our hip product sales growth through 2009 and may continue to have a negative impact through 2009.in 2010.
Following our action, product liability lawsuits and other claims were asserted against us and we expect additional similar claims willmay be asserted. In addition, we expect that our entry into the growing U.S. hip resurfacing market has been delayed as theDuromCup had been integral to our plans for entry into that market.
The implementation of our enhanced global compliance program is requiring us to devote substantial resources, is disruptive to normal business activities and may place us at a competitive disadvantage.
Since entering into the DPA and CIA, we have devoted substantial resources to meet our obligations under those agreements and implemented enhancements to our global compliance program applicable in most respects to all of our businesses on a global basis. These efforts have not only involved significant expense, but also required management and other key employees to focus extensively on these matters, preventing them from devoting as much time as they otherwise would to other business matters. If our competitors do not make similar enhancements to their compliance programs, this may place us at a competitive disadvantage and adversely affect our results of operations.
We believe we have lost market share as a result of recent events. If we are not able to recover or grow our market share, our operating results could be materially adversely affected.
We believe that the disruptive effects of the product suspensions and recalls in 2008 and the implementation of our enhanced global compliance initiatives contributed to customer losses during the last half of 2008. We may not be able to recapture market share lost due to these events and we may continue to lose customers due to these factors in the future.
If we fail to retain the independent agents and distributors upon whom we rely heavily to market our products, customers may not buy our products and our revenue and profitability may decline.
Our marketing success in the United States and abroad depends significantly upon our agents’ and distributors’ sales and service expertise in the marketplace. Many of these agents have developed professional relationships with existing and potential customers because of the agents’ detailed knowledge of products and instruments. A loss of a significant number of these agents could have a material adverse effect on our business and results of operations.
14
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
If we do not introduce new products in a timely manner, our products may become obsolete over time, customers may not buy our products and our revenue and profitability may decline.
Demand for our products may change, in certain cases, in ways we may not anticipate because of:
| |
| • | evolving customer needs; |
| • | changing demographics; |
| • | slowing industry growth rates; |
| • | declines in the reconstructive implant market; |
| • | the introduction of new products and technologies; |
| • | evolving surgical philosophies; and |
| • | evolving industry standards. |
Without the timely introduction of new products and enhancements, our products may become obsolete over time. If that happens, our revenue and operating results would suffer. The success of our new product offerings will depend on several factors, including our ability to:
| |
| • | properly identify and anticipate customer needs; |
| • | commercialize new products in a timely manner; |
| • | manufacture and deliver instruments and products in sufficient volumes on time; |
| • | differentiate our offerings from competitors’ offerings; |
| • | achieve positive clinical outcomes for new products; |
| • | satisfy the increased demands by healthcare payors, providers and patients for shorter hospital stays, faster post-operative recovery and lower-cost procedures; |
| • | innovate and develop new materials, product designs and surgical techniques; and |
| • | provide adequate medical education relating to new products. |
In addition, new materials, product designs and surgical techniques that we develop may not be accepted quickly, in some or all markets, because of, among other factors:
| |
| • | entrenched patterns of clinical practice; |
| • | the need for regulatory clearance; and |
| • | uncertainty with respect to third-party reimbursement. |
Moreover, innovations generally require a substantial investment in research and development before we can determine their commercial viability and we may not have the financial resources necessary to fund the production. In addition, even if we are able to successfully develop enhancements or new generations of our products, these
14
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
enhancements or new generations of products may not produce revenue in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.
We conduct a significant amount of our sales activity outside of the United States, which subjects us to additional business risks and may cause our profitability to decline due to increased costs.
We sell our products in more than 100 countries and derive more than 40%40 percent of our net sales from outside the United States. We intend to continue to pursue growth opportunities in sales internationally, which could expose us to additional risks associated with international sales and operations. Our international operations are, and will continue to be, subject to a number of risks and potential costs, including:
| |
| • | changes in foreign medical reimbursement policies and programs; |
| • | unexpected changes in foreign regulatory requirements; |
| • | differing local product preferences and product requirements; |
| • | fluctuations in foreign currency exchange rates; |
| • | diminished protection of intellectual property in some countries outside of the United States; |
| • | trade protection measures and import or export requirements that may prevent us from shipping products to a particular market and may increase our operating costs; |
| • | foreign exchange controls that might prevent us from repatriating cash earned in countries outside the United States; |
| • | complex data privacy requirements and labor relations laws; |
| • | extraterritorial effects of U.S. laws such as the Foreign Corrupt Practices Act; |
| • | difficulty in staffing and managing foreign operations; |
| • | labor force instability; |
| • | potentially negative consequences from changes in tax laws; and |
| • | political and economic instability. |
Violations of foreign laws or regulations could result in fines, criminal sanctions against us, our officers or our employees, prohibitions on the conduct of our business and damage to our reputation.
We are subject to risks arising from currency exchange rate fluctuations, which can increase our costs, cause our profitability to decline and expose us to counterparty risks.
A substantial portion of our foreign revenues are generated in Europe and Japan. The United States dollar value of our foreign-generated revenues varies with currency exchange rate fluctuations. Significant increases in the value of the United States dollar relative to the Euro or the Japanese Yen, as well as other currencies, could have a material adverse effect on our results of operations. Although we address currency risk management through regular operating and financing activities, and, on a limited basis, through the use of derivative financial instruments, those actions may not prove to be fully effective. The current global economic crisis has generally increased the risk of entering into derivative financial instruments, even if major international financial institutions act as counterparties.
We may fail to adequately protect our proprietary technology and other intellectual property, which would allow competitors or others to take advantage of our research and development efforts.
Our long-term success largely depends on our ability to market technologically competitive products. If we fail to obtain or maintain adequate intellectual property protection, we may not be able to prevent third parties from using our proprietary technologies. Also, our currently pending or future patent applications may not result in issued patents, and issued patents are subject to claims concerning priority, scope and other issues.
15
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
The United States Patent and Trademark Office and the courts have not consistently treated the breadth of claims allowed or interpreted in orthopaedic reconstructive implant and biotechnology patents. Future changes in, or unexpected interpretations of, the patent laws may adversely affect our ability to enforce our patent position.
In addition, intellectual property rights may be unavailable or of limited effect in some foreign countries. If we do not obtain sufficient international protection for our intellectual property, our competitiveness in international markets could be impaired, which could limit our growth and revenue.
We also attempt to protect our trade secrets, proprietary know-how and continuing technological innovation with security measures, including the use of confidentiality agreements with our employees, consultants and collaborators. These measures may prove to be ineffective and any remedies available to us may be insufficient to compensate our damages.
We may be subject to intellectual property litigation and infringement claims, which could cause us to incur significant expenses or prevent us from selling our products.
A successful claim of patent or other intellectual property infringement against us could adversely affect our growth and profitability, in some cases materially. From time to time, we receive notices from third parties of potential infringement and receive claims of potential infringement. We may be unaware of intellectual property rights of others that may cover some of our technology. If someone claims that our products infringed their intellectual property rights, any resulting litigation could be costly and time consuming and would divert the attention of management and key personnel from other business issues. If we were to lose such litigation involving material intellectual property rights, we may be unable to manufacture, sell or use some of our products.
We may make additional acquisitions or enter into strategic alliances that could increase our costs or liabilities or be disruptive.
We intend to continue to look for additional strategic acquisitions of other businesses that are complementary to our businesses and other companies with whom we could form strategic alliances or enter into other arrangements to develop or exploit intellectual property rights. These activities involve risks, including the following:
| |
| • | we may need to divert more management resources to integration than we planned, which may adversely affect our ability to pursue other more profitable activities; |
15
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
| |
| • | the difficulties of integrating acquired businesses may be increased if we need to integrate geographically separated organizations, personnel with disparate business backgrounds and companies with different corporate cultures; |
| • | we may not recognize expected cost savings from acquisitions or the anticipated benefits of acquisitions or strategic alliances; |
| • | our acquisition candidates or strategic partners may have unexpected liabilities or prove unable to meet their obligations to us or the joint venture; and |
| • | the priorities of our strategic partners may prove incompatible with ours. |
We depend on a limited number of suppliers for some key raw materials and outsourced activities.
We use a number of suppliers for raw materials that we need to manufacture our products and to outsource some key manufacturing activities. These suppliers must provide the materials and perform the activities to our standards for us to meet our quality and regulatory requirements. Some key raw materials and outsourced activities can only be obtained from a single source or a limited number of sources. A prolonged disruption or other inability to obtain these materials or outsource key manufacturing activities could materially and adversely affect our ability to satisfy demand for our products.
We are subject to putative stockholder class action lawsuits that could be costly to defend and distracting to management.
We and a number of our related parties are defending putative stockholder class action lawsuits alleging violations of the securities laws breaches of fiduciary duties or violations of the federal Employee Retirement Income Security Act of 1974 arising out of trading or ownership of our common stock. We believe these lawsuits are without merit, and we intend to defend them vigorously. We may incur significant expenses associated with the defense of these lawsuits, however, and the necessary participation of our executive officers could detract from their ability to devote their full time and attention to our business operations.
RISKS RELATED TO OUR INDUSTRY
The ongoing informal investigation by the U.S. Securities and Exchange Commission and the U.S. Department of Justice regarding potential violations of the Foreign Corrupt Practices Act in the sale of medical devices in a number of foreign countries by companies in the medical device industry could have a material adverse effect on our business, financial condition and cash flows.
We are cooperating fully with the U.S. Securities and Exchange Commission and the U.S. Department of Justice with regard to an ongoing informal investigation of potential violations of the Foreign Corrupt Practices Act in the sale of medical devices in a number of foreign countries by companies in the medical device industry. Although we have adopted policies and procedures designed to prevent improper payments and we train our employees, distributors and others concerning these issues, we cannot assure that violations of these requirements will not occur. If we are found to have violated the Foreign Corrupt Practices Act, we may face sanctions including fines, criminal penalties, disgorgement of profits and suspension or debarment of our ability to contract with governmental agencies or receive export licenses.
The impact of healthcare reform in the U.S. on us is uncertain.
There is increasing emphasis within the federal government to reform healthcare in the U.S., though it is uncertain whether new legislation will be enacted. To the extent that the number of uninsured or underinsured patients is reduced, demand for our products could marginally increase. However, efforts to pay for healthcare reform through a proposed new tax on medical device companies and efforts to contain healthcare costs, directly through pricing or reimbursement controls or indirectly by government-sponsored healthcare insurance, could have a material adverse effect on our sales and results of operations. Accordingly, the impact of healthcare reform on the medical device industry in general or us in particular remains uncertain.
We are subject to healthcare fraud and abuse regulations on an ongoing basis that could require us to change our business practices and restrict our operations in the future.
Our industry is subject to various federal and state laws pertaining to healthcare fraud and abuse, including false claims
16
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
laws, the federal Anti-Kickback Statute, similar state laws and physician self-referral laws. Violations of these laws are punishable by criminaland/or civil sanctions, including, in some instances, fines, imprisonment and, within the United States, exclusion from participation in government healthcare programs, including Medicare, Medicaid and Veterans Administration (VA) health programs. The interpretation and enforcement of these laws and regulations are uncertain and subject to rapid change.
If third-party payors decline to reimburse our customers for our products or reduce reimbursement levels, the demand for our products may decline and our ability to sell our products profitably may be harmed.
We sell our products and services to hospitals, doctors, dentists and other healthcare providers, all of which receive reimbursement for the healthcare services provided to their patients from third-party payors, such as domestic and international government programs, private insurance plans and managed care programs. These third-party payors may deny reimbursement if they determine that a device used in a procedure was not in accordance with cost-effective treatment methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors may also decline to reimburse for experimental procedures and devices. If our products are not considered cost-effective by third-party payors, our customers may not be reimbursed for our products.
In addition, third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products and services. If third-party payors reduce reimbursement levels to hospitals and other healthcare providers for our products, demand for our products may decline, or we may experience pressure to
16
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
reduce the prices of our products, which could have a material adverse effect on our sales and results of operations.
We have also experienced downward pressure on product pricing and other effects of healthcare reform in our international markets. If key participants in government healthcare systems reduce the reimbursement levels for our products, our sales and results of operations may be adversely affected.
The ongoing cost-containment efforts of healthcare purchasing organizations may have a material adverse effect on our results of operations.
Many customers for our products have formed group purchasing organizations in an effort to contain costs. Group purchasing organizations negotiate pricing arrangements with medical supply manufacturers and distributors, and these negotiated prices are made available to a group purchasing organization’s affiliated hospitals and other members. If we are not one of the providers selected by a group purchasing organization, affiliated hospitals and other members may be less likely to purchase our products, and, if the group purchasing organization has negotiated a strict compliance contract for another manufacturer’s products, we may be precluded from making sales to members of the group purchasing organization for the duration of the contractual arrangement. Our failure to respond to the cost-containment efforts of group purchasing organizations may cause us to lose market share to our competitors and could have a material adverse effect on our sales and results of operations.
Continuing weakness in the global economy is likely to adversely affect our business until an economic recovery is underway.
A significant portion of our products are used in procedures covered by private insurance, many of which, including procedures using our dental products, may be considered elective procedures. We expect the current global economic crisis is likely to reduce the availability or affordability of private insurance or may impact patient decisions to have an elective procedure performed. If current economic conditions continue or worsen, we expect that increasing levels of unemployment and pressures to contain healthcare costs could adversely affect the global growth rate of hip and knee procedure volume, which could have a material adverse effect on our sales and results of operations.
Our success depends on our ability to effectively develop and market our products against those of our competitors.
We operate in a highly competitive environment. Our present or future products could be rendered obsolete or uneconomical by technological advances by one or more of our present or future competitors or by other therapies, including orthobiologicalbiological therapies. To remain competitive, we must continue to develop and acquire new products and technologies. Competition is primarily on the basis of:
| |
| • | technology; |
| • | innovation; |
| • | quality; |
| • | reputation; and |
| • | customer service. |
In markets outside of the United States, other factors influence competition as well, including:
| |
| • | local distribution systems; |
| • | complex regulatory environments; and |
| • | differing medical philosophies and product preferences. |
Our competitors may:
| |
| • | have greater financial, marketing and other resources than us; |
| • | respond more quickly to new or emerging technologies; |
| • | undertake more extensive marketing campaigns; |
| • | adopt more aggressive pricing policies; or |
| • | be more successful in attracting potential customers, employees and strategic partners. |
Any of these factors, alone or in combination, could cause us to have difficulty maintaining or increasing sales of our products.
17
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
We and our customers are subject to various governmental regulations relating to the manufacturing, labeling and marketing of our products, and we may incur significant expenses to comply with these regulations and develop products compatible with these regulations.
The medical devices we design, develop, manufacture and market are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time consuming and approvals might not be granted for future products on a timely basis, if at all. Delays in receipt of, or failure to obtain, approvals for future products could result in delayed realization of product revenues or in substantial additional costs.
In addition, if we fail to comply with applicable material regulatory requirements, including, for example, the Quality System Regulation, recordkeeping regulations, labeling requirements and adverse event reporting regulations, we may be subject to a range of sanctions including:
| |
| • | warning letters; |
| • | fines or civil penalties; |
| • | injunctions; |
| • | repairs, replacements or refunds; |
| • | recalls or seizures of products; |
| • | total or partial suspension of production; |
| • | the FDA’s refusal to grant future premarket clearances or approvals; |
| • | withdrawals or suspensions of current product applications; and |
| • | criminal prosecution. |
Our products and operations are also often subject to the rules of industrial standards bodies, such as the International Standards Organization. If we fail to adequately address any of these regulations, our business will be harmed.
We may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.
In the ordinary course of business, we are the subject of product liability lawsuits alleging that component failures, manufacturing flaws, design defects or inadequate disclosure of product-related risks or product-related information resulted in an unsafe condition or injury to patients. Product liability lawsuits and claims, safety alerts or product recalls, regardless of their ultimate outcome, could have a material adverse effect on our business and reputation and on our ability to attract and retain customers.
Although we maintain third-party product liability insurance coverage, it is possible that claims against us may exceed the coverage limits of our insurance policies or cause us to record a self-insured loss. Even if any product liability loss is covered by an insurance policy, these policies typically have substantial retentions or deductibles that we are responsible for. Product liability claims in excess of applicable
17
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
insurance could have a material adverse effect on our business, financial condition and results of operations.
| | |
| ITEM 1B. | | Unresolved Staff Comments |
Not Applicable.
18
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
We have the following properties:
| | | | | | | | | |
| Location | | Use | | Owned/Leased | | | Square Feet |
| |
| Warsaw, Indiana | | Research & Development, Manufacturing, Warehousing, Marketing & Administration | | | Owned | | | 1,400,000 |
| Warsaw, Indiana | | Corporate Headquarters &and The Zimmer Institute | | | Owned | | | 117,000 |
| Warsaw, Indiana | | Offices, Manufacturing & Warehousing | | | Leased | | | 90,000 |
| Carlsbad, California | | Offices, Research & Development & Manufacturing | | | Leased | | | 118,000 |
| Minneapolis, Minnesota | | Offices & Research & Development | | | Owned | | | 51,000 |
Cedar Knolls, New Jersey | | Manufacturing & Warehousing | | | Leased | | | 23,000 |
Parsippany, New Jersey | | Research & Development, Manufacturing & Warehousing | | | Leased | | | 115,000 |
| Statesville, North Carolina | | Manufacturing & Warehousing | | | Owned | | | 156,000 |
| Dover, Ohio | | Offices, Research & Development & Manufacturing | | | Owned | | | 140,000 |
| Dover, Ohio | | Warehousing | | | Leased | | | 61,000 |
| Parsippany, New Jersey | | Office, Research & Development, Manufacturing, | | | Leased | | | 115,000 |
| Memphis, Tennessee | | Offices & Warehousing | | | Leased | | | 30,000 |
| Austin, Texas | | Offices, Administration, Research & Development & Distribution | | | Leased | | | 97,000 |
| Sydney, Australia | | Offices & Warehousing | | | Leased | | | 36,000 |
Vienna,Mödling, Austria | | Offices & Warehousing | | | LeasedOwned | | | 15,00014,000 |
| Wemmel, Belgium | | Offices & Warehousing | | | Leased | | | 15,000 |
| Mississauga, Canada | | Offices & Warehousing | | | Leased | | | 52,000 |
| Shanghai, China | | Offices & Warehousing | | | Leased | | | 18,000 |
| Etupes, France | | Offices, Manufacturing & Warehousing | | | Owned | | | 90,000 |
| Eschbach, Germany | | Distribution Center | | | Owned | | | 94,000 |
| Freiburg, Germany | | Offices & Warehousing | | | Leased | | | 51,000 |
| Kiel, Germany | | Offices & Warehousing | | | Leased | | | 21,000 |
| Shannon, Ireland | | Offices Manufacturing & WarehousingManufacturing | | | Owned | | | 125,000 |
| Milan, Italy | | Offices & Warehousing | | | Leased | | | 47,000 |
| Gotemba, Japan | | Offices, Service Center & Warehousing | | | Owned | | | 87,000 |
| Tokyo, Japan | | Offices & Warehousing | | | Leased | | | 24,000 |
| Seoul, Korea | | Offices & Warehousing | | | Leased | | | 22,000 |
| Utrecht, Netherlands | | Offices & Warehousing | | | Leased | | | 16,000 |
| Ponce, Puerto Rico | | Offices, Manufacturing & Warehousing | | | Owned | | | 213,000 |
| Singapore | | Offices & Warehousing | | | Leased | | | 10,00019,000 |
| Barcelona, Spain | | Offices & Warehousing | | | Leased | | | 16,000 |
Baar, Switzerland | | Warehousing | | | Leased | | | 40,000 |
| Winterthur, Switzerland | | Offices, Research & Development & Manufacturing | | | Leased | | | 358,000374,000 |
| Münsingen, Switzerland | | Offices & Warehousing | | | Owned | | | 76,000 |
| Swindon, United Kingdom | | Offices & Warehousing | | | Leased | | | 70,000 |
We began construction ofDuring 2009 we commenced manufacturing operations in our new 125,000 square feet Shannon, Ireland facility in 2008 and expect to begin manufacturing operations at thisbegan utilizing our new 94,000 square feet warehouse facility in the second half of 2009. InEschbach, Germany in an effort to expand our global distribution network, we have begun construction on a 130,000 square feet warehouse facility in Eschbach, Germany. We expect to begin utilizing this facility in the second half of 2009.network. We believe the current facilities, including manufacturing, warehousing, research and development and office space together with the planned expansion provide sufficient capacity to meet ongoing demands. Once a facility reaches 85 percent utilization, we examine alternatives for either expanding that facility or acquiring new facilities to meet our ongoing demands.
In addition to the above, we maintain more than 100 other offices and warehouse facilities in more than 25 countries around the world, including the United States, Japan, Australia, France, Russia, India, Germany, Italy, Switzerland and China. We believe that all of the facilities and equipment are in good condition, well maintained and able to operate at present levels.
Information pertaining to legal proceedings can be found in Note 1617 to the Consolidated Financial Statements, which are included in this report under Item 8.
| | |
| ITEM 4. | | Submission of Matters to a Vote of Security Holders |
Not Applicable.
19
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 5. | | Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |
Our common stock is traded on the New York Stock Exchange and the SWXSIX Swiss Exchange under the symbol “ZMH.” The high and low sales prices for our common stock on the New York Stock Exchange for the calendar quarters of fiscal years 20082009 and 20072008 are set forth as follows:
| | | | | | | | | | | | | | | | | |
| Quarterly High-Low Share Prices | | High | | Low | | | High | | Low | |
| | | | |
| Year Ended December 31, 2009: | | | | | | | |
| First Quarter | | | $ | 44.36 | | | $ | 30.67 | |
| Second Quarter | | | $ | 47.41 | | | $ | 35.36 | |
| Third Quarter | | | $ | 55.25 | | | $ | 38.55 | |
| Fourth Quarter | | | $ | 60.64 | | | $ | 49.14 | |
| | | | | | | | | |
| Year Ended December 31, 2008: | | | | | | | | | | | | |
| First Quarter | | $ | 79.78 | | | $ | 63.80 | | | $ | 79.78 | | | $ | 63.80 | |
| Second Quarter | | $ | 80.92 | | | $ | 66.12 | | | $ | 80.92 | | | $ | 66.12 | |
| Third Quarter | | $ | 74.55 | | | $ | 60.41 | | | $ | 74.55 | | | $ | 60.41 | |
| Fourth Quarter | | $ | 66.42 | | | $ | 34.10 | | | $ | 66.42 | | | $ | 34.10 | |
| | | | | | | | |
| Year Ended December 31, 2007: | | | | | | | |
| First Quarter | | $ | 88.18 | | | $ | 76.90 | | |
| Second Quarter | | $ | 94.38 | | | $ | 83.67 | | |
| Third Quarter | | $ | 91.00 | | | $ | 75.14 | | |
| Fourth Quarter | | $ | 85.91 | | | $ | 63.00 | | |
We have not declared or paid dividends on our common stock since becoming a public company on August 6,in 2001. Currently, we do not anticipate paying any cash dividends on the common stock in the foreseeable future. Our credit facility also restricts the payment of dividends under certain circumstances.
The number of beneficial ownersholders of our common stock on February 13, 200912, 2010 was approximately 470,800.350,200. On February 13, 2009,12, 2010, the closing price of the common stock, as reported on the New York Stock Exchange, was $41.06$57.24 per share.
The information required by this Item concerning equity compensation plans is incorporated by reference to Item 12 of this report.
The following table summarizes repurchases of common stock settled during the three months ended December 31, 2008:2009:
| | | | | | | | | | | | | | | | | |
| | | | | | | | | Total Number of Shares
| | | Approximate Dollar Value of
| |
| | | | | | | | | Purchased as Part of
| | | Shares that May Yet Be
| |
| | | Total Number of
| | | Average Price
| | | Publicly Announced Plans
| | | Purchased Under Plans
| |
| | | Shares Purchased | | | Paid per Share | | | or Programs(1) | | | or Programs | |
| | |
| October 2008 | | | 1,189,100 | | | $ | 40.47 | | | | 30,066,500 | | | $ | 1,134,346,296 | |
| November 2008 | | | – | | | | – | | | | – | | | | – | |
| December 2008 | | | – | | | | – | | | | – | | | | – | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | | 1,189,100 | | | $ | 40.47 | | | | 30,066,500 | | | $ | 1,134,346,296 | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | Total Number of Shares
| | | Approximate Dollar Value of
| |
| | | | | | | | | Purchased as Part of
| | | Shares that May Yet Be
| |
| | | Total Number of
| | | Average Price
| | | Publicly Announced Plans
| | | Purchased Under Plans
| |
| | | Shares Purchased | | | Paid per Share | | | or Programs(1) | | | or Programs | |
| | |
| October 2009 | | | – | | | $ | – | | | | 40,940,867 | | | $ | 730,190,146 | |
| November 2009 | | | 3,892,800 | | | | 56.88 | | | | 44,833,667 | | | | 508,750,284 | |
| December 2009 | | | 5,059,981 | | | | 58.82 | | | | 49,893,648 | | | | 211,110,839 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | | 8,952,781 | | | $ | 57.98 | | | | 49,893,648 | | | $ | 211,110,839 | |
| | | | | | | | | | | | | | | | | |
| |
| (1) | Includes repurchases made under expired programs as well as the program announced in April 2008 authorizing $1.25 billion of repurchases through December 31, 2009.2010. |
20
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 6. | | Selected Financial Data |
The financial information for each of the past five years ended December 31 is set forth below (in millions, except per share amounts):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Summary of Operations | | 2008 | | 2007 | | 2006 | | 2005 | | 2004 | | | 2009 | | 2008 | | 2007 | | 2006 | | 2005 | |
| | | | | |
| Net sales | | $ | 4,121.1 | | | $ | 3,897.5 | | | $ | 3,495.4 | | | $ | 3,286.1 | | | $ | 2,980.9 | | | $ | 4,095.4 | | | $ | 4,121.1 | | | $ | 3,897.5 | | | $ | 3,495.4 | | | $ | 3,286.1 | |
| Net earnings | | | 848.6 | | | | 773.2 | | | | 834.5 | | | | 732.5 | | | | 541.8 | | |
| Net earnings of Zimmer Holdings, Inc. | | | | 717.4 | | | | 848.6 | | | | 773.2 | | | | 834.5 | | | | 732.5 | |
| Earnings per common share | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Basic | | $ | 3.73 | | | $ | 3.28 | | | $ | 3.43 | | | $ | 2.96 | | | $ | 2.22 | | | $ | 3.34 | | | $ | 3.73 | | | $ | 3.28 | | | $ | 3.43 | | | $ | 2.96 | |
| Diluted | | | 3.72 | | | | 3.26 | | | | 3.40 | | | | 2.93 | | | | 2.19 | | | | 3.32 | | | | 3.72 | | | | 3.26 | | | | 3.40 | | | | 2.93 | |
| Average common shares outstanding | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Basic | | | 227.3 | | | | 235.5 | | | | 243.0 | | | | 247.1 | | | | 244.4 | | | | 215.0 | | | | 227.3 | | | | 235.5 | | | | 243.0 | | | | 247.1 | |
| Diluted | | | 228.3 | | | | 237.5 | | | | 245.4 | | | | 249.8 | | | | 247.8 | | | | 215.8 | | | | 228.3 | | | | 237.5 | | | | 245.4 | | | | 249.8 | |
Balance Sheet Data | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total assets | | $ | 7,239.0 | | | $ | 6,633.7 | | | $ | 5,974.4 | | | $ | 5,721.9 | | | $ | 5,695.5 | | | $ | 7,785.5 | | | $ | 7,239.0 | | | $ | 6,633.7 | | | $ | 5,974.4 | | | $ | 5,721.9 | |
| Short-term debt | | | – | | | | – | | | | – | | | | – | | | | 27.5 | | |
| Long-term debt | | | 460.1 | | | | 104.3 | | | | 99.6 | | | | 81.6 | | | | 624.0 | | | | 1,127.6 | | | | 460.1 | | | | 104.3 | | | | 99.6 | | | | 81.6 | |
| Other long-term obligations | | | 353.9 | | | | 328.4 | | | | 323.4 | | | | 348.3 | | | | 420.9 | | | | 328.5 | | | | 353.9 | | | | 328.4 | | | | 323.4 | | | | 348.3 | |
| Stockholders’ equity | | | 5,650.3 | | | | 5,449.6 | | | | 4,920.5 | | | | 4,682.8 | | | | 3,942.5 | | | | 5,638.7 | | | | 5,653.9 | | | | 5,452.4 | | | | 4,923.2 | | | | 4,685.1 | |
| |
21
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 7. | | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
The following discussion and analysis should be read in conjunction with the consolidated financial statements and the corresponding notes included elsewhere in thisForm 10-K.
OVERVIEW
We are a global leader in the design, development, manufacture and marketing of orthopaedic andreconstructive implants, dental reconstructive implants, spinal implants, trauma products and related surgical products (sometimes referred to in this report as “OSP”)OSP). We also provide other healthcare related services. Orthopaedic reconstructive implants restore joint function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Dental reconstructive implants restore function and aesthetics in patients who have lost teeth due to trauma or disease. Spinal implants are utilized by orthopaedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities and trauma in all regions of the spine. Trauma products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. OSP include supplies and instruments designed to aid in orthopaedic surgical procedures and post-operation rehabilitation. We have operations in more than 25 countries and market products in more than 100 countries. We manage operations through three reportable geographic segments –— the Americas, Europe and Asia Pacific.
Certain percentages presented in this discussion and analysis are calculated from the underlying whole-dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes. Certain amounts in the 20072008 and 20062007 consolidated financial statements have been reclassified to conform to the 20082009 presentation.
Beginning in 2008,2009, we no longer include our HipsDental product category sales no longer include bone cement and accessory sales, which have been reclassified towithin our OSP and Other productReconstructive products category. Amounts in the years ended December 31, 20072008 and 20062007 related to sales of bone cement and accessoryDental products have been reclassified to conform to the 20082009 presentation.
We believe the following developments or trends are important in understanding our financial condition, results of operations and cash flows for the year ended December 31, 2008.2009.
Demand (Volume and Mix) Trends
Increased volume and changes in the mix of product sales contributed 32 percentage points of 20082009 sales growth, which is 61 percentage pointspoint below the rate of growth from 20072008 compared to 2006. 2007.
We estimate thatbelieve the market for orthopaedic procedure volume markettemporarily decelerated from mid single digit growth raterates to low single digit growth rates on a global basis due to the weakened global economy. We believe long-term market growth rates will be in the mid single digits in the coming years driven by an aging global population, obesity, proven clinical benefits, new material technologies, advances in surgical techniques and more active lifestyles, among other factors. In addition, the continuedongoing shift in demand to premium products, such asLongevity,DurasulandProlongHighly Crosslinked Polyethylenes,Trabecular MetalTechnology products, hip stems withKinectivTechnology, high-flex knees, knee revision products, and porous hip stems continueand the introduction of patient specific devices continues to positively affect sales growth. Our 2008 increase of 32 percentage points of sales growth in 2009 from volume and changes in mix decreased from 20072008 and was lower than market growth due to the factorsimpact of the disruptive events discussed below.
Pricing Trends
Global selling prices decreased 1 percent during 2009 compared to flat pricing in 2008. Selling prices in the Americas decreased 1 percent during the year ended December 31, 2009, compared to flat pricing in the same 2008 period. Europe selling prices were flat during 2008, which is similar to 2007 when compared to 2006. Asia Pacific selling prices decreased 3 percentage points for the year ended December 31, 2009, which is similar to the 2008 period. Asia Pacific selling prices decreased 1 percent for the year ended December 31, 2009, compared to a 13 percent decrease in 2007 when compared to 2006. Japan and Australia reported 4 percent and 3 percent decreases, respectively, in average selling pricesthe same 2008 period, as a resultwe anniversaried out of scheduled reductions in reimbursement prices. Japan and Australia combined represent approximately 10 percent of our sales. Selling prices in the Americas were flat during 2008, compared to a 1 percent increase in 2007. In Europe, selling prices for 2008 were flat, compared to a 1 percent decrease in 2007.Japan. With the effect of governmental healthcare cost containment efforts and continuing pressure from group purchasing organizations,local hospitals and health systems, we expect global selling prices to remain flat in 2009.decrease approximately 1 to 2 percent on a global basis for 2010.
Foreign Currency Exchange Rates
For 2008,2009, foreign currency exchange rates hadresulted in a positive 32 percent effect on global sales growth.decline in sales. If foreign currency exchange rates remain consistent with the2009 year end rates, we estimate that a strongerweaker dollar versus foreign currency exchange rates will have a negativepositive effect in 20092010 of approximately 41 percent on sales. We address currency risk through regular operating and financing activities, and, under appropriate circumstances and subject to proper authorization, through the use of forward contracts and options solely for managing foreign currency volatility and risk. Changes to foreign currency exchange rates affect sales growth, but due to offsetting gains/losses on hedge contracts and options, which are recorded in cost of products sold, the effect on net earnings in the near term is expected to be minimal.
Abbott Spine AcquisitionDisruptive Events
In October 2008, we acquired Abbott Spine, previously a subsidiary of Abbott Laboratories, for approximately $360 million. The purchase price was funded by a combination of cash on hand and borrowings under existing credit facilities. This investment adds a number of innovative products and helps build toward critical mass in the Spine product category. The acquisition also enhances our research and development capabilities in the Spine product category and strengthens our sales coverage. We recorded $48.7 million of acquisition and integration costs in 2008suffered customer losses as a result of this transaction,disruptive factors experienced during 2008, including $38.5 millionthe implementation of in-process research and development expense. For more information regarding the acquisition of Abbott Spine, see Note 4 to the consolidated financial statements included elsewhere in thisForm 10-K.
22
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Compliance-Related Matters
In September 2007, we and other major U.S. orthopaedic manufacturers reached a settlement with the U.S. government to resolve claims related to an investigation into financial relationships between the industry and consulting orthopaedic surgeons. We paid the government $169.5 million and entered into a Deferred Prosecution Agreement (DPA) under which we will remain subject to oversight by a federally-appointed monitor through March 27, 2009.
We also entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the U.S. Department of Health and Human Services, which has a term of 5 years. For more information regarding the settlement, see Note 16 to the consolidated financial statements included elsewhere in thisForm 10-K.
We did not record any tax benefit related to the $169.5 million payment in 2007. During 2008, we reached an agreement with the U.S. Internal Revenue Service confirming the deductibility of a portion of the payment and recorded a current tax benefit of $31.7 million, resulting in a decrease to the current period effective tax rate. For more information regarding the tax treatment of the settlement expense, see Note 12 to the consolidated financial statements included elsewhere in thisForm 10-K.
We have developed and substantially implementedour enhanced global compliance initiatives, which address areas such as product development, marketing, surgeon training and educational and charitable funding. The principles of this program meet or exceed the requirements of the DPA and CIA, as those principles are being applied in most respects to all product segments and reach all worldwide operations. Costs related to the DPA, CIA and the enhanced compliance initiatives in 2008 were approximately $60 million, including the fees incurred for the federally-appointed monitor.
Durom Acetabular Component
In July 2008, we temporarily suspended marketing and distribution of theDurom Acetabular Component (DuromCup) in the U.S. to permit us to update product labeling to provide more detailed surgical technique instructions and implement an enhanced surgical training program in the U.S. We resumed marketing and distribution of theDuromCup in the U.S. in August 2008.
During 2008, we received claims from a number ofDuromCup patients seeking reimbursement for costs and payments for alleged pain and suffering and we expect to receive additional similar claims. We recorded a provision for certain claims of $69.0 million in 2008, which represents management’s estimate of liability to patients undergoing revision surgeries related to theDurom Cup. The estimate is limited to revisions associated with surgeries occurring before July 2008 and within two years of the original surgery date. Any claims received outside of these defined parameters will be managed in the normal course and reflected in our standard product liability accruals.
We believe we lost hip product sales during 2008, in large part as a consequence of the events involving theDuromCup. In addition, we expect that our entry into the U.S. hip resurfacing market has been hindered or delayed as theDuromCup had previously been integral to our plans for entry into that market.
Orthopaedic Surgical Products (OSP) Actions
In the first half of 2008, we initiated voluntary product recalls of certain OSP patient care products manufactured at our Dover, Ohio facility that we determined did not meet internal quality standards and we temporarily suspended production and sales of certain OSP products manufactured at the Dover facility. We estimate that these actions adversely impacted 2008 OSP revenues by approximately $70 million and 2008 diluted earnings per share by $0.18 including related inventory charges, idle plant costs and other non-recurring charges. We expect to have a significant portion of these products back in production in the first quarter of 2009, with most other products coming back into production in the second quarter of 2009.
Impact of Disruptive Events on Market Share
As a result of the disruptive factors discussed above, including our temporary suspension of U.S. marketing and distribution of theDuromCup and our voluntary recall and suspension of production of certain OSP patient care products, and the implementation of our enhanced global compliance initiatives, we have suffered customer losses during 2008.products. We estimate that these customer losses reduced our global knee market share by approximately 1.5 percent and hip market share by 1.5 to 2.0approximately 2 percent as measured from fourth quarter results. We expect ouron a cumulative basis through the end of 2008. These share losses affected sales growth to be at a rate slower than the marketin 2009, especially in the near term duefirst six to these disruptive factors.nine months of the year, but stabilized as we concluded the year.
2009 OutlookGlobal Economic Conditions
We expectbelieve adverse conditions in the broader economy will resulthave resulted in a temporary slowdown in elective hospital procedures. We saw evidence of recovery in 2009, although the large developed countries in Europe appear to be lagging the U.S. and Japan. Although many of our products are used in elective procedures, we believe our core knee and hip franchises remain more insulated than mostmany medical product categories from swings in the broader economy because the need for these procedures does not diminish, even if the timing is affected.
We expect to experience further customer losses in 2009 affecting our knee and hip market share as a result of the ongoing effects of the disruptive factors discussed above. Our assumption is that share loss should stabilize by year-end 2009, as we anniversary out of the majority of the 2008 customer and product-related losses, and as we launch new products in sufficient quantities to recover some of the product-related losses.
Among our other product categories, we expect extremities and trauma sales growth to be in line with market growth rates. We expect dental revenues to reflect the weak economic environment and to underperform relative to market growth rates given company-specific operational challenges. Finally, we expect spine revenues to increase as a result of the Abbott Spine acquisition and reflect sales dis-synergies associated with the ongoing integration of the two businesses.
2322
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
timing is affected. In particular, our dental revenues have experienced pressure due to the weak economic environment as many of those procedures are not reimbursed by third-party payors.
2010 Outlook
In the second half of 2009, our operating expenseswe saw encouraging signs that orthopaedic procedure volumes in certain markets were recovering. Our market assumptions are that in 2010 knee and hip procedures will be impacted by a number of factors, whichgrow in mid single digits within the Americas and Asia Pacific markets, and remain flat to slightly positive in the aggregate arelarge developed markets in Europe. Given the expected pacing of our new product launches, such as theZimmer MMCCup,Continuum Acetabular System andZimmerPatient Specific Instruments, we anticipate our sales growth in 2010 to resultbe greater in a modest net decrease in total expense compared to 2008. the second half of the year.
We expect to realize significant savings from third-party fees related to compliance with the DPA and the implementation of our enhanced compliance initiatives, Durom-related certain claims and acquisition, integration and other expenses. For 2009, however, we intend to partially offset those savings with increased spendingcontinue making investments in areas that suffered disruption in 2008, including product development and medical education. We also continue tostep-up our level of spending on quality systems to achieve our continuous improvement objectivesR&D in the areasrange of design and process control5 to 6 percent of sales. Assuming currency rates remain at year end 2009 levels, we expect our gross margin to be approximately 75 percent of sales in 2010. This takes into account the higher cost inventory we carry into 2010 as well as ongoingprojected foreign currency hedge losses partially offset by lower anticipated excess and obsolete inventory charges in 2010. We expect the gross margin ratio to be slightly lower in the first half of 2010 as compared to the second half of the year. SG&A as a percent of sales is expected to decrease for the full year as we restore leverage from revenue growth offset, in part, by sales and marketing investments in support of new product surveillance.launches. We have completed the infrastructure investment projects in Eschbach, Germany, our automated, centralized distribution facility for the Europe, Middle East and Africa region, and in Shannon, Ireland, our new implant manufacturing facility. Both facilities are now operational and should provide economic benefits for the full year 2010.
We expect interest expense will be unfavorableyear-over-year due to the $1 billion senior notes offering we completed in the fourth quarter of 2009. The impact of this expense on our diluted earnings per share should be more than offset by the additional shares we repurchased with a portion of the proceeds from the notes offering.
RESULTS OF OPERATIONS
Year Ended December 31, 20082009 Compared to Year Ended December 31, 20072008
| |
| | Net Sales by OperatingReportable Segment |
The following table presents net sales by operatingreportable segment and the components of the percentage changes (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | Volume/
| | | | Foreign
| | | Year Ended December 31, | | | | Volume/
| | | | Foreign
| |
| | | 2008 | | 2007 | | % Inc | | Mix | | Price | | Exchange | | | 2009 | | 2008 | | % Inc/(Dec) | | Mix | | Price | | Exchange | |
| | | | | |
| |
| Americas | | $ | 2,353.9 | | | $ | 2,277.0 | | | | 3 | % | | | 3 | % | | | – | % | | | – | % | | $ | 2,372.4 | | | $ | 2,353.9 | | | | 1 | % | | | 2 | % | | | (1 | )% | | | – | % |
| Europe | | | 1,179.1 | | | | 1,081.0 | | | | 9 | | | | 4 | | | | – | | | | 5 | | | | 1,119.2 | | | | 1,179.1 | | | | (5 | ) | | | 1 | | | | – | | | | (6 | ) |
| Asia Pacific | | | 588.1 | | | | 539.5 | | | | 9 | | | | 5 | | | | (3 | ) | | | 7 | | | | 603.8 | | | | 588.1 | | | | 3 | | | | 1 | | | | (1 | ) | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 4,121.1 | | | $ | 3,897.5 | | | | 6 | | | | 3 | | | | – | | | | 3 | | | $ | 4,095.4 | | | $ | 4,121.1 | | | | (1 | ) | | | 2 | | | | (1 | ) | | | (2 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
“Foreign Exchange” as used in the tables in this report represents the effect of changes in foreign currency exchange rates on sales growth.
| |
| | Net Sales by Product Category |
The following table presents net sales by product category and the components of the percentage changes (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | Volume/
| | | | Foreign
| | | Year Ended December 31, | | | | Volume/
| | | | Foreign
| |
| | | 2008 | | 2007 | | % Inc (Dec) | | Mix | | Price | | Exchange | | | 2009 | | 2008 | | % Inc (Dec) | | Mix | | Price | | Exchange | |
| | | | | |
| |
| Reconstructive | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Knees | | $ | 1,763.0 | | | $ | 1,634.6 | | | | 8 | % | | | 7 | % | | | (1 | )% | | | 2 | % | | $ | 1,760.6 | | | $ | 1,763.1 | | | | – | % | | | 3 | % | | | (1 | )% | | | (2 | )% |
| Hips | | | 1,279.5 | | | | 1,221.4 | | | | 5 | | | | 2 | | | | (1 | ) | | | 4 | | | | 1,228.5 | | | | 1,279.4 | | | | (4 | ) | | | (1 | ) | | | (1 | ) | | | (2 | ) |
| Extremities | | | 121.0 | | | | 104.0 | | | | 16 | | | | 14 | | | | 1 | | | | 1 | | | | 135.6 | | | | 121.0 | | | | 12 | | | | 14 | | | | – | | | | (2 | ) |
| Dental | | | 227.5 | | | | 221.0 | | | | 3 | | | | – | | | | 1 | | | | 2 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
| Total | | | 3,391.0 | | | | 3,181.0 | | | | 7 | | | | 5 | | | | (1 | ) | | | 3 | | | | 3,124.7 | | | | 3,163.5 | | | | (1 | ) | | | 1 | | | | (1 | ) | | | (1 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
| Dental | | | | 204.7 | | | | 227.5 | | | | (10 | ) | | | (9 | ) | | | 1 | | | | (2 | ) |
| Trauma | | | 221.4 | | | | 205.8 | | | | 8 | | | | 4 | | | | 1 | | | | 3 | | | | 234.8 | | | | 222.3 | | | | 6 | | | | 5 | | | | 1 | | | | – | |
| Spine | | | 230.6 | | | | 197.0 | | | | 17 | | | | 14 | | | | 2 | | | | 1 | | | | 253.6 | | | | 229.7 | | | | 10 | | | | 12 | | | | – | | | | (2 | ) |
| OSP and other | | | 278.1 | | | | 313.7 | | | | (11 | ) | | | (14 | ) | | | – | | | | 3 | | | | 277.6 | | | | 278.1 | | | | – | | | | (1 | ) | | | 1 | | | | – | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 4,121.1 | | | $ | 3,897.5 | | | | 6 | | | | 3 | | | | – | | | | 3 | | | $ | 4,095.4 | | | $ | 4,121.1 | | | | (1 | ) | | | 2 | | | | (1 | ) | | | (2 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
23
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
The following table presents net sales by product category by region (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2009 | | | 2008 | | | % Inc (Dec) | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | | | | | | | | | | | |
Americas | | $ | 1,101.9 | | | $ | 1,089.8 | | | | 1 | |
Europe | | | 429.2 | | | | 452.6 | | | | (5 | ) |
Asia Pacific | | | 229.5 | | | | 220.7 | | | | 4 | |
| Hips | | | | | | | | | | | | |
Americas | | | 565.9 | | | | 576.1 | | | | (2 | ) |
Europe | | | 448.6 | | | | 493.9 | | | | (9 | ) |
Asia Pacific | | | 214.0 | | | | 209.4 | | | | 2 | |
| Extremities | | | | | | | | | | | | |
Americas | | | 103.7 | | | | 88.1 | | | | 18 | |
Europe | | | 23.9 | | | | 25.8 | | | | (7 | ) |
Asia Pacific | | | 8.0 | | | | 7.1 | | | | 15 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 3,124.7 | | | | 3,163.5 | | | | (1 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Dental | | | | | | | | | | | | |
Americas | | | 102.8 | | | | 114.9 | | | | (11 | ) |
Europe | | | 78.2 | | | | 82.2 | | | | (5 | ) |
Asia Pacific | | | 23.7 | | | | 30.4 | | | | (22 | ) |
| Trauma | | | | | | | | | | | | |
Americas | | | 125.9 | | | | 126.7 | | | | (1 | ) |
Europe | | | 52.7 | | | | 47.4 | | | | 11 | |
Asia Pacific | | | 56.2 | | | | 48.2 | | | | 17 | |
| Spine | | | | | | | | | | | | |
Americas | | | 192.6 | | | | 180.4 | | | | 7 | |
Europe | | | 46.9 | | | | 40.1 | | | | 17 | |
Asia Pacific | | | 14.1 | | | | 9.2 | | | | 54 | |
| OSP and other | | | | | | | | | | | | |
Americas | | | 179.6 | | | | 177.9 | | | | 1 | |
Europe | | | 39.7 | | | | 37.1 | | | | 7 | |
Asia Pacific | | | 58.3 | | | | 63.1 | | | | (8 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 4,095.4 | | | $ | 4,121.1 | | | | (1 | ) |
| | | | | | | | | |
| | | | | | | | | |
TheNexGenComplete Knee Solution product line, includingGender SolutionsKnee Femoral Implants, theNexGenLPS-Flex Knee, theNexGenCR-Flex Knee and theNexGenLCCK Revision Knee, led knee sales. In addition, theZimmer Unicompartmental High-Flex Knee and theGender Solutions Natural-KneeFlex System exhibitedmade a strong growth.contribution. In Europe, changes in foreign currency exchange rates negatively affected knee sales by 6 percent.
The continued conversion to porous stems, including theZimmerM/L Taper Stem, theZimmerM/L Taper Stem withKinectivTechnology, theCLS SpotornoStem from theCLSHip System,and theAlloclassic ZweymüllerHip Stem, led hip stem sales, but wasthose sales were partially offset by weaker sales of cemented stems.Trabecular MetalAcetabular Cups andLongevityandDurasulHighly Crosslinked Polyethylene Liners also made strong contributions. In the U.S. hip market, we had strongsome product gaps related to our acetabular cups which have affected sales growth. The temporary suspensionThis was most noticeable in the area of marketingmetal-on-metal articulation. In November 2009, theContinuum Acetabular System and distribution of theDuromZimmer MMCCup were cleared for sale in the U.S. These systems give surgeons a comprehensive array of acetabular cup solutions that, in concert with our comprehensive stem portfolio, provide additional patient matching options. These cups have also received approval in various countries outside the U.S. and will help complete our product portfolios in those countries as well. In Europe, changes in foreign currency exchange rates negatively impactedaffected hip sales growth. Additionally, with the lack of a hip resurfacing product within our U.S. hip portfolio, we expect to face a continuing challengeby 6 percent. In Asia Pacific, changes in foreign currency exchange rates positively affected hip sales growth with the adoption of hip resurfacing in the U.S. market.by 4 percent.
As a result of the disruptive factors discussed above, we suffered customer losses during 2008. We estimate that these customer losses reduced our knee and hip market share by 1.5 to 2.0 percent as measured from fourth quarter results. We expect to experience further customer losses in 2009 as a result of the ongoing effects of these disruptive factors.
TheBigliani/FlatowComplete Shoulder Solution and theZimmer Trabecular MetalReverse Shoulder System led extremities sales. Orthobiologicals and prosthetic implants, including strong growth ofTrabecular MetalTechnology is playing a critical role in addressing previously unmet clinical needs in the expanding extremities market.
TheTapered Screw-VentImplant System led dental sales. Negative sales growth for our dental business reflects overall weakness in the global economy. We continue to believe the dental market will rebound as the global economy recovers and look forward to new opportunities as our product line is expanded through internal and external development efforts.
ZimmerPeriarticular Locking Plates and theI.T.S.T.ITST Intertrochanteric/Subtrochanteric Fixation System led trauma sales. Thesales but were partially offset by declining sales of compression hip screws. Femoral and tibial nails within the newZimmer Natural Nailsystem also made a contribution during the year.
In the fourth quarter of 2008, we acquired Abbott Spine. As a result of the acquisition, spine sales have increased but the increase is offset in part by sales losses associated with the integration of the business. Solid sales of acquired fusion devices as well as legacy interbody devices and bone graft substitutes partly offset a significant decline in sales of theDynesysDynamic Stabilization System during the year. We expect our spinal business will continue to experience reimbursement challenges related to theDynesys Dynamic Stabilizationsystem. Following the November 2009 non-approvable recommendation by the FDA advisory panel of our request for additional approved uses for theDynesys system, we are exploring our options, which are presently uncertain. We believe that we generally have a solid portfolio of spine products as well as broad global distribution capabilities that should lead to improved performance over time.
OSP sales were led byPALACOSBone Cement. OSP product sales growth improved in the second half of 2009 due to the effect of anniversarying out of the voluntary suspension and recall of certain products during 2008 and by the reintroduction of wound debridement products in 2009.
24
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
System and theTrinicaSelect Anterior Cervical Plate System led spine sales, which also reflect an increase as a result of the Abbott Spine acquisition. OSP sales were negatively affected by the patient care product recalls and related voluntary suspension of production of certain products, but these negative factors were partially offset by strong growth inPALACOSBone Cement.
The following table presents estimated* 20082009 global market size and market share information (dollars in billions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Global
| | | | Zimmer
| | Zimmer
| | | Global
| | | | Zimmer
| | Zimmer
| |
| | | Market
| | Global Market
| | Market
| | Market
| | | Market
| | Global Market
| | Market
| | Market
| |
| | | Size | | % Growth** | | Share | | Position | | | Size | | % Growth** | | Share | | Position | |
| | | | | |
| |
| Reconstructive | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Knees | | $ | 6.4 | | | | 8 | % | | | 27 | % | | | 1 | | | $ | 6.4 | | | | 5 | % | | | 27 | % | | | 1 | |
| Hips | | | 5.7 | | | | 6 | | | | 22 | | | | 1 | | | | 5.8 | | | | 4 | | | | 21 | | | | 2 | |
| Extremities | | | 0.8 | | | | 13 | | | | 14 | | | | 3 | | | | 1.0 | | | | 15 | | | | 13 | | | | 3 | |
| Dental | | | 3.2 | | | | 7 | | | | 7 | | | | 4 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | |
| Total | | $ | 16.1 | | | | 7 | | | | 21 | | | | 1 | | | $ | 13.2 | | | | 5 | | | | 24 | | | | 1 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | |
| Dental | | | $ | 3.3 | | | | (5 | ) | | | 6 | | | | 5 | |
| Trauma | | $ | 4.1 | | | | 10 | | | | 5 | | | | 5 | | | $ | 4.4 | | | | 6 | | | | 5 | | | | 5 | |
| Spine*** | | $ | 6.8 | | | | 10 | | | | 3 | | | | 5 | | | $ | 8.7 | | | | 10 | | | | 3 | | | | 6 | |
| |
| * | Estimates are not precise and are based on competitor annual filings, Wall Street equity research and Company estimates |
| |
| ** | Excludes the effect of changes in foreign currency exchange rates on sales growth |
| |
| *** | Spine includes related orthobiologics |
| |
| | AmericasExpenses as a Percent of Net Sales |
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2009 | | | 2008 | | | Inc (Dec) | |
| | |
| |
| Cost of products sold | | | 24.2 | % | | | 24.2 | % | | | – | |
| Research and development | | | 5.0 | | | | 4.7 | | | | 0.3 | |
| Selling, general and administrative | | | 42.2 | | | | 41.3 | | | | 0.9 | |
| Certain claims | | | 0.9 | | | | 1.7 | | | | (0.8 | ) |
| Goodwill impairment | | | 1.8 | | | | – | | | | 1.8 | |
| Acquisition, integration, realignment and other | | | 1.8 | | | | 1.6 | | | | 0.2 | |
| Net curtailment and settlement | | | (0.8 | ) | | | – | | | | (0.8 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Operating expenses | | | 50.9 | | | | 49.3 | | | | 1.6 | |
| | | | | | | | | |
| | | | | | | | | |
| Operating profit | | | 24.9 | | | | 26.5 | | | | (1.6 | ) |
| Interest and other income (expense), net | | | (0.5 | ) | | | 0.8 | | | | 1.3 | |
Gross margin in 2009 was unchanged compared to 2008. Manufacturing costs per unit increased in 2009 due to lower production levels. Excess inventory and obsolescence charges increased in 2009 as a result of certain product-specific matters and new product launches. These costs were offset by foreign currency hedge gains recognized in the 2009 period compared to hedge losses recognized in 2008.
Under our hedging program, for derivatives which qualify as hedges of future cash flows, the effective portion of changes in fair value is temporarily recorded in other comprehensive income and then recognized in cost of products sold when the hedged item affects earnings.
The following table reconciles the gross margin for 2008 to 2009:
| | | | |
| Year ended December 31, 2008 gross margin | | | 75.8 | % |
| Increased unit manufacturing costs | | | (1.7 | ) |
| Excess and obsolete inventory | | | (0.4 | ) |
| Foreign currency exchange impact, net | | | 2.0 | |
| Other | | | 0.1 | |
|
|
| Year ended December 31, 2009 gross margin | | | 75.8 | % |
|
|
Research and development expense, or R&D, increased to $205.4 million in 2009 from $192.3 million in 2008. This increase reflects additional spending on certain development, clinical and external research activities throughout 2009 in contrast to the delay in activities experienced in 2008 as we implemented our enhanced compliance program.
Selling, general and administrative expense, or SG&A, increased to $1,729.2 million in 2009, from $1,704.0 million in 2008. This is an increase of approximately 90 basis points compared to the prior year. SG&A expense in the 2008 period included approximately $60 million of incremental costs, such as monitor fees and consulting and legal fees associated with the global roll-out of our enhanced compliance program. The savings from these costs in 2009 have been offset by increased spending to fund enhanced medical education programs, Abbott Spine costs and increased product liability claims. In this challenging economic environment, we are carefully managing our SG&A spend, reducing expenses in certain areas in order to fund growth and productivity initiatives. Areas of investment include marketing and promotion and medical education and training. The acquisition of Abbott Spine increased SG&A costs for items such as selling expenses, increased instrument depreciation and amortization of the acquired intangible assets. Additionally, SG&A as a percentage of net sales is negatively impacted by the decrease in revenues caused by changes in foreign currency rates. A majority of our SG&A spend is incurred in the U.S., primarily from our corporate headquarters and similar functions at our various businesses such as Dental, Trauma, Spine and OSP. Therefore, SG&A expense does not respond to changes in foreign currency rates proportionally to our revenue, which has caused SG&A as a percentage of net sales to increase.
Certain claims expense is a provision for estimatedDuromCup patients undergoing revision surgeries within specified times. A provision of $69.0 million was originally recorded during 2008 with an additional $35.0 million recorded during 2009, bringing the total provision to $104.0 million for these claims. For more information regarding these claims, see Note 17 to the consolidated financial statements.
In connection with our annual goodwill impairment test performed in the fourth quarter of 2009, we noted that the carrying value of the assets of our U.S. Spine reporting unit was in excess of its estimated fair value. As a result, we recorded a related goodwill impairment charge of $73.0 million during the year ended December 31, 2009. For more information regarding goodwill impairment and the factors that led to the impairment, see Note 8 to the consolidated financial statements. We have five other reporting units with goodwill assigned to them. We estimate the fair value of those reporting units using the income approach by discounting to present value the estimated future cash flows of the reporting unit. For each of those five reporting units, the estimated fair value substantially exceeds its carrying value.
25
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Acquisition, integration, realignment and other expenses for 2009 were $75.3 million compared to $68.5 million in 2008. During 2009, we initiated a workforce realignment, which included the elimination of positions in some areas and increases in others to support long-term growth. As a result of this realignment and headcount reductions from acquisitions, we incurred approximately $19.0 million of severance and termination-related expenses. Other items in acquisition, integration, realignment and other expenses in 2009 included approximately $9.4 million of expenses related to contract termination costs, $23.4 million of certain litigation matters that were recognized during the period and various costs incurred to integrate the Abbott Spine business acquired in the fourth quarter of 2008. Included in acquisition, integration, realignment and other expenses in 2008 was $38.5 million of in-process research and development related to the Abbott Spine acquisition and other costs related to the integration of Abbott Spine. See Note 2 to the consolidated financial statements for a more complete description of these charges.
We recognized a net curtailment and settlement gain of $32.1 million during 2009 related to amending our U.S. and Puerto Rico postretirement benefit plans. For more information regarding the net curtailment and settlement gain, see Note 12 to the consolidated financial statements.
| |
| Operating Profit, Income Taxes and Net Earnings |
Operating profit for 2009 decreased 7 percent to $1,018.8 million from $1,090.0 million in 2008. The decrease in operating profit is due to higher operating expenses, most notably the goodwill impairment charge.
Interest and other expense for 2009 increased to $20.6 million compared to income of $31.8 million in 2008. Interest and other income in 2008 included a realized gain of $38.8 million related to the sale of certain marketable securities. Interest expense increased in the 2009 period as the result of increased long-term debt used to partially fund the Abbott Spine acquisition and the $1.0 billion senior notes offering during 2009.
The effective tax rate on earnings before income taxes increased to 28.1 percent for 2009, up from 24.3 percent in 2008. The effective tax rate for 2009 is negatively impacted by the goodwill impairment charge of $73.0 million recorded during 2009 for which no tax benefit was recorded. The effective tax rate for 2008 includes the impact of a current tax benefit of $31.7 million related to the 2007 settlement expense, resulting in a decrease of approximately 3 percent in the 2008 effective tax rate. This impact on the 2008 effective tax rate was partially offset by Abbott Spine acquisition-related in-process research and development charges recorded during 2008 for which no tax benefit was recorded. These discrete items account for the majority of the change in our effective tax rateyear-over-year.
Net earnings decreased 15 percent to $717.4 million for 2009, compared to $848.6 million in 2008, as a result of decreased operating profit, increased interest expense and an increased effective tax rate. Basic earnings per share in 2009 decreased 10 percent to $3.34 from $3.73 in 2008. Diluted earnings per share decreased 11 percent to $3.32 from $3.72 in 2008. The disproportional change in earnings per share as compared to net earnings is attributed to the effect of 2009 and 2008 share repurchases.
Year Ended December 31, 2008 Compared to Year Ended December 31, 2007
| |
| Net Sales by Reportable Segment |
The following table presents Americas net sales by reportable segment and the components of the percentage changes (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2008 | | | 2007 | | | % Inc (Dec) | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | $ | 1,089.8 | | | $ | 1,029.8 | | | | 6 | % |
| Hips | | | 576.1 | | | | 568.3 | | | | 1 | |
| Extremities | | | 88.1 | | | | 73.9 | | | | 19 | |
| Dental | | | 114.9 | | | | 118.9 | | | | (3 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 1,868.9 | | | | 1,790.9 | | | | 4 | |
| | | | | | | | | |
| | | | | | | | | |
| Trauma | | | 125.8 | | | | 122.9 | | | | 2 | |
| Spine | | | 181.3 | | | | 160.3 | | | | 13 | |
| OSP and other | | | 177.9 | | | | 202.9 | | | | (12 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 2,353.9 | | | $ | 2,277.0 | | | | 3 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | | | Volume/
| | | | | | Foreign
| |
| | | 2008 | | | 2007 | | | % Inc | | | Mix | | | Price | | | Exchange | |
| | |
| |
| Americas | | $ | 2,353.9 | | | $ | 2,277.0 | | | | 3 | % | | | 3 | % | | | – | % | | | – | % |
| Europe | | | 1,179.1 | | | | 1,081.0 | | | | 9 | | | | 4 | | | | – | | | | 5 | |
| Asia Pacific | | | 588.1 | | | | 539.5 | | | | 9 | | | | 5 | | | | (3 | ) | | | 7 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Total | | $ | 4,121.1 | | | $ | 3,897.5 | | | | 6 | | | | 3 | | | | – | | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
26
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
| |
| Net Sales by Product Category |
The following table presents net sales by product category and the components of the percentage changes (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | | | Volume/
| | | | | | Foreign
| |
| | | 2008 | | | 2007 | | | % Inc (Dec) | | | Mix | | | Price | | | Exchange | |
| | |
| |
| Reconstructive | | | | | | | | | | | | | | | | | | | | | | | | |
| Knees | | $ | 1,763.1 | | | $ | 1,634.6 | | | | 8 | % | | | 7 | % | | | (1 | )% | | | 2 | % |
| Hips | | | 1,279.4 | | | | 1,221.4 | | | | 5 | | | | 2 | | | | (1 | ) | | | 4 | |
| Extremities | | | 121.0 | | | | 104.0 | | | | 16 | | | | 14 | | | | 1 | | | | 1 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Total | | | 3,163.5 | | | | 2,960.0 | | | | 7 | | | | 5 | | | | (1 | ) | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Dental | | | 227.5 | | | | 221.0 | | | | 3 | | | | – | | | | 1 | | | | 2 | |
| Trauma | | | 222.3 | | | | 205.8 | | | | 8 | | | | 4 | | | | 1 | | | | 3 | |
| Spine | | | 229.7 | | | | 197.0 | | | | 17 | | | | 14 | | | | 2 | | | | 1 | |
| OSP and other | | | 278.1 | | | | 313.7 | | | | (11 | ) | | | (14 | ) | | | – | | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Total | | $ | 4,121.1 | | | $ | 3,897.5 | | | | 6 | | | | 3 | | | | – | | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
The following table presents net sales by product category by region (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2008 | | | 2007 | | | % Inc (Dec) | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | | | | | | | | | | | |
Americas | | $ | 1,089.8 | | | $ | 1,029.8 | | | | 6 | % |
Europe | | | 452.6 | | | | 407.8 | | | | 11 | |
Asia Pacific | | | 220.7 | | | | 197.0 | | | | 12 | |
| Hips | | | | | | | | | | | | |
Americas | | | 576.1 | | | | 568.3 | | | | 1 | |
Europe | | | 493.9 | | | | 459.9 | | | | 7 | |
Asia Pacific | | | 209.4 | | | | 193.2 | | | | 8 | |
| Extremities | | | | | | | | | | | | |
Americas | | | 88.1 | | | | 73.9 | | | | 19 | |
Europe | | | 25.8 | | | | 23.2 | | | | 11 | |
Asia Pacific | | | 7.1 | | | | 6.9 | | | | 3 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 3,163.5 | | | | 2,960.0 | | | | 7 | |
| | | | | | | | | |
| | | | | | | | | |
| Dental | | | | | | | | | | | | |
Americas | | | 114.9 | | | | 118.9 | | | | (3 | ) |
Europe | | | 82.2 | | | | 71.3 | | | | 15 | |
Asia Pacific | | | 30.4 | | | | 30.8 | | | | (1 | ) |
| Trauma | | | | | | | | | | | | |
Americas | | | 126.7 | | | | 122.9 | | | | 2 | |
Europe | | | 47.4 | | | | 41.1 | | | | 16 | |
Asia Pacific | | | 48.2 | | | | 41.8 | | | | 15 | |
| Spine | | | | | | | | | | | | |
Americas | | | 180.4 | | | | 160.3 | | | | 13 | |
Europe | | | 40.1 | | | | 31.2 | | | | 29 | |
Asia Pacific | | | 9.2 | | | | 5.5 | | | | 65 | |
| OSP and other | | | | | | | | | | | | |
Americas | | | 177.9 | | | | 202.9 | | | | (12 | ) |
Europe | | | 37.1 | | | | 46.5 | | | | (20 | ) |
Asia Pacific | | | 63.1 | | | | 64.3 | | | | (2 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 4,121.1 | | | $ | 3,897.5 | | | | 6 | |
| | | | | | | | | |
| | | | | | | | | |
TheNexGenComplete Knee Solution product line, including theGender SolutionsKnee Femoral Implants, theNexGenLPS-Flex Knee, theNexGenLCCK RevisionCR-Flex Knee and theNexGenCR-FlexLCCK Revision Knee, led knee sales. TheIn addition, theZimmerUnicompartmental High-Flex Knee and theGender Solutions Natural-KneeFlex System also made aexhibited strong contribution.growth. Changes in foreign currency exchange rates positively affected knee sales by 5 percent in Europe and by 6 percent in Asia Pacific.
Growth inThe continued conversion to porous stems, including growth of theZimmerM/L Taper Stem, and theZimmerM/L Taper Stem withKinectivTechnology, theCLS SpotornoStem from theCLSHip System and theAlloclassic ZweymüllerHip Stem, led hip stem sales, but wasthose sales were partially offset by weaker sales of cemented stems.Trabecular Metal Acetabular Cups andLongevityHighly Crosslinked Polyethylene Liners also made ahad strong contribution. As noted above, thegrowth. The temporary suspension of marketing and distribution of theDuromCup in the U.S. will continue to negatively impactimpacted hip sales and we also expect that the adoption of hip resurfacinggrowth. Changes in the U.S. market will continue to adversely affect ourforeign currency exchange rates positively affected hip sales growth.by 5 percent in Europe and by 8 percent in Asia Pacific.
As a result of the disruptive factors discussed above, we suffered customer losses during 2008. These customer losses negatively impacted sales growth, primarily in the knee and hip product segments. We expect to experience further customer losses in 2009 as a result of the ongoing effects of these disruptive factors.
TheBigliani/FlatowComplete Shoulder Solution and theZimmer Trabecular MetalReverse Shoulder System led extremities sales. Negative sales
Orthobiologicals and prosthetic implants, including strong growth for ourof theTapered Screw-VentImplant System, led dental business reflects disruptions caused by the implementation of our enhanced compliance initiatives and overall weakness in the U.S. economy.sales.
ZimmerPeriarticular Locking Plates and theI.T.S.T.ITSTIntertrochanteric/Subtrochanteric Fixation System led trauma sales.
TheDynesysDynamic Stabilization System and theTrinicaSelect Anterior Cervical Plate System led spine sales, which also reflect an increase as a result of the Abbott Spine acquisition.
OSP sales were negatively affected by the patient care product recalls and related voluntary suspension of production of certain products, but these negative factors
27
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
were partially offset by strong growth inPALACOSBone Cement.
| |
| | EuropeExpenses as a Percent of Net Sales |
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2008 | | | 2007 | | | Inc (Dec) | |
| | |
| |
| Cost of products sold | | | 24.2 | % | | | 22.5 | % | | | 1.7 | |
| Research and development | | | 4.7 | | | | 4.7 | | | | – | |
| Selling, general and administrative | | | 41.3 | | | | 38.9 | | | | 2.4 | |
| Settlement | | | – | | | | 4.4 | | | | (4.4 | ) |
| Certain claims | | | 1.7 | | | | – | | | | 1.7 | |
| Acquisition, integration, realignment and other | | | 1.6 | | | | 0.6 | | | | 1.0 | |
| | | | | | | | | |
| | | | | | | | | |
| Operating expenses | | | 49.3 | | | | 48.6 | | | | 0.7 | |
| | | | | | | | | |
| | | | | | | | | |
| Operating profit | | | 26.5 | | | | 28.9 | | | | (2.4 | ) |
| Interest and other income, net | | | 0.8 | | | | 0.1 | | | | 0.7 | |
The following table presents Europe net sales (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2008 | | | 2007 | | | % Inc (Dec) | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | $ | 452.6 | | | $ | 407.8 | | | | 11 | % |
| Hips | | | 493.9 | | | | 459.9 | | | | 7 | |
| Extremities | | | 25.8 | | | | 23.2 | | | | 11 | |
| Dental | | | 82.2 | | | | 71.3 | | | | 15 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 1,054.5 | | | | 962.2 | | | | 10 | |
| | | | | | | | | |
| | | | | | | | | |
| Trauma | | | 47.4 | | | | 41.1 | | | | 16 | |
| Spine | | | 40.1 | | | | 31.2 | | | | 29 | |
| OSP and other | | | 37.1 | | | | 46.5 | | | | (20 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 1,179.1 | | | $ | 1,081.0 | | | | 9 | |
| | | | | | | | | |
| | | | | | | | | |
Changes in foreign exchange rates positively affected both knee and hip sales by 5 percent. TheNexGenComplete Knee Solution product line, including theNexGenLPS-Flex Knee, theNexGenLCCK Revision Knee and theNexGenCR-Flex Knee, led knee sales in our Europe region.
Growth in porous stems, including theCLS SpotornoStem, led hip stem sales.LongevityandDurasulHighly Crosslinked Polyethylene Liners,Trabecular Metal Acetabular Cups and theAllofit®Hip Acetabular System also contributed to hip sales.
As a result of the disruptive factors discussed above, we suffered customer losses during 2008. These customer losses negatively impacted sales growth, primarily in the knee and hip product segments. We expect to experience further customer losses in 2009 as a result of the ongoing effects of these disruptive factors.
TheAnatomical ShoulderSystem and the Coonrad/Morrey Total Elbow led extremities sales. TheTapered Screw-VentImplant System led dental sales. TheCable-Ready®Cable Grip System and theNCBPlating System led
25
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
trauma sales, which were offset by weaker sales of our intramedullary fixation systems. TheDynesysDynamic Stabilization System and theOptimatm5 ZS Spinal Fixation System led spine sales. OSP sales were negatively affected by the patient care product recalls and related voluntary suspension of production of certain products.
The following table presents Asia Pacific net sales (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2008 | | | 2007 | | | % Inc (Dec) | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | $ | 220.6 | | | $ | 197.0 | | | | 12 | % |
| Hips | | | 209.5 | | | | 193.2 | | | | 8 | |
| Extremities | | | 7.1 | | | | 6.9 | | | | 3 | |
| Dental | | | 30.4 | | | | 30.8 | | | | (1 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 467.6 | | | | 427.9 | | | | 9 | |
| | | | | | | | | |
| | | | | | | | | |
| Trauma | | | 48.2 | | | | 41.8 | | | | 15 | |
| Spine | | | 9.2 | | | | 5.5 | | | | 65 | |
| OSP and other | | | 63.1 | | | | 64.3 | | | | (2 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 588.1 | | | $ | 539.5 | | | | 9 | |
| | | | | | | | | |
| | | | | | | | | |
Changes in foreign exchange rates positively affected knee sales by 6 percent and hip sales by 8 percent. Reported decreases in average selling prices negatively affected both knee and hip sales by 4 percent. TheNexGenComplete Knee Solution product line, theNexGenCR-Flex Knee and theNexGenLPS-Flex Knee led knee sales. TheGender SolutionsKnee Femoral Implant also made strong contributions to knee sales for the period.
The continued conversion to porous stems, including the Fiber Metal Taper Stem from theVerSysHip System, theAlloclassic ZweymüllerHip System and theCLS SpotornoStem, led hip stem sales. Sales ofLongevityandDurasulHighly Crosslinked Polyethylene Liners, theTrilogyAcetabular System andTrabecular MetalAcetabular Cups also increased.
As a result of the disruptive factors discussed above, we suffered customer losses during 2008. These customer losses negatively impacted sales growth, primarily in the knee and hip product segments. We expect to experience further customer losses in 2009 as a result of the ongoing effects of these disruptive factors.
TheBigliani/FlatowShoulder Solution and the Coonrad/Morrey Total Elbow led extremities sales. TheTapered Screw-VentImplant System led dental sales. Trauma sales were led by theI.T.S.T.Intertrochanteric/Subtrochanteric Fixation System. TheDynesysDynamic Stabilization System led spine sales. OSP sales were negatively affected by the patient care product recalls and related voluntary suspension of production of certain products.
| |
| Gross ProfitCost of Products Sold |
Gross profitmargin decreased in 2008 primarily due to the unfavorable effect ofyear-over-year changes in foreign currency hedge gains and losses as well as an increase in excess inventory and obsolescence charges due to write-offs related to the OSP patient care product recalls and increased inventory levels as a percentageresult of net sales was 75.8 percent inlower than forecasted sales. Inventorystep-up related to the completion of the Abbott Spine acquisition during 2008 compared to 77.5 percent in 2007. also had an unfavorable impact on gross margin.
The following table reconciles the gross margin for 2007 to 2008:
| | | | | |
| Year ended December 31, 2007 gross margin | | | 77.5 | % |
| Foreign currency exchange impact, net | | | (0.8 | ) |
| Excess and obsolete inventory | | | (0.6 | ) |
Inventorystep-up | | | (0.2 | ) |
| Other | | | (0.1 | ) |
| |
| |
| Year ended December 31, 2008 gross margin | | | 75.8 | % |
| |
| |
Gross margin decreased in 2008 primarily due to the unfavorable effect of year-over-year changes in foreign currency hedge gains and losses as well as an increase in excess inventory and obsolescence charges due to write-offs related to the OSP patient care product recalls and increased inventory levels as a result of lower than forecasted sales. Inventorystep-up related to the completion of the Abbott Spine acquisition during 2008 also had an unfavorable impact on gross margin.
Research and Development, or R&D as a percentage of net sales was 4.7 percent for 2008, comparedincreased to 5.4 percent in 2007. R&D decreased to $194.0$192.3 million for 2008 from $209.6$182.6 million in 2007 reflecting decreased spending on certain development, clinical and external research activities due to delays connected with our operational compliance with the DPA and CIA and implementation of our enhanced compliance and ethics initiatives. We do not expect delays with our development programs in 2009 and therefore our R&D expensebut remained unchanged as a percentagepercent of revenue is expectedtotal sales. Theyear-over-year increase represents our continued investment in R&D to return to historical levels of 5 to 6 percent.grow at or above sales growth.
Selling, general and administrative, or SG&A, as a percentage of net sales was 41.3 percent for 2008, compared to 38.2 percent in 2007. SG&A expense increased to $1,702.3$1,704.0 million for 2008 from $1,489.7$1,516.7 million in 2007. Increased SG&A costs include monitor fees paid as part of our 2007 civil settlement with the U.S. government regarding financial relationships with consulting orthopaedic surgeons, as well as consulting and legal fees associated with the global implementation of our enhanced compliance initiatives. Expenses related to other operating initiatives also caused an increase in SG&A as a percentage of net sales. Such operating initiatives include the planned implementation of a global IT system and improving quality systems at our Dover facility. Additionally, selling costs increased as a result of the ORTHOsoft acquisition, an increase in the headcount of our sales force in certain locations, increased commission incentives to sell certain key products and a change in the mix of commissions earned as a result of lower OSP sales.
Settlement expense of $169.5 million for 2007 relates to the settlementpayment we made as part of the federal investigation into financial relationships between major orthopaedic manufacturers and consulting orthopaedic surgeons.2007 civil settlement.
5 Trademark of U & i Corporation
26
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Certain claims expense of $69.0 million is a provision for estimated claims fromDuromCup patients undergoing revision surgeries within specified periods. For more information regarding these claims, see Note 17 to the consolidated financial statements.
Acquisition, integration and other expenses increased to $68.5 million for 2008, compared to $25.2 million in 2007. The acquisition, integration and other expenses recorded during 2008 include $38.5 million for in-process research and development related to the Abbott Spine acquisition, costs related to the integration of Abbott Spine, facility consolidation costs, legal fees and retention and termination payments, partially offset by favorable adjustments to certain liabilities of acquired companies. The acquisition, integration and other expenses recorded during 2007 reflect in-process research and development write-offs related to acquisitions, costs related to the integration of acquired U.S. distributors, estimated settlements for certain pre-acquisition product liability claims, integration consulting fees and costs for integrating information technology systems. See Note 2 to the consolidated financial statements for a more complete description of these charges.
| |
| | Operating Profit, Income Taxes and Net Earnings |
Operating profit for 2008 decreased 3 percent to $1,090.0 million from $1,127.6 million in 2007. Operating profit for 2007 includesincluded the effect of the non-recurring settlement expense of $169.5 million. Excluding the impact of the settlement expense in 2007, operating profit for 2008 would still have been unfavorable compared to 2007 as a result of lower gross margins, significant but temporary increases in SG&A costs attributable to the implementation of our enhanced compliance initiatives and certain claims expense of $69.0 million.
Interest and other income for 2008 increased to $31.8 million from $4.0 million in 2007. Interest and other income for 2008 includes a realized gain of $38.8 million related to the sale of certain marketable securities, partially offset by increased interest expense as a result of an increase in outstanding long-term debt.
The effective tax rate on earnings before income taxes and minority interest decreased to 24.3 percent for 2008, down from 31.6 percent in 2007. The effective tax rate for the 2007 period reflects the effect of the $169.5 million settlement expense for which no tax benefit had previously been recognized. During 2008, we recorded a current tax benefit of $31.7 million related to the settlement expense, resulting in a decrease of approximately 3 percent to the current period effective tax rate. The effective tax rate for 2008 was further reduced as a result of increased profits in lower tax jurisdictions. These decreases in the effective tax rate were partially offset by Abbott Spine acquisition-related in-process research and development
28
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
charges recorded during 2008 for which no tax benefit was recorded.
Net earnings increased 10 percent to $848.6 million for 2008 compared to $773.2 million in 2007, as the decrease in operating profit was more than offset by favorable items in interest and other income and a lower effective tax rate. Basic and diluted earnings per share increased 14 percent to $3.73 and $3.72, respectively, from $3.28 and $3.26 in 2007. The higher growth rate in earnings per share as compared to net earnings is attributed to the effect of 2008 and 2007 share repurchases.
Year Ended December 31, 2007 Compared to Year Ended December 31, 2006
| |
| Net Sales by Operating Segment |
The following table presents net sales by operating segment and the components of the percentage changes (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | | | Volume/
| | | | | | Foreign
| |
| | | 2007 | | | 2006 | | | % Inc | | | Mix | | | Price | | | Exchange | |
| | |
| |
| Americas | | $ | 2,277.0 | | | $ | 2,076.5 | | | | 10 | % | | | 8 | % | | | 1 | % | | | 1 | % |
| Europe | | | 1,081.0 | | | | 931.1 | | | | 16 | | | | 8 | | | | (1 | ) | | | 9 | |
| Asia Pacific | | | 539.5 | | | | 487.8 | | | | 11 | | | | 9 | | | | (1 | ) | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Total | | $ | 3,897.5 | | | $ | 3,495.4 | | | | 12 | | | | 9 | | | | – | | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
27
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
| |
| Net Sales by Product Category |
The following table presents net sales by product category and the components of the percentage changes (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | | | Volume/
| | | | | | Foreign
| |
| | | 2007 | | | 2006 | | | % Inc | | | Mix | | | Price | | | Exchange | |
| | |
| |
| Reconstructive | | | | | | | | | | | | | | | | | | | | | | | | |
| Knees | | $ | 1,634.6 | | | $ | 1,460.5 | | | | 12 | % | | | 9 | % | | | – | % | | | 3 | % |
| Hips | | | 1,221.4 | | | | 1,126.9 | | | | 8 | | | | 6 | | | | (1 | ) | | | 3 | |
| Extremities | | | 104.0 | | | | 77.6 | | | | 34 | | | | 30 | | | | 1 | | | | 3 | |
| Dental | | | 221.0 | | | | 179.0 | | | | 23 | | | | 16 | | | | 4 | | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Total | | | 3,181.0 | | | | 2,844.0 | | | | 12 | | | | 9 | | | | – | | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Trauma | | | 205.8 | | | | 194.7 | | | | 6 | | | | 2 | | | | 1 | | | | 3 | |
| Spine | | | 197.0 | | | | 177.4 | | | | 11 | | | | 9 | | | | 1 | | | | 1 | |
| OSP and other | | | 313.7 | | | | 279.3 | | | | 12 | | | | 9 | | | | 1 | | | | 2 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Total | | $ | 3,897.5 | | | $ | 3,495.4 | | | | 12 | | | | 9 | | | | – | | | | 3 | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
TheNexGenComplete Knee Solution product line, including theGender Solutions Knee Femoral Implants, theNexGenLPS-Flex Knee, theNexGenCR-Flex Knee, theNexGenRotating Hinge Knee and theNexGenLCCK Revision Knee led knee sales. In addition, theZimmerUnicompartmental High-Flex Knee and theInnex Total Knee System exhibited strong growth.
Growth in porous stems, including theZimmerM/L Taper Stem, theCLS Spotorno Stem from theCLSHip System,and theAlloclassic ZweymüllerHip Stem led hip stem sales, but was partially offset by weaker sales of cemented and revision stems.Trabecular MetalAcetabular Cups,Trabecular MetalPrimary Hip Prosthesis, DuromAcetabular Cups withMetasul LDH® Large Diameter Heads, andLongevityandDurasulHighly Crosslinked Polyethylene Liners also had strong growth.
TheBigliani/FlatowComplete Shoulder Solution and the Coonrad/Morrey Total Elbow led extremities sales. Orthobiologicals and prosthetic implants, including strong growth of theTapered Screw-VentImplant System, led dental sales.ZimmerPeriarticular Locking Plates andZimmerPlates and Screws led trauma sales. TheDynesysDynamic Stabilization System, theTiTLE2 lumbar pedicle screw system, theTrinicaSelect Anterior Cervical Plate System andTrabecular MetalImplants led spine sales. Extremity surgical products andPALACOSBone Cement led OSP sales.
The following table presents Americas net sales (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2007 | | | 2006 | | | % Inc | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | $ | 1,029.8 | | | $ | 940.8 | | | | 10 | % |
| Hips | | | 568.3 | | | | 533.8 | | | | 6 | |
| Extremities | | | 73.9 | | | | 54.2 | | | | 36 | |
| Dental | | | 118.9 | | | | 105.4 | | | | 13 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 1,790.9 | | | | 1,634.2 | | | | 10 | |
| | | | | | | | | |
| | | | | | | | | |
| Trauma | | | 122.9 | | | | 117.1 | | | | 5 | |
| Spine | | | 160.3 | | | | 146.9 | | | | 9 | |
| OSP and other | | | 202.9 | | | | 178.3 | | | | 14 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 2,277.0 | | | $ | 2,076.5 | | | | 10 | |
| | | | | | | | | |
| | | | | | | | | |
TheNexGenComplete Knee Solution product line, including theGender Solutions Knee Femoral Implants,NexGenLPS-Flex Knee,NexGen Trabecular MetalTibial Components, theNexGenLCCK Revision Knee and theNexGenCR-Flex Knee led knee sales. TheZimmerUnicompartmental High-Flex Knee also made a strong contribution.
Growth in porous stems, including growth of theZimmerM/L Taper Stem andTrabecular MetalPrimary Hip Prosthesis, led hip stem sales, but was partially offset by weaker sales of cemented stems.Trabecular MetalAcetabular Cups andDuromAcetabular Cups withMetasul LDHLarge Diameter Heads also exhibited strong growth.
TheBigliani/FlatowShoulder Solution and theTrabecular MetalHumeral Stem led extremities sales. TheTapered Screw-VentImplant System led dental sales.ZimmerPeriarticular Plates andZimmerPlates and Screws led trauma sales, but were offset by declining sales of intramedullary nails and compression hip screws. TheDynesysDynamic Stabilization System, theTrinicaSelect Anterior Cervical Plate System and SpinalTrabecular MetalImplants led spine sales.PALACOSBone Cement led OSP sales.
28
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
The following table presents Europe net sales (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2007 | | | 2006 | | | % Inc | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | $ | 407.8 | | | $ | 352.2 | | | | 16 | % |
| Hips | | | 459.9 | | | | 408.3 | | | | 13 | |
| Extremities | | | 23.2 | | | | 17.9 | | | | 30 | |
| Dental | | | 71.3 | | | | 47.2 | | | | 51 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 962.2 | | | | 825.6 | | | | 17 | |
| | | | | | | | | |
| | | | | | | | | |
| Trauma | | | 41.1 | | | | 38.2 | | | | 8 | |
| Spine | | | 31.2 | | | | 24.8 | | | | 26 | |
| OSP and other | | | 46.5 | | | | 42.5 | | | | 9 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 1,081.0 | | | $ | 931.1 | | | | 16 | |
| | | | | | | | | |
| | | | | | | | | |
Changes in foreign exchange rates positively affected knee sales by 9 percent and hip sales by 8 percent. Excluding these foreign exchange rate effects, the following product categories experienced positive sales growth in our Europe region: theNexGenComplete Knee Solution product line, including theNexGen LPS-Flex Knee,NexGen Trabecular MetalTibial Components, theNexGenCR-Flex Knee, and theInnexTotal Knee System. Growth in porous stems, including theCLS SpotornoStem, led hip stem sales.LongevityandDurasulHighly Crosslinked Polyethylene Liners, theDuromHip Resurfacing System,Trabecular Metal Acetabular Cups and theAllofitHip Acetabular System also contributed to hip sales.
TheAnatomical ShoulderSystem, theAnatomical ShoulderInverse/Reverse System and the Coonrad/Morrey Total Elbow led extremities sales. The addition of a direct sales force in Italy as a result of a distributor acquisition contributed to growth in dental sales and theTapered Screw-VentImplant System led dental sales. TheCable-ReadyCable Grip System,ZimmerPeriarticular Plates and theNCBPlating System led trauma sales, which were offset by weaker sales of our intramedullary fixation systems. TheDynesysDynamic Stabilization System andTrabecular MetalImplants led spine sales. Wound management products led OSP sales.
The following table presents Asia Pacific net sales (dollars in millions):
| | | | | | | | | | | | | |
| | | Year Ended December 31, | | | | |
| | | 2007 | | | 2006 | | | % Inc (Dec) | |
| | |
| |
| Reconstructive | | | | | | | | | | | | |
| Knees | | $ | 197.0 | | | $ | 167.5 | | | | 18 | % |
| Hips | | | 193.2 | | | | 184.8 | | | | 5 | |
| Extremities | | | 6.9 | | | | 5.5 | | | | 27 | |
| Dental | | | 30.8 | | | | 26.4 | | | | 17 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | | 427.9 | | | | 384.2 | | | | 11 | |
| | | | | | | | | |
| | | | | | | | | |
| Trauma | | | 41.8 | | | | 39.4 | | | | 6 | |
| Spine | | | 5.5 | | | | 5.7 | | | | (4 | ) |
| OSP and other | | | 64.3 | | | | 58.5 | | | | 10 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 539.5 | | | $ | 487.8 | | | | 11 | |
| | | | | | | | | |
| | | | | | | | | |
Changes in foreign exchange rates positively affected knee sales by 5 percent and positively affected hip sales by 2 percent. Reported decreases in average selling prices negatively affected hip sales by 3 percent. TheNexGenComplete Knee Solution product line, includingNexGen Trabecular MetalTibial Components, theNexGenCR-Flex Knee and theNexGenLPS-Flex Knee led knee sales. Launch of theGender SolutionsKnee Femoral Implant in Australia also contributed to strong knee sales for the year. The continued conversion to porous stems, including the Fiber Metal Taper Stem from theVerSysHip System, theAlloclassic ZweymüllerHip System and theCLS SpotornoStem led hip stem sales. Sales ofLongevityHighly Crosslinked Polyethylene Liners andTrabecular MetalAcetabular Cups also exhibited growth.
Extremities sales increased due to stronger sales of our shoulder and elbow products. TheTapered Screw-VentImplant System led dental sales. Trauma sales were led by strong growth inZimmerPeriarticular Plates andZimmer Plates and Screws, but were partially offset by a reported 5 percent decrease in average selling prices during 2007. A registration issue with theST360°® Spinal Fixation System in Japan resulted in a decrease in sales of this device, contributing to the negative growth in Spine sales for 2007. Powered surgical instruments and Bone Cement and accessories led OSP sales.
Gross profit as a percentage of net sales was 77.5 percent in 2007, compared to 77.7 percent in 2006. The following table reconciles the gross margin for 2006 to 2007:
| | | | |
Year ended December 31, 2006 gross margin | | | 77.7 | % |
Foreign exchange impact, net | | | (0.3 | ) |
Other | | | 0.1 | |
|
|
Year ended December 31, 2007 gross margin | | | 77.5 | % |
|
|
The unfavorable effect of year over year changes in foreign currency hedge gains and losses were partially offset by lower unit manufacturing costs due to productivity gains as well as favorable geographic sales mix. These gains were further offset by increased inventory charges due to the impact of our newer products on aging product lines.
R&D as a percentage of net sales was 5.4 percent for 2007, which is unchanged from 2006. R&D increased to $209.6 million for 2007 from $188.3 million in 2006, reflecting increased spending on new product development across all of our product segments. In 2007, we continued to make investments in our research and development facilities in Warsaw, Indiana. We continued working with our third party partners on genetically engineered tissues for regenerative therapies, including soft tissue biological repair and replacement.
SG&A, as a percentage of net sales was 38.2 percent for 2007, compared to 38.8 percent in 2006. The improvement in SG&A as a percent of net sales from the prior year is due to sales growth and well controlled spending.
29
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Settlement expense of $169.5 million for 2007 relates to the settlement of the federal investigation into financial relationships between major orthopaedic manufacturers and consulting orthopaedic surgeons. Acquisition, integration and other items for 2007 were $25.2 million compared to $6.1 million in 2006. The acquisition, integration and other expenses recorded during 2007 reflect in-process research and development write-offs related to acquisitions, costs related to the integration of acquired U.S. distributors, estimated settlements for certain pre-acquisition product liability claims, integration consulting fees and costs for integrating information technology systems. The acquisition, integration and other expenses recorded during 2006 included $27.7 million of income related to three unrelated matters — the sale of the former Centerpulse Austin land and facilities for a gain of $5.1 million and the favorable settlement of two pre-acquisition contingent liabilities.
| |
| Operating Profit, Income Taxes and Net Earnings |
Operating profit for 2007 decreased 3 percent to $1,127.6 million, from $1,165.2 million in 2006. The decrease is due principally to the $169.5 million settlement expense. Without the settlement expense, operating profit would have been favorable to 2006 due to increased sales and controlled operating expenses.
The effective tax rate on earnings before income taxes and minority interest increased to 31.6 percent for 2007, up from 28.6 percent in 2006. The increase in the effective tax rate is primarily due to the effect of the $169.5 million settlement expense in 2007 for which no tax benefit was recognized. Without the effect of the settlement expense, the effective tax rate for 2007 would have been favorable to 2006 due to increased profitability in lower tax jurisdictions.
Net earnings decreased 7 percent to $773.2 million for 2007, compared to $834.5 million in 2006. The decrease was due to the $169.5 million settlement expense and the higher effective tax rate that resulted from the settlement expense. Basic and diluted earnings per share decreased 4 percent to $3.28 and $3.26, respectively, from $3.43 and $3.40 in 2006 due to fewer outstanding shares as a result of our stock repurchase program.
LIQUIDITY AND CAPITAL RESOURCES
Cash flows provided by operating activities were $1,117.5 million in 2009 compared to $1,038.1 million in 2008 compared to $1,084.4 million in 2007.2008. The principal source of cash from operating activities in 2009 was net earnings of $848.6 million.earnings. Non-cash charges included in net earnings accounted for another $353.7$446.4 million of operating cash. Income tax-related balances decreased by $77.3 million in 2008, primarily reflecting the impact of accelerated tax payments resulting from changes in Federal and State tax rules. All other items of operating cash flows accounted forin 2009 reflect a use of $86.9$46.3 million of cash pertainingcash. The resolution of outstanding payments to pension funding and to investments in working capital in support of sales services. Operating cash flows continued to be positively affected by delayed payments related to various contractual arrangements with healthcare professionals or institutions. Forand institutions resulted in increased cash outflows during the 2009 period compared to the delay in similar payments during the 2008 period as we estimate this delay hadimplemented our enhanced global compliance program. The resolution of these outstanding payments, along with a positive effect on operating cash flowschange in the timing of approximately $26 million.employee bonus payments compared to the 2008 period and product liability payments, contributed to increased outflows from accrued expenses in 2009. These outflows were partially offset by improved accounts receivable collections and better inventory management.
At December 31, 2008,2009, we had 5956 days of sales outstanding in trade accounts receivable, an increasea decrease of 73 days when compared to December 31, 2007,2008, reflecting a change inimproved collections across all geographic mix of outstanding accounts receivable balances and a general weakening in the broader economy.segments. At December 31, 2008,2009, we had 344302 days of inventory on hand, abovea decrease of 42 days compared to December 31, 2007 by 86 days, reflecting a planned increase2008. Over the past two years we have made significant investments in inventory, including investments in response to growing demand for systems that provide more versatility and better fit for patients. In 2009 we made progress rationalizing these investments through reductions in field-based consignments and through the use of new inventory deploymentsmanagement tools to speed returns and redeployments. The continued build out of pipeline inventory for planned product launches should partially offset these reductions in the U.S., a build-out of our inventory pipeline for certain new products we are preparing to launchfield consignments in 2009, lower than expected sales in the fourth quarter of 2008 and the year-over-year change in foreign currency hedge gains/losses impacting cost of goods sold.2010.
Cash flows used in investing activities were $381.2 million in 2009 compared to $924.2 million in 2008,2008. Additions to instruments decreased in 2009 compared to $491.5the 2008 period, asyear-over-year spending on instruments declined compared to the significant investments made in 2008. In 2010, we expect to spend approximately $170 – $180 million on instruments to support new products and sales growth. Spending on other property, plant and equipment decreased to $105.1 million during 2009 compared to $250.0 million in 2007. The most significant contributors to the increase in cash flows used in investing activities were the acquisition of Abbott Spinesame 2008 period. Spending on property, plant and the acquisition of intellectual property rights. Cash payments related to the acquisition of Abbott Spine were $363.0 millionequipment decreased compared to total acquisition-related payments of $160.32008 levels, as certain planned infrastructure initiatives from 2008 were completed and as we adjusted spending to lower production volumes. During 2010, we expect to purchase approximately $150 – $160 million in 2007, which related primarilyother property, plant and equipment, reflecting the cash outlays necessary to the acquisitionscomplete new product-related investments and normal replacement of Endiusolder machinery and ORTHOsoft.equipment. Acquired intellectual property rights ofwere $35.8 million in 2009 compared to $109.4 million in 2008. These items relate to lump-sum payments made to certain healthcare professionals and institutions in place of future royalty payments that otherwise would have been due under the terms of an existing contractual arrangement.arrangements. These lump-sum payments were based upon a third party fair market valuation of the current net present value of the contractual arrangement. Inarrangements. During 2009 we anticipate making additional lump-suminvested excess cash of approximately $66.4 million in certificates of deposit that have original maturities greater than 90 days. Investments in other assets in both 2009 and 2008 primarily relate to payments to acquire intellectual property rights. Additionscertain foreign-based distributors. Investments in other assets in 2007 primarily related to instruments duringpayments to acquire Endius and ORTHOsoft. Included in investing cash flows in 2008 were $237.9$363.0 million comparedpaid to $138.5 million in 2007. Additions to instruments increased in 2008 compared to 2007 due to an increase in instrument deployments to permit our salesacquire Abbott Spine and distribution networks to respond more rapidly to changes in surgical demand patterns and capitalize on new business opportunities. In 2009, we expect to spend approximately $160 — $170 million on instruments to support new products and sales. Additions to other property, plant and equipment during 2008 were $250.0 million compared to $192.7 million in 2007. This increase reflects spending on planned infrastructure improvements such as opening a new manufacturing facility in Ireland, improving our quality system infrastructure and investing in a central distribution center for our Europe segment. During 2009, we expect to purchase approximately $230 — $240 million in other property, plant and equipment, reflecting the cash necessary to complete capital expansions initiated in 2008 as well as new product-related investments and normal replacement of older machinery and equipment. Also included in investing activities for 2008 is $54.9 million inof proceeds we received from the sale of certain equity securities.
Cash flows used in financing activities were $262.1 million for 2009 compared to $343.5 million in 2008. In November 2009, we sold $1.0 billion aggregate principal amount of senior unsecured notes (Senior Notes) in a public offering. We received net proceeds of approximately $998.8 million, net of an offering discount of $1.2 million. We also paid an additional $8.5 million of debt issuance costs related to the sale of the Senior Notes. The proceeds of the offering were used to repay amounts outstanding under our senior credit facility, to finance our stock repurchase program and for 2008, compared to $399.5 million in 2007.general corporate purposes. We repurchased $737.0$923.7 million of our common stock in 20082009 as compared with $576.3$737.0 million in 20072008 under our stock repurchase programs.
The Senior Notes include two tranches: $500 million aggregate principal amount of 4.625% Senior Notes due November 30, 2019, and $500 million aggregate principal amount of 5.75% Senior Notes due November 30, 2039. Interest on the Senior Notes is payable on May 30 and November 30 of each year beginning on May 30, 2010 until maturity. The Senior Notes are rated A- by Standard & Poor’s Ratings Services and are rated Baa1 by Moody’s Investors’ Service, Inc.
We may redeem the Senior Notes at our election in whole or in part at any time prior to maturity at a redemption price equal to the greater of 1) 100 percent of the principal amount of the notes being redeemed; or 2) the sum of the present values of the remaining scheduled payments of principal and interest (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semi-annual basis at the Treasury Rate (as defined in the debt agreement), plus 20 basis points, in the case of the 2019 notes, and 25 basis points, in the case of the 2039 notes. We will also pay the accrued and unpaid interest on the Senior Notes to the redemption date.
3029
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
repurchase programs. We utilized cash generated from operating activities, $57.0 million in cash proceeds received from employee stock compensation plans and borrowings under credit facilities to fund the repurchases. During 2008, we borrowed $330.0 million from our existing credit facilities to fund stock repurchases and partially fund the acquisition of Abbott Spine.
We may use excess cash or further borrow from our credit facilities to repurchase additional common stock under the $1.25 billion program which expires December 31, 2009.
We have a five year $1,350 million revolving, multi-currency, senior unsecured credit facility maturing November 30, 2012 (the “Senior(Senior Credit Facility”)Facility). We had $460.1$128.8 million outstanding under the Senior Credit Facility at December 31, 2008,2009, and an availability of $889.9$1,221.2 million. The Senior Credit Facility contains provisions by which we can increase the line to $1,750 million and request that the maturity date be extended for two additional one-year periods.
We and certain of our wholly owned foreign subsidiaries are the borrowers under the Senior Credit Facility. Borrowings under the Senior Credit Facility are used for general corporate purposes and bear interest at a LIBOR-based rate plus an applicable margin determined by reference to our senior unsecured long-term credit rating and the amounts drawn under the Senior Credit Facility, at an alternate base rate, or at a fixed rate determined through a competitive bid process. The Senior Credit Facility contains customary affirmative and negative covenants and events of default for an unsecured financing arrangement, including, among other things, limitations on consolidations, mergers and sales of assets. Financial covenants include a maximum leverage ratio of 3.0 to 1.0 and a minimum interest coverage ratio of 3.5 to 1.0. If we fall below an investment grade credit rating, additional restrictions would result, including restrictions on investments, payment of dividends and stock repurchases. We were in compliance with all covenants under the Senior Credit Facility as of December 31, 2008. Commitments under the Senior Credit Facility are subject to certain fees, including a facility and a utilization fee. The Senior Credit Facility is rated A- by Standard & Poor’s Ratings Services and is not rated by Moody’s Investors’ Service, Inc. Notwithstanding recent interruptions in global credit markets, as of the date of this report, we believe our access to our Senior Credit Facility has not been impaired.
In October 2008, we funded a portion of the acquisition of Abbott Spine with approximately $110 million of new borrowings under the Senior Credit Facility. Each of the lenders under the Senior Credit Facility funded its portion of the new borrowings in accordance with its commitment percentage.million.
We also have available uncommitted credit facilities totaling $71.4$84.1 million.
We may use excess cash or further borrow against our Senior Credit Facility, subject to limits set by our Board of Directors, to repurchase additional common stock under the $1.25 billion program which expires December 31, 2010. Approximately $211.1 million remains authorized for future repurchases under this plan.
Management believes that cash flows from operations together withand available borrowings under the Senior Credit Facility are sufficient to meet our expected working capital, capital expenditure and debt service needs. Should investment opportunities arise, we believe that our earnings, balance sheet and cash flows will allow us to obtain additional capital, if necessary.
CONTRACTUAL OBLIGATIONS
We have entered into contracts with various third parties in the normal course of business which will require future payments. The following table illustrates our contractual obligations (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | 2010
| | 2012
| | 2014
| | | | | | | 2011
| | 2013
| | 2015
| |
| | | | | | | and
| | and
| | and
| | | | | | | and
| | and
| | and
| |
| Contractual Obligations | | Total | | 2009 | | 2011 | | 2013 | | Thereafter | | | Total | | 2010 | | 2012 | | 2014 | | Thereafter | |
| | | | | |
| |
| Long-term debt | | $ | 460.1 | | | $ | – | | | $ | – | | | $ | 460.1 | | | $ | – | | | $ | 1,127.6 | | | $ | – | | | $ | 128.8 | | | $ | – | | | $ | 998.8 | |
| Interest payments | | | | 1,095.6 | | | | 53.7 | | | | 103.8 | | | | 103.8 | | | | 834.3 | |
| Operating leases | | | 149.3 | | | | 38.2 | | | | 51.0 | | | | 30.2 | | | | 29.9 | | | | 134.6 | | | | 37.3 | | | | 47.6 | | | | 26.6 | | | | 23.1 | |
| Purchase obligations | | | 56.8 | | | | 47.7 | | | | 7.6 | | | | 1.5 | | | | – | | | | 33.0 | | | | 27.8 | | | | 5.1 | | | | 0.1 | | | | – | |
| Long-term income taxes payable | | | 116.9 | | | | – | | | | 69.6 | | | | 24.9 | | | | 22.4 | | | | 94.3 | | | | – | | | | 56.5 | | | | 15.3 | | | | 22.5 | |
| Other long-term liabilities | | | 237.0 | | | | – | | | | 30.7 | | | | 15.1 | | | | 191.2 | | | | 234.2 | | | | – | | | | 81.7 | | | | 26.2 | | | | 126.3 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Total contractual obligations | | $ | 1,020.1 | | | $ | 85.9 | | | $ | 158.9 | | | $ | 531.8 | | | $ | 243.5 | | | $ | 2,719.3 | | | $ | 118.8 | | | $ | 423.5 | | | $ | 172.0 | | | $ | 2,005.0 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
CRITICAL ACCOUNTING ESTIMATES
Our financial results are affected by the selection and application of accounting policies and methods. Significant accounting policies which require management’s judgment are discussed below.
Excess Inventory and Instruments – We must determine as of each balance sheet date how much, if any, of our inventory may ultimately prove to be unsaleable or unsaleable at our carrying cost. Similarly, we must also determine if instruments on hand will be put to productive use or remain undeployed as a result of excess supply. Reserves are established to effectively adjust inventory and instruments to net realizable value. To determine the appropriate level of reserves, we evaluate current stock levels in relation to historical and expected patterns of demand for all of our products and instrument systems and components. The basis for the determination is generally the same for all inventory and instrument items and categories except forwork-in-progress inventory, which is recorded at cost. Obsolete or discontinued items are generally destroyed and completely written off. Management evaluates the need for changes to valuation reserves based on market conditions, competitive offerings and other factors on a regular basis.
Income Taxes – Our income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. We are subject to income taxes in both the U.S. and numerous foreign jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense.
We estimate income tax expense and income tax liabilities and assets by taxable jurisdiction. Realization of deferred tax assets in each taxable jurisdiction is dependent on our ability to generate future taxable income sufficient to realize the benefits. We evaluate deferred tax assets on an ongoing basis and provide valuation allowances if it is determined to be “more likely than not” that the deferred tax benefit will not be realized. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. We operate within numerous taxing jurisdictions.
The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. We are subject to regulatory
31
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
review or audit in virtually all of those jurisdictions and those reviews and audits may require extended periods of time to resolve. We make userecord our income tax provisions based on our knowledge of all availablerelevant facts and circumstances, including existing tax laws, our experience with previous settlement agreements, the status of current examinations and our understanding of how the tax authorities view certain relevant industry and commercial matters.
We recognize tax liabilities in accordance with the Financial Accounting Standards Board’s (FASB) guidance on income taxes and we adjust these liabilities when our judgment changes as a result of the evaluation of new information and make reasoned judgments regarding matters requiring interpretationnot previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in establishinga payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense liabilities and reserves. We believe adequate provisions exist for income taxes for all periods and jurisdictions subject to review or audit.in the period in which they are determined.
Commitments and Contingencies – Accruals for product liability and other claims are established with the assistance of internal and external legal counsel based on current information and historical settlement information for claims, related legal fees and for claims incurred but not reported. We use an actuarial model to assist management in determining an appropriate level of accruals for product liability claims. Historical patterns of claim loss development
30
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
over time are statistically analyzed to arrive at factors which are then applied to loss estimates in the actuarial model. During 2008,2009, in addition to our general product liability estimates and the $69.0 million provision recorded in 2008 related to theDuromCup, we recorded aan additional provision for certain claims of $69.0$35.0 million representing management’s updated estimate of liability toDuromCup patients undergoing revisions associated with surgeries occurring before July 2008 and within two years of the original surgery date. These parameters are consistent with our data which indicates that cup loosenings associated with surgical technique are most likely to occur within that time period. We expect to pay the majority of these claims within the next three years. Any claims received outside of these defined parameters will be managed in the normal course and reflected in our standard product liability accruals. The amounts established for our general product liability estimates, excluding certain claims for theDuromCup, equate to less than 5 percent of total liabilities and represent management’s best estimate of the ultimate costs that we will incur under the various contingencies.
Goodwill and Intangible Assets – We evaluate the carrying value of goodwill and indefinite life intangible assets annually, or whenever events or circumstances indicate the carrying value may not be recoverable. We evaluate the carrying value of finite life intangible assets whenever events or circumstances indicate the carrying value may not be recoverable. Significant assumptions are required to estimate the fair value of goodwill and intangible assets, most notably estimated future cash flows generated by these assets. As such, these fair valuation measurements use significant unobservable inputs as defined under Statement of Financial Accounting Standards No. 157, Fair Value Measurements.inputs. Changes to these assumptions could require us to record impairment charges on these assets.
In the fourth quarter of 2009, we determined our U.S. Spine reporting unit’s carrying value was in excess of its estimated fair value. Fair value was determined using an equal weighting of income and market approaches. Fair value under the income approach was determined by discounting to present value the estimated future cash flows of the reporting unit. Fair value under the market approach utilized the comparable transaction methodology, which uses valuation indicators determined from sales of other businesses that are similar to our U.S. Spine reporting unit. Factors that contributed to the estimated fair value of the reporting unit being below its carrying value included a decrease in projected revenues related to theDynesysDynamic Stabilization System. This product line experienced increased competition and insurance reimbursement issues in 2009. We have been seeking approval from the FDA to market this product differently in the U.S., which would enhance its position in the market. However, in November 2009 an FDA advisory panel issued a non-approvable recommendation, increasing the uncertainty of the estimated future cash flows. In addition to theDynesysproduct, revenues from other products have been affected as we work through the integration of the sales channel following the Abbott Spine acquisition.
As a result, we recorded a related goodwill impairment charge of $73.0 million during the year ended December 31, 2009.
We have five other reporting units with goodwill assigned to them. We estimate the fair value of those reporting units using the income approach by discounting to present value the estimated future cash flows of the reporting unit. For each of those five reporting units, the estimated fair value substantially exceeds its carrying value.
Share-based Payment – We account formeasure share-based payment expense in accordance with the fair value recognition provisions of SFAS 123(R). Under the fair value recognition provisions of SFAS 123(R), share-based payment expense is measured at the grant date based on the fair value of the award and is recognizedrecognize expense over the requisite service period. Determining the fair value of share-based awards at the grant date requires judgment, including estimating the expected life of stock options and the expected volatility of our stock. Additionally, we must estimate the amount of share-based awards that are expected to be forfeited. We estimate expected volatility based upon the implied volatility of our actively traded options. The expected life of stock options and estimated forfeitures are based upon our employees’ historical exercise and forfeiture behaviors. The assumptions used in determining the grant date fair value and the expected forfeitures represent management’s best estimates.
RECENT ACCOUNTING PRONOUNCEMENTS
Information about recent accounting pronouncements is included in Note 2 to the Consolidated Financial Statements, which are included in this report under Item 8.
3231
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 7A. | | Quantitative and Qualitative Disclosures About Market Risk |
MARKET RISK
We are exposed to certain market risks as part of our ongoing business operations, including risks from changes in foreign currency exchange rates, interest rates and commodity prices that could affect our financial condition, results of operations and cash flows. We manage our exposure to these and other market risks through regular operating and financing activities and through the use of derivative financial instruments. We use derivative financial instruments solely as risk management tools and not for speculative investment purposes.
FOREIGN CURRENCY EXCHANGE RISK
We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and net assets denominated in Euros, Swiss Francs, Japanese Yen, British Pounds, Canadian Dollars, Australian Dollars, Korean Won and Korean Won.Swedish Krona. We manage the foreign currency exposure centrally, on a combined basis, which allows us to net exposures and to take advantage of any natural offsets. To reduce the uncertainty of foreign currency exchange rate movements on transactions denominated in foreign currencies, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts and options with major financial institutions. These forward contracts and options are designed to hedge anticipated foreign currency transactions, primarily intercompany sale and purchase transactions, for periods consistent with commitments. Realized and unrealized gains and losses on these contracts and options that qualify as cash flow hedges are temporarily recorded in other comprehensive income, then recognized in cost of products sold when the hedged item affects net earnings.
For contracts outstanding at December 31, 2008,2009, we had obligations to purchase U.S. Dollars and sell Euros, Japanese Yen, British Pounds, Canadian Dollars, Australian Dollars, and Korean Won orand Swedish Krona and purchase Swiss Francs and sell U.S. Dollars at set maturity dates ranging from January 20092010 through June 2011.2012. The notional amounts of outstanding forward contracts entered into with third parties to purchase U.S. Dollars at December 31, 2009 and 2008 were $1.1 billion and 2007 were $1,343.0 million and $1,244.6 million,$1.3 billion, respectively. The notional amounts of outstanding forward contracts entered into with third parties to purchase Swiss Francs at December 31, 2009 and 2008 and 2007 were $207.5$202.4 million and $138.4$207.5 million, respectively. The weighted average contract rates outstanding are Euro:USD 1.41,1.40, USD:Swiss Franc 1.10, USD:Japanese Yen 101,94, British Pound:USD 1.86,1.66, USD:Canadian Dollar 1.09,1.11, Australian Dollar:USD 0.82 and0.75, USD:Korean Won 1,000.1,208 and USD:Swedish Krona 7.52.
We maintain written policies and procedures governing our risk management activities. Our policy requires that critical terms of hedging instruments are the same as hedged forecasted transactions. On this basis, with respect to cash flow hedges, changes in cash flows attributable to hedged transactions are generally expected to be completely offset by changes in the fair value of hedge instruments. As part of our risk management program, we also perform sensitivity analyses to assess potential changes in revenue, operating results, cash flows and financial position relating to hypothetical movements in currency exchange rates. A sensitivity analysis of changes in the fair value of foreign currency exchange forward contracts outstanding at December 31, 20082009 indicated that, if the U.S. Dollar uniformly changed in value by 10 percent relative to the Euro, Swiss Franc, Japanese Yen, British Pound, Canadian Dollar, Australian Dollar, and Korean Won and Swedish Krona, with no change in the interest differentials, the fair value of those contracts would increase or decrease earnings before income taxes in periods through 2011,2012, depending on the direction of the change, by an average approximate amount of $72.3$54.9 million, $21.1$20.5 million, $32.4$25.0 million, $10.4$10.2 million, $7.1$4.7 million, $7.2$9.9 million, $2.9 million and $1.9$1.8 million for the Euro, Swiss Franc, Japanese Yen, British Pound, Canadian Dollar, Australian Dollar, and Korean Won and Swedish Krona contracts, respectively. Any change in the fair value of foreign currency exchange forward contracts as a result of a fluctuation in a currency exchange rate is expected to be largely offset by a change in the value of the hedged transaction. Consequently, foreign currency exchange contracts would not subject us to material risk due to exchange rate movements because gains and losses on these contracts offset gains and losses on the assets, liabilities and transactions being hedged.
We had net investment exposures to net foreign currency denominated assets and liabilities of approximately $2,003$2,346 million at December 31, 2008,2009, primarily in Swiss Francs, Japanese Yen and Euros. Approximately $1,234$1,309 million of the net asset exposure at December 31, 20082009 relates to goodwill recorded in the Europe and Asia Pacific geographic segments.
We enter into foreign currency forward exchange contracts with terms of one month to manage currency exposures for assets and liabilities denominated in a currency other than an entity’s functional currency. As a result, foreign currency remeasurement gains/losses recognized in earnings under SFAS No. 52, “Foreign Currency Translation,” are generally offset with gains/losses on the foreign currency forward exchange contracts in the same reporting period.
COMMODITY PRICE RISK
We purchase raw material commodities such as cobalt chrome, titanium, tantalum, polymer and sterile packaging. We enter into supply contracts generally with terms of 12 to 24 months, where available, on these commodities to alleviate the effect of market fluctuation in prices. As part of our risk management program, we perform sensitivity analyses related to potential commodity price changes. A 10 percent price change across all these commodities would not have a material effect on our consolidated financial position, results of operations or cash flows.
3332
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
material effect on our consolidated financial position, results of operations or cash flows.
INTEREST RATE RISK
In the normal course of business, we are exposed to market risk from changes in interest rates that could affect our results of operations and financial condition. We manage our exposure to interest rate risks through our regular operations and financing activities.
Presently, we invest our cash and cash equivalents primarily in U.S. government treasury funds and bank deposits. The primary investment objective is to ensure capital preservation of our invested principal funds by limiting default and market risk. Currently, we do not use derivative financial instruments in our investment portfolio.
Our principal exposure to interest rate risk arises from the variable rates associated with our credit facilities. Our Senior Notes have fixed interest rates and are not exposed to any risk from movement in interest rates. We are subject to interest rate risk through movements in interest rates on the committed Senior Credit Facility and our uncommitted credit facilities. Presently, all of our debt outstanding under the Senior Credit Facility bears interest at short-term rates. We currently do not hedge our interest rate exposure, but we may do so in the future. Based upon our overall interest rate exposure as of December 31, 2008,2009, a change of 10 percent in interest rates, assuming the amount outstanding remains constant, would not have a material effect on interest expense. Further, this analysis does not consider the effect of the change in the level of overall economic activity that could exist in such an environment.
CREDIT RISK
Financial instruments, which potentially subject us to concentrations of credit risk, are primarily cash, cash equivalents, counterparty transactions and accounts receivable.
We place our investments in highly rated financial institutions and money market instruments and limit the amount of credit exposure to any one entity. We believe we do not have any significant credit risk on our cash and cash equivalents and investments.
We are exposed to credit loss if the financial institutions with which we conduct business fail to perform. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed our obligation. We also minimize exposure to credit risk by dealing with a diversified group of major financial institutions. We manage credit risk by monitoring the financial condition of our counterparties using standard credit guidelines. We do not anticipate any nonperformance by any of the counterparties.
Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers and their dispersion across a number of geographic areas and by frequent monitoring of the creditworthiness of the customers to whom credit is granted in the normal course of business. However, essentially all of our trade receivables are concentrated in the public and private hospital and healthcare industry in the U.S. and internationally or with distributors or dealers who operate in international markets and, accordingly, are exposed to their respective business, economic and country specific variables. Repayment is dependent upon the financial stability of these industry sectors and the respective countries’ national economic and healthcare systems. Exposure to credit risk is controlled through credit approvals, credit limits and monitoring procedures, and we believe that reserves for losses are adequate. There is no significant net exposure due to any individual customer or other major concentration of credit risk.
3433
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Management’s Report on Internal Control Over Financial Reporting
The management of Zimmer Holdings, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined inRules 13a-15(f) or15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and includes those policies and procedures that:
| | |
| | • | Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; |
| |
| | • | Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company;��and |
| |
| | • | Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements. |
Because of its inherent limitations, the company’s internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
The company’s management assessed the effectiveness of the company’s internal control over financial reporting as of December 31, 2008.2009. In making this assessment, the company’s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) inInternal Control-Integrated Framework.
Based on that assessment, management has concluded that, as of December 31, 2008,2009, the company’s internal control over financial reporting is effective based on those criteria.
The company’s independent registered public accounting firm has audited the effectiveness of the company’s internal control over financial reporting as of December 31, 2008,2009, as stated in its report which appears in Item 8 of this Annual Report onForm 10-K.
3534
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 8. | | Financial Statements and Supplementary Data |
| |
| Index to Consolidated Financial Statements | Page |
| | | | | |
| Financial Statements: | | | |
| | | | | |
| | | 3736 | |
| | | 37 | |
| | | 38 | |
| | | 39 | |
| | | 40 | |
| | | 4140 | |
| | | 4241 | |
| | | 4342 | |
3635
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
To theThe Stockholders and Board of Directors of Zimmer Holdings, Inc.:
In our opinion, the consolidated financial statements listed in the index appearing under Item 15(a)(1) present fairly, in all material respects, the financial position of Zimmer Holdings, Inc., and its subsidiaries at December 31, 20082009 and 2007,2008, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 20082009 in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion, the financial statement schedule listed in the accompanying index appearing under Item 15(a)(2) presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2008,2009, based on criteria established inInternal Control –— Integrated Frameworkissued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Report of Management on Internal Control over Financial Reporting. Our responsibility is to express opinions on these financial statements and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
As discussed in Note 122 to the consolidated financial statements, the Company changed the manner in which it accounts for uncertain tax positions in 2007. As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for defined benefit pension and other postretirement plans effective December 31, 2006.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
PricewaterhouseCoopers LLP
Chicago, Illinois
February 23, 2009
24, 2010
3736
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| (in millions, except per share amounts) | (in millions, except per share amounts) | | (in millions, except per share amounts) | |
| For the Years Ended December 31, | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
Net Sales | | $ | 4,121.1 | | | $ | 3,897.5 | | | $ | 3,495.4 | | | $ | 4,095.4 | | | $ | 4,121.1 | | | $ | 3,897.5 | |
| Cost of products sold | | | 997.3 | | | | 875.9 | | | | 780.1 | | | | 990.8 | | | | 997.3 | | | | 875.9 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Gross Profit | | | 3,123.8 | | | | 3,021.6 | | | | 2,715.3 | | | | 3,104.6 | | | | 3,123.8 | | | | 3,021.6 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Research and development | | | 194.0 | | | | 209.6 | | | | 188.3 | | | | 205.4 | | | | 192.3 | | | | 182.6 | |
| Selling, general and administrative | | | 1,702.3 | | | | 1,489.7 | | | | 1,355.7 | | | | 1,729.2 | | | | 1,704.0 | | | | 1,516.7 | |
| Settlement (Note 16) | | | – | | | | 169.5 | | | | – | | |
| Certain claims (Note 16) | | | 69.0 | | | | – | | | | – | | |
| Acquisition, integration and other | | | 68.5 | | | | 25.2 | | | | 6.1 | | |
| Settlement (Note 17) | | | | – | | | | – | | | | 169.5 | |
| Certain claims (Note 17) | | | | 35.0 | | | | 69.0 | | | | – | |
| Goodwill impairment (Note 8) | | | | 73.0 | | | | – | | | | – | |
| Acquisition, integration, realignment and other (Note 2) | | | | 75.3 | | | | 68.5 | | | | 25.2 | |
| Net curtailment and settlement (Note 12) | | | | (32.1 | ) | | | – | | | | – | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Operating expenses | | | 2,033.8 | | | | 1,894.0 | | | | 1,550.1 | | | | 2,085.8 | | | | 2,033.8 | | | | 1,894.0 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Operating Profit | | | 1,090.0 | | | | 1,127.6 | | | | 1,165.2 | | | | 1,018.8 | | | | 1,090.0 | | | | 1,127.6 | |
| Interest and other, net | | | 31.8 | | | | 4.0 | | | | 3.8 | | |
| Interest and other income (expense), net | | | | (20.6 | ) | | | 31.8 | | | | 4.0 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Earnings before income taxes and minority interest | | | 1,121.8 | | | | 1,131.6 | | | | 1,169.0 | | |
| Earnings before income taxes | | | | 998.2 | | | | 1,121.8 | | | | 1,131.6 | |
| Provision for income taxes | | | 272.3 | | | | 357.9 | | | | 334.0 | | | | 280.8 | | | | 272.3 | | | | 357.9 | |
| Minority interest | | | (0.9 | ) | | | (0.5 | ) | | | (0.5 | ) | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Net Earnings | | $ | 848.6 | | | $ | 773.2 | | | $ | 834.5 | | |
| Net earnings | | | | 717.4 | | | | 849.5 | | | | 773.7 | |
| Less: Net earnings attributable to noncontrolling interest | | | | – | | | | (0.9 | ) | | | (0.5 | ) |
| | | | | | | | | |
| | | | | | | | |
Net Earnings of Zimmer Holdings, Inc. | | | $ | 717.4 | | | $ | 848.6 | | | $ | 773.2 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Earnings Per Common Share – Basic | | $ | 3.73 | | | $ | 3.28 | | | $ | 3.43 | | | $ | 3.34 | | | $ | 3.73 | | | $ | 3.28 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Earnings Per Common Share – Diluted | | $ | 3.72 | | | $ | 3.26 | | | $ | 3.40 | | | $ | 3.32 | | | $ | 3.72 | | | $ | 3.26 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Weighted Average Common Shares Outstanding | | | | | | | | | | | | | | | | | | |
| Basic | | | 227.3 | | | | 235.5 | | | | 243.0 | | | | 215.0 | | | | 227.3 | | | | 235.5 | |
| Diluted | | | 228.3 | | | | 237.5 | | | | 245.4 | | | | 215.8 | | | | 228.3 | | | | 237.5 | |
The accompanying notes are an integral part of these consolidated financial statements.
37
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
| | | | | | | | | |
| (in millions) | |
| December 31, | | 2009 | | | 2008 | |
| | |
ASSETS | | | | | | | | |
Current Assets: | | | | | | | | |
| Cash and cash equivalents | | | $691.7 | | | $ | 212.6 | |
| Restricted cash | | | 0.1 | | | | 2.7 | |
| Certificates of deposit | | | 66.4 | | | | – | |
| Accounts receivable, less allowance for doubtful accounts | | | 751.4 | | | | 732.8 | |
| Inventories, net | | | 913.2 | | | | 928.3 | |
| Prepaid expenses and other current assets | | | 105.3 | | | | 103.9 | |
| Deferred income taxes | | | 209.9 | | | | 198.3 | |
| | | | | |
| | | | | |
| Total Current Assets | | | 2,738.0 | | | | 2,178.6 | |
| Property, plant and equipment, net | | | 1,221.7 | | | | 1,264.1 | |
| Goodwill | | | 2,783.5 | | | | 2,774.8 | |
| Intangible assets, net | | | 858.0 | | | | 872.1 | |
| Other assets | | | 184.3 | | | | 149.4 | |
| | | | | |
| | | | | |
Total Assets | | | $7,785.5 | | | $ | 7,239.0 | |
| | | | | |
| | | | | |
| | | | | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | |
Current Liabilities: | | | | | | | | |
| Accounts payable | | | $134.6 | | | $ | 186.4 | |
| Income taxes | | | 57.5 | | | | 26.6 | |
| Other current liabilities | | | 498.6 | | | | 558.1 | |
| | | | | |
| | | | | |
| Total Current Liabilities | | | 690.7 | | | | 771.1 | |
| Other long-term liabilities | | | 328.5 | | | | 353.9 | |
| Long-term debt | | | 1,127.6 | | �� | | 460.1 | |
| | | | | |
| | | | | |
Total Liabilities | | | 2,146.8 | | | | 1,585.1 | |
| | | | | |
| | | | | |
Commitments and Contingencies (Note 17) | | | | | | | | |
Stockholders’ Equity: | | | | | | | | |
| Zimmer Holdings, Inc. Stockholders’ Equity: | | | | | | | | |
Common stock, $0.01 par value, one billion shares authorized,
254.1 million (253.7 million in 2008) issued | | | 2.5 | | | | 2.5 | |
| Paid-in capital | | | 3,214.6 | | | | 3,138.5 | |
| Retained earnings | | | 5,102.5 | | | | 4,385.5 | |
| Accumulated other comprehensive income | | | 358.6 | | | | 240.0 | |
| Treasury stock, 49.9 million shares (30.1 million shares in 2008) | | | (3,039.5 | ) | | | (2,116.2 | ) |
| | | | | |
| | | | | |
| Total Zimmer Holdings, Inc. stockholders’ equity | | | 5,638.7 | | | | 5,650.3 | |
| Noncontrolling interest | | | – | | | | 3.6 | |
| | | | | |
| | | | | |
Total Stockholders’ Equity | | | 5,638.7 | | | | 5,653.9 | |
| | | | | |
| | | | | |
Total Liabilities and Stockholders’ Equity | | | $7,785.5 | | | $ | 7,239.0 | |
| | | | | |
| | | | | |
The accompanying notes are an integral part of these consolidated financial statements.
38
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | | | | | | | | |
| (in millions) | |
| December 31, | | 2008 | | | 2007 | |
| | |
ASSETS | | | | | | | | |
Current Assets: | | | | | | | | |
| Cash and equivalents | | | $ 212.6 | | | $ | 463.9 | |
| Restricted cash | | | 2.7 | | | | 2.5 | |
| Accounts receivable, less allowance for doubtful accounts | | | 732.8 | | | | 674.3 | |
| Inventories, net | | | 928.3 | | | | 727.8 | |
| Prepaid expenses and other current assets | | | 103.9 | | | | 59.4 | |
| Deferred income taxes | | | 198.3 | | | | 154.8 | |
| | | | | |
| | | | | |
| Total Current Assets | | | 2,178.6 | | | | 2,082.7 | |
| Property, plant and equipment, net | | | 1,264.1 | | | | 971.9 | |
| Goodwill | | | 2,774.8 | | | | 2,621.4 | |
| Intangible assets, net | | | 872.1 | | | | 743.8 | |
| Other assets | | | 149.4 | | | | 213.9 | |
| | | | | |
| | | | | |
Total Assets | | | $7,239.0 | | | $ | 6,633.7 | |
| | | | | |
| | | | | |
| | | | | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | |
Current Liabilities: | | | | | | | | |
| Accounts payable | | | $186.4 | | | $ | 174.1 | |
| Income taxes payable | | | 6.6 | | | | 85.1 | |
| Other current liabilities | | | 578.1 | | | | 489.4 | |
| | | | | |
| | | | | |
| Total Current Liabilities | | | 771.1 | | | | 748.6 | |
| Other long-term liabilities | | | 353.9 | | | | 328.4 | |
| Long-term debt | | | 460.1 | | | | 104.3 | |
| | | | | |
| | | | | |
Total Liabilities | | | 1,585.1 | | | | 1,181.3 | |
| | | | | |
| | | | | |
Commitments and Contingencies (Note 16) | | | | | | | | |
| Minority Interest | | | 3.6 | | | | 2.8 | |
Stockholders’ Equity: | | | | | | | | |
| Common stock, $0.01 par value, one billion shares authorized, | | | | | | | | |
| 253.7 million (252.2 million in 2007) issued | | | 2.5 | | | | 2.5 | |
| Paid-in capital | | | 3,138.5 | | | | 2,999.1 | |
| Retained earnings | | | 4,385.5 | | | | 3,536.9 | |
| Accumulated other comprehensive income | | | 240.0 | | | | 290.3 | |
| Treasury stock, 30.1 million shares (19.3 million shares in 2007) | | | (2,116.2 | ) | | | (1,379.2 | ) |
| | | | | |
| | | | | |
Total Stockholders’ Equity | | | 5,650.3 | | | | 5,449.6 | |
| | | | | |
| | | | | |
Total Liabilities and Stockholders’ Equity | | | $7,239.0 | | | $ | 6,633.7 | |
| | | | | |
| | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in millions) | |
| | | Zimmer Holdings, Inc. Stockholders | | | | | | | |
| | | | | | | | | | | | | | | Accumulated
| | | | | | | | | | | | | |
| | | | | | | | | | | | | | | Other
| | | | | | | | | | | | Total
| |
| | | Common Shares | | | Paid-in
| | | Retained
| | | Comprehensive
| | | Treasury Shares | | | Noncontrolling
| | | Stockholders’
| |
| | | Number | | | Amount | | | Capital | | | Earnings | | | Income | | | Number | | | Amount | | | Interest | | | Equity | |
| | |
Balance January 1, 2007 | | | 248.9 | | | $ | 2.5 | | | $ | 2,743.2 | | | $ | 2,768.5 | | | $ | 209.2 | | | | (12.1 | ) | | $ | (802.9 | ) | | $ | 2.7 | | | $ | 4,923.2 | |
| Net earnings | | | – | | | | – | | | | – | | | | 773.2 | | | | – | | | | – | | | | – | | | | 0.5 | | | | 773.7 | |
| Other comprehensive income | | | – | | | | – | | | | – | | | | – | | | | 81.1 | | | | – | | | | – | | | | – | | | | 81.1 | |
| Adoption of FASB’s uncertain tax position guidance | | | – | | | | – | | | | – | | | | (4.8 | ) | | | – | | | | – | | | | – | | | | – | | | | (4.8 | ) |
| Stock compensation plans, including tax benefits | | | 3.3 | | | | – | | | | 255.9 | | | | – | | | | – | | | | – | | | | – | | | | – | | | | 255.9 | |
| Share repurchases | | | | | | | | | | | | | | | | | | | | | | | (7.2 | ) | | | (576.3 | ) | | | | | | | (576.3 | ) |
| Currency translation | | | – | | | | – | | | | – | | | | – | | | | – | | | | – | | | | – | | | | (0.4 | ) | | | (0.4 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance December 31, 2007 | | | 252.2 | | | | 2.5 | | | | 2,999.1 | | | | 3,536.9 | | | | 290.3 | | | | (19.3 | ) | | | (1,379.2 | ) | | | 2.8 | | | | 5,452.4 | |
| Net earnings | | | – | | | | – | | | | – | | | | 848.6 | | | | – | | | | – | | | | – | | | | 0.9 | | | | 849.5 | |
| Other comprehensive loss | | | – | | | | – | | | | – | | | | – | | | | (50.3 | ) | | | – | | | | – | | | | – | | | | (50.3 | ) |
| Stock compensation plans, including tax benefits | | | 1.5 | | | | – | | | | 139.4 | | | | – | | | | – | | | | – | | | | – | | | | – | | | | 139.4 | |
| Share repurchases | | | – | | | | – | | | | – | | | | – | | | | – | | | | (10.8 | ) | | | (737.0 | ) | | | – | | | | (737.0 | ) |
| Currency translation | | | – | | | | – | | | | – | | | | – | | | | – | | | | – | | | | – | | | | (0.1 | ) | | | (0.1 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance December 31, 2008 | | | 253.7 | | | | 2.5 | | | | 3,138.5 | | | | 4,385.5 | | | | 240.0 | | | | (30.1 | ) | | | (2,116.2 | ) | | | 3.6 | | | | 5,653.9 | |
| Net earnings | | | – | | | | – | | | | – | | | | 717.4 | | | | – | | | | – | | | | – | | | | – | | | | 717.4 | |
| Other comprehensive income | | | – | | | | – | | | | – | | | | – | | | | 118.6 | | | | – | | | | – | | | | – | | | | 118.6 | |
| Purchase of noncontrolling interest | | | – | | | | – | | | | (5.0 | ) | | | – | | | | – | | | | – | | | | – | | | | (3.6 | ) | | | (8.6 | ) |
| Stock compensation plans, including tax benefits | | | 0.4 | | | | – | | | | 81.1 | | | | (0.4 | ) | | | – | | | | – | | | | 0.4 | | | | – | | | | 81.1 | |
| Share repurchases | | | – | | | | – | | | | – | | | | – | | | | – | | | | (19.8 | ) | | | (923.7 | ) | | | – | | | | (923.7 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance December 31, 2009 | | | 254.1 | | | $ | 2.5 | | | $ | 3,214.6 | | | $ | 5,102.5 | | | $ | 358.6 | | | | (49.9 | ) | | $ | (3,039.5 | ) | | $ | – | | | $ | 5,638.7 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
The accompanying notes are an integral part of these consolidated financial statements.
39
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in millions) | |
| | | | | | | | | | | | | | | Accumulated
| | | | | | | | | | |
| | | | | | | | | | | | | | | Other
| | | | | | | | | Total
| |
| | | Common Shares | | | Paid-in
| | | Retained
| | | Comprehensive
| | | Treasury Shares | | | Stockholders’
| |
| | | Number | | | Amount | | | Capital | | | Earnings | | | Income | | | Number | | | Amount | | | Equity | |
| | |
Balance January 1, 2006 | | | 247.8 | | | $ | 2.5 | | | $ | 2,601.1 | | | $ | 1,934.0 | | | $ | 149.3 | | | | (0.1 | ) | | $ | (4.1 | ) | | $ | 4,682.8 | |
| Net earnings | | | – | | | | – | | | | – | | | | 834.5 | | | | – | | | | – | | | | – | | | | 834.5 | |
| Other comprehensive income | | | – | | | | – | | | | – | | | | – | | | | 95.3 | | | | – | | | | – | | | | 95.3 | |
| Impact of adoption of SFAS 158 | | | – | | | | – | | | | – | | | | – | | | | (35.4 | ) | | | – | | | | – | | | | (35.4 | ) |
| Stock compensation plans, including tax benefits | | | 1.1 | | | | – | | | | 142.1 | | | | – | | | | – | | | | – | | | | – | | | | 142.1 | |
| Share repurchases | | | – | | | | – | | | | – | | | | – | | | | – | | | | (12.0 | ) | | | (798.8 | ) | | | (798.8 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance December 31, 2006 | | | 248.9 | | | | 2.5 | | | | 2,743.2 | | | | 2,768.5 | | | | 209.2 | | | | (12.1 | ) | | | (802.9 | ) | | | 4,920.5 | |
| Net earnings | | | – | | | | – | | | | – | | | | 773.2 | | | | – | | | | – | | | | – | | | | 773.2 | |
| Other comprehensive income | | | – | | | | – | | | | – | | | | – | | | | 81.1 | | | | – | | | | – | | | | 81.1 | |
| Impact of adoption of FIN 48 | | | – | | | | – | | | | – | | | | (4.8 | ) | | | – | | | | – | | | | – | | | | (4.8 | ) |
| Stock compensation plans, including tax benefits | | | 3.3 | | | | – | | | | 255.9 | | | | – | | | | – | | | | – | | | | – | | | | 255.9 | |
| Share repurchases | | | – | | | | – | | | | – | | | | – | | | | – | | | | (7.2 | ) | | | (576.3 | ) | | | (576.3 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance December 31, 2007 | | | 252.2 | | | | 2.5 | | | | 2,999.1 | | | | 3,536.9 | | | | 290.3 | | | | (19.3 | ) | | | (1,379.2 | ) | | | 5,449.6 | |
| Net earnings | | | – | | | | – | | | | – | | | | 848.6 | | | | – | | | | – | | | | – | | | | 848.6 | |
| Other comprehensive loss | | | – | | | | – | | | | – | | | | – | | | | (50.3 | ) | | | – | | | | – | | | | (50.3 | ) |
| Stock compensation plans, including tax benefits | | | 1.5 | | | | – | | | | 139.4 | | | | – | | | | – | | | | – | | | | – | | | | 139.4 | |
| Share repurchases | | | – | | | | – | | | | – | | | | – | | | | – | | | | (10.8 | ) | | | (737.0 | ) | | | (737.0 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance December 31, 2008 | | | 253.7 | | | $ | 2.5 | | | $ | 3,138.5 | | | $ | 4,385.5 | | | $ | 240.0 | | | | (30.1 | ) | | $ | (2,116.2 | ) | | $ | 5,650.3 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| (in millions) | |
| For the Years Ended December 31, | | 2009 | | | 2008 | | | 2007 | |
| | |
| Cash flows provided by (used in) operating activities: | | | | | | | | | | | | |
| Net earnings of Zimmer Holdings, Inc. | | $ | 717.4 | | | $ | 848.6 | | | $ | 773.2 | |
| Adjustments to reconcile net earnings to net cash provided | | | | | | | | | | | | |
| by operating activities: | | | | | | | | | | | | |
| Depreciation and amortization | | | 337.4 | | | | 275.1 | | | | 230.0 | |
| Goodwill impairment | | | 73.0 | | | | – | | | | – | |
| Gain on sale of investments | | | – | | | | (38.8 | ) | | | – | |
| In-process research and development | | | – | | | | 38.5 | | | | 6.5 | |
| Net curtailment and settlement | | | (32.1 | ) | | | – | | | | – | |
| Share-based compensation | | | 75.3 | | | | 69.9 | | | | 70.1 | |
Inventorystep-up | | | 12.5 | | | | 7.0 | | | | 0.5 | |
| Deferred income tax provision | | | (19.7 | ) | | | 2.0 | | | | 63.9 | |
| Income tax benefit from stock option exercises | | | 3.5 | | | | 12.5 | | | | 40.8 | |
| Excess income tax benefit from stock option exercises | | | (0.4 | ) | | | (6.5 | ) | | | (27.0 | ) |
| Changes in operating assets and liabilities, net of acquired assets and liabilities | | | | | | | | | | | | |
| Income taxes payable | | | 7.0 | | | | (77.3 | ) | | | 6.1 | |
| Receivables | | | (4.6 | ) | | | (44.4 | ) | | | (12.5 | ) |
| Inventories | | | 36.2 | | | | (148.1 | ) | | | (58.0 | ) |
| Accounts payable and accrued liabilities | | | (132.6 | ) | | | 119.3 | | | | 61.9 | |
| Other assets and liabilities | | | 44.6 | | | | (19.7 | ) | | | (71.1 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Net cash provided by operating activities | | | 1,117.5 | | | | 1,038.1 | | | | 1,084.4 | |
| | | | | | | | | |
| | | | | | | | | |
| Cash flows provided by (used in) investing activities: | | | | | | | | | | | | |
| Additions to instruments | | | (123.7 | ) | | | (237.9 | ) | | | (138.5 | ) |
| Additions to other property, plant and equipment | | | (105.1 | ) | | | (250.0 | ) | | | (192.7 | ) |
| Acquisition of intellectual property rights | | | (35.8 | ) | | | (109.4 | ) | | | – | |
| Purchases of certificates of deposit | | | (66.4 | ) | | | – | | | | – | |
| Proceeds from sale of investments | | | – | | | | 54.9 | | | | – | |
| Abbott Spine acquisition, net of acquired cash | | | – | | | | (363.0 | ) | | | – | |
| Investments in other assets | | | (50.2 | ) | | | (18.8 | ) | | | (160.3 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Net cash used in investing activities | | | (381.2 | ) | | | (924.2 | ) | | | (491.5 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Cash flows provided by (used in) financing activities: | | | | | | | | | | | | |
| Net proceeds (payments) under revolving credit facility | | | (330.0 | ) | | | 330.0 | | | | – | |
| Debt issuance costs | | | (8.5 | ) | | | – | | | | – | |
| Proceeds from employee stock compensation plans | | | 9.5 | | | | 57.0 | | | | 149.8 | |
| Excess income tax benefit from stock option exercises | | | 0.4 | | | | 6.5 | | | | 27.0 | |
| Repurchase of common stock | | | (923.7 | ) | | | (737.0 | ) | | | (576.3 | ) |
| Proceeds from issuance of notes | | | 998.8 | | | | – | | | | – | |
| Acquisition of noncontrolling interest | | | (8.6 | ) | | | – | | | | – | |
| | | | | | | | | |
| | | | | | | | | |
| Net cash used in financing activities | | | (262.1 | ) | | | (343.5 | ) | | | (399.5 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Effect of exchange rates on cash and cash equivalents | | | 4.9 | | | | (21.7 | ) | | | 4.8 | |
| | | | | | | | | |
| | | | | | | | | |
| Increase (decrease) in cash and cash equivalents | | | 479.1 | | | | (251.3 | ) | | | 198.2 | |
| Cash and cash equivalents, beginning of year | | | 212.6 | | | | 463.9 | | | | 265.7 | |
| | | | | | | | | |
| | | | | | | | | |
| Cash and cash equivalents, end of year | | $ | 691.7 | | | $ | 212.6 | | | $ | 463.9 | |
| | | | | | | | | |
| | | | | | | | | |
The accompanying notes are an integral part of these consolidated financial statements.
40
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | | | | | | | | | | | | |
| (in millions) | |
| For the Years Ended December 31, | | 2008 | | | 2007 | | | 2006 | |
| | |
| Cash flows provided by (used in) operating activities: | | | | | | | | | | | | |
| Net earnings | | $ | 848.6 | | | $ | 773.2 | | | $ | 834.5 | |
| Adjustments to reconcile net earnings to net cash provided | | | | | | | | | | | | |
| by operating activities: | | | | | | | | | | | | |
| Depreciation and amortization | | | 275.1 | | | | 230.0 | | | | 197.4 | |
| Gain on sale of investments | | | (38.8 | ) | | | – | | | | – | |
| In-process research and development | | | 38.5 | | | | 6.5 | | | | 2.9 | |
| Share-based compensation | | | 69.9 | | | | 70.1 | | | | 76.0 | |
Inventorystep-up | | | 7.0 | | | | 0.5 | | | | – | |
| Deferred income tax provision | | | 2.0 | | | | 63.9 | | | | 43.8 | |
| Income tax benefit from stock option exercises | | | 12.5 | | | | 40.8 | | | | 11.6 | |
| Excess income tax benefit from stock option exercises | | | (6.5 | ) | | | (27.0 | ) | | | (8.0 | ) |
| Changes in operating assets and liabilities, net of | | | | | | | | | | | | |
| acquired assets and liabilities | | | | | | | | | | | | |
| Income taxes payable | | | (77.3 | ) | | | 6.1 | | | | 24.9 | |
| Receivables | | | (44.4 | ) | | | (12.5 | ) | | | (76.9 | ) |
| Inventories | | | (148.1 | ) | | | (58.0 | ) | | | (39.2 | ) |
| Accounts payable and accrued liabilities | | | 119.3 | | | | 61.9 | | | | (29.9 | ) |
| Other assets and liabilities | | | (19.7 | ) | | | (71.1 | ) | | | 3.6 | |
| | | | | | | | | |
| | | | | | | | | |
| Net cash provided by operating activities | | | 1,038.1 | | | | 1,084.4 | | | | 1,040.7 | |
| | | | | | | | | |
| | | | | | | | | |
| Cash flows provided by (used in) investing activities: | | | | | | | | | | | | |
| Additions to instruments | | | (237.9 | ) | | | (138.5 | ) | | | (126.2 | ) |
| Additions to other property, plant and equipment | | | (250.0 | ) | | | (192.7 | ) | | | (142.1 | ) |
| Acquisition of intellectual property rights | | | (109.4 | ) | | | – | | | | – | |
| Proceeds from sale of investments | | | 54.9 | | | | – | | | | – | |
| Proceeds from sale of property, plant and equipment | | | – | | | | – | | | | 16.2 | |
| Abbott Spine acquisition, net of acquired cash | | | (363.0 | ) | | | – | | | | – | |
| Other acquisitions, net of acquired cash | | | (18.8 | ) | | | (160.3 | ) | | | (34.9 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Net cash used in investing activities | | | (924.2 | ) | | | (491.5 | ) | | | (287.0 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Cash flows provided by (used in) financing activities: | | | | | | | | | | | | |
| Net borrowings under credit facilities | | | 330.0 | | | | – | | | | 18.8 | |
| Proceeds from employee stock compensation plans | | | 57.0 | | | | 149.8 | | | | 41.3 | |
| Excess income tax benefit from stock option exercises | | | 6.5 | | | | 27.0 | | | | 8.0 | |
| Repurchase of common stock | | | (737.0 | ) | | | (576.3 | ) | | | (798.8 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Net cash used in financing activities | | | (343.5 | ) | | | (399.5 | ) | | | (730.7 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Effect of exchange rates on cash and equivalents | | | (21.7 | ) | | | 4.8 | | | | 9.5 | |
| | | | | | | | | |
| | | | | | | | | |
| Increase (decrease) in cash and equivalents | | | (251.3 | ) | | | 198.2 | | | | 32.5 | |
| Cash and equivalents, beginning of year | | | 463.9 | | | | 265.7 | | | | 233.2 | |
| | | | | | | | | |
| | | | | | | | | |
| Cash and equivalents, end of year | | $ | 212.6 | | | $ | 463.9 | | | $ | 265.7 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | | | | | |
| (in millions) | |
| For the Years Ended December 31, | | 2009 | | | 2008 | | | 2007 | |
| | |
| Net Earnings | | $ | 717.4 | | | $ | 849.5 | | | | $773.7 | |
| Other Comprehensive Income (Loss): | | | | | | | | | | | | |
| Foreign currency cumulative translation adjustments | | | 114.0 | | | | (49.4 | ) | | | 101.1 | |
Unrealized foreign currency hedge gains/(losses), net of tax effects of
$8.9 in 2009, $0.7 in 2008 and $11.5 in 2007 | | | (28.9 | ) | | | 35.0 | | | | (49.8 | ) |
Reclassification adjustments on foreign currency hedges, net of tax effects of
$(0.1) in 2009, $(9.2) in 2008 and $(1.3) in 2007 | | | (18.1 | ) | | | 43.4 | | | | 27.0 | |
Unrealized gains/(losses) on securities, net of tax effects of $0.1 in 2009,
$(15.2) in 2008 and $0.9 in 2007 | | | (0.3 | ) | | | 24.4 | | | | (1.4 | ) |
| Reclassification adjustments on securities, net of tax effects of $15.0 in 2008 | | | – | | | | (23.8 | ) | | | – | |
Prior service cost and unrecognized gain/(loss) in actuarial assumptions,
net of tax effects of $(1.4) in 2009, $14.1 in 2008 and $(0.4) in 2007 | | | 51.9 | | | | (79.9 | ) | | | 4.2 | |
| | | | | | | | | |
| | | | | | | | | |
| Total Other Comprehensive Income (Loss) | | | 118.6 | | | | (50.3 | ) | | | 81.1 | |
| Comprehensive (Loss) Attributable to Noncontrolling Interest | | | – | | | | (0.9 | ) | | | (0.5 | ) |
| | | | | | | | | |
| | | | | | | | | |
| Comprehensive Income Attributable to Zimmer Holdings, Inc. | | $ | 836.0 | | | $ | 798.3 | | | | $854.3 | |
| | | | | | | | | |
| | | | | | | | | |
The accompanying notes are an integral part of these consolidated financial statements.
41
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | | | | | | | | | | | | |
| (in millions) | |
| For the Years Ended December 31, | | 2008 | | | 2007 | | | 2006 | |
| | |
| Net Earnings | | $ | 848.6 | | | $ | 773.2 | | | | $834.5 | |
| Other Comprehensive Income (Loss): | | | | | | | | | | | | |
| Foreign currency cumulative translation adjustments | | | (49.4 | ) | | | 101.1 | | | | 143.8 | |
Unrealized foreign currency hedge gains/(losses), net of tax effects of
$0.7 in 2008, $11.5 in 2007 and $7.6 in 2006 | | | 35.0 | | | | (49.8 | ) | | | (56.7 | ) |
Reclassification adjustments on foreign currency hedges, net of tax effects of
$(10.9) in 2008, $(1.3) in 2007 and $(1.8) in 2006 | | | 43.4 | | | | 27.0 | | | | 8.7 | |
Unrealized gains/(losses) on securities, net of tax effects of $(15.2) in 2008,
$0.9 in 2007 and $0.9 in 2006 | | | 24.4 | | | | (1.4 | ) | | | (1.4 | ) |
| Reclassification adjustments on securities, net of tax effects of $15.0 in 2008 | | | (23.8 | ) | | | – | | | | – | |
Prior service cost and unrecognized gain/(loss) in actuarial assumptions,
net of tax effects of $14.1 in 2008 and $(0.4) in 2007 | | | (79.9 | ) | | | 4.2 | | | | – | |
| Minimum pension liability adjustment, net of tax effects of $(0.6) in 2006 | | | – | | | | – | | | | 0.9 | |
| | | | | | | | | |
| | | | | | | | | |
| Other comprehensive income (loss) | | | (50.3 | ) | | | 81.1 | | | | 95.3 | |
| | | | | | | | | |
| | | | | | | | | |
| Comprehensive Income | | $ | 798.3 | | | $ | 854.3 | | | | $929.8 | |
| | | | | | | | | |
| | | | | | | | | |
The accompanying notes are an integral part of these consolidated financial statements.
42
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
We design, develop, manufacture and market orthopaedic andreconstructive implants, dental reconstructive implants, spinal implants, trauma products and related surgical products. We also provide other healthcare related services. Orthopaedic reconstructive implants restore function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Dental reconstructive implants restore function and aesthetics in patients who have lost teeth due to trauma or disease. Spinal implants are utilized by orthopaedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities and trauma in all regions of the spine. Trauma products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. Our related surgical products include surgical supplies and instruments designed to aid in orthopaedic surgical procedures and post-operation rehabilitation. We have operations in more than 25 countries and market our products in more than 100 countries. We operate in a single industry but have three reportable geographic segments, the Americas, Europe and Asia Pacific.
The words “we”, “us”, “our” and similar words refer to Zimmer Holdings, Inc. and its subsidiaries. Zimmer Holdings refers to the parent company only.
| | |
| 2. | | SIGNIFICANT ACCOUNTING POLICIES |
Basis of Presentation – The consolidated financial statements include the accounts of Zimmer Holdings and its subsidiaries in which it holds a controlling equity position. Investments in companies in which we exercise significant influence over the operating and financial affairs, but do not control, are accounted for under the equity method. Under the equity method, we record the investment at cost and adjust the carrying amount of the investment by our proportionate share of the investee’s net earnings or losses. All significant intercompany accounts and transactions are eliminated. Certain amounts in the 20072008 and 20062007 consolidated financial statements have been reclassified to conform to the 20082009 presentation.
Use of Estimates – The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States and include amounts that are based on management’s bestwhich require us to make estimates and judgments.assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Foreign Currency Translation – The financial statements of our foreign subsidiaries are translated into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for operating results. Unrealized translation gains and losses are included in accumulated other comprehensive income in stockholders’ equity. When a transaction is denominated in a currency other than the subsidiary’s functional currency, we recognize a transaction gain or loss when the transaction is settled. Foreign currency transaction gains and losses included in net earnings for the years ended December 31, 2009, 2008 2007 and 20062007 were not significant.
Revenue Recognition – We sell product through three principal channels: 1) direct to healthcare institutions, referred to as direct channel accounts; 2) through stocking distributors and healthcare dealers; and 3) directly to dental practices and dental laboratories. The direct channel accounts represent approximately 80 percent of our net sales. Through this channel, inventory is generally consigned to sales agents or customers so that products are available when needed for surgical procedures. No revenue is recognized upon the placement of inventory into consignment as we retain title and maintain the inventory on our balance sheet. Upon implantation, we issue an invoice and revenue is recognized. Pricing for products is generally predetermined by contracts with customers, agents acting on behalf of customer groups or by government regulatory bodies, depending on the market. Price discounts under group purchasing contracts are generally linked to volume of implant purchases by customer healthcare institutions within a specified group. At negotiated thresholds within a contract buying period, price discounts may increase. Sales to stocking distributors, healthcare dealers, dental practices and dental laboratories account for approximately 20 percent of our net sales. With these types of sales, revenue is recognized when title to product passes, either upon shipment of the product or in some cases upon implantation of the product. Product is generally sold at contractually fixed prices for specified periods. Payment terms vary by customer, but are typically less than 90 days. In some cases sales incentives may be earned by a customer for purchasing a specified amount of our product. We estimate whether such incentives will be achieved and, if so, recognize these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. Occasionally products are returned, and, accordingly, we maintain an estimated sales return reserve that is recorded as a reduction in revenue. Product returns were not significant for the years ended December 31, 2009, 2008 2007 and 2006.2007.
The reserves for doubtful accounts were $20.0$18.8 million and $21.7$20.0 million as of December 31, 20082009 and 2007,2008, respectively.
Shipping and Handling – Amounts billed to customers for shipping and handling of products are reflected in net sales and are not significant. Expenses incurred related to shipping and handling of products are reflected in selling, general and administrative and were $121.8 million, $117.3 million $104.1 million and $95.5$104.1 million for the years ended December 31, 2009, 2008 2007 and 2006,2007, respectively.
Acquisition, Integration, Realignment and Other – We recognize incremental expenses resulting directly from our business combinations and significant nonrecurring and unusualother items as “Acquisition, integration, and other” expenses. Acquisition, integration and other expenses for the years ended
4342
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
realignment and other” expenses. Acquisition, integration, realignment and other expenses for the years ended December 31, 2009, 2008 2007 and 2006,2007, included (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Gain on disposition, adjustment or impairment of acquired assets and obligations | | $ | (9.0 | ) | | $ | (1.2 | ) | | $ | (19.2 | ) | |
| Adjustment or impairment of acquired assets and obligations, net | | | $ | (1.5 | ) | | $ | (10.4 | ) | | $ | (1.2 | ) |
| Consulting and professional fees | | | 10.1 | | | | 1.0 | | | | 8.8 | | | | 11.7 | | | | 13.2 | | | | 1.0 | |
| Employee severance and retention | | | 1.9 | | | | 1.6 | | | | 3.3 | | |
| Employee severance and retention, including share-based compensation acceleration | | | | 19.0 | | | | 0.2 | | | | 1.6 | |
| Information technology integration | | | 0.9 | | | | 2.6 | | | | 3.0 | | | | 1.1 | | | | 0.7 | | | | 2.6 | |
| In-process research & development | | | 38.5 | | | | 6.5 | | | | 2.9 | | | | – | | | | 38.5 | | | | 6.5 | |
| Integration personnel | | | – | | | | – | | | | 2.5 | | |
| Vacated facilities | | | | 1.4 | | | | – | | | | – | |
| Facility and employee relocation | | | 7.5 | | | | – | | | | 1.0 | | | | 5.4 | | | | 7.5 | | | | – | |
| Distributor acquisitions | | | 7.3 | | | | 4.1 | | | | – | | | | 1.1 | | | | 6.9 | | | | 4.1 | |
| Sales agent and lease contract terminations | | | 8.1 | | | | 5.4 | | | | 0.2 | | |
| Certain litigation matters | | | | 23.4 | | | | – | | | | – | |
| Contract terminations | | | | 9.4 | | | | 5.7 | | | | 5.4 | |
| Other | | | 3.2 | | | | 5.2 | | | | 3.6 | | | | 4.3 | | | | 6.2 | | | | 5.2 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Acquisition, Integration and Other | | $ | 68.5 | | | $ | 25.2 | | | $ | 6.1 | | |
| Acquisition, integration, realignment and other | | | $ | 75.3 | | | $ | 68.5 | | | $ | 25.2 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Included in the gain on disposition, adjustmentAdjustment or impairment of acquired assets and obligations for 2008 is a favorable adjustmentrelates to impairment on assets that were acquired in business combinations or adjustments to certain liabilities of acquired companies due to changes in circumstances surrounding those liabilities subsequent to the related measurement period. Included in the gain on disposition, adjustment or impairment of acquired assets and obligations for 2006 is the sale of the former Centerpulse Austin land and facilities for a gain of $5.1 million and the favorable settlement of two pre-acquisition contingent liabilities. These gains were offset by a $13.4 million impairment charge for certain Centerpulse tradename and trademark intangibles based principally in our Europe operating segment. In-process research and development charges for 2008 are related to the acquisition of Abbott Spine. In-process research and development charges for 2007 are related to the acquisitions of Endius and ORTHOsoft.
Consulting and professional fees relate to third-party integration consulting performed in a variety of areas such as tax, compliance, logistics and human resources and include third-party fees related to severance and termination benefits matters. These fees also include legal fees related to litigation matters involving acquired businesses that existed prior to our acquisition or resulted from our acquisition.
During 2009, we commenced a global realignment initiative to focus on business opportunities that best support our strategic priorities. As part of this realignment, we initiated changes in our work force, eliminating positions in some areas and increasing others. Approximately 300 employees from across the globe were affected by these actions. As a result of these changes in our work force and headcount reductions from acquisitions, we recorded expense of $19.0 million related to severance and other employee termination-related costs. These termination benefits were provided in accordance with our existing or local government policies and are considered ongoing benefits. These costs were accrued when they became probable and estimable and were recorded as part of other current liabilities. The majority of these costs were paid during 2009.
Information technology integration relates to the non-capitalizable costs associated with integrating the information systems of acquired businesses.
In-process research and development charges for 2008 relate to the acquisition of Abbott Spine. In-process research and development charges for 2007 relate to the acquisitions of Endius and ORTHOsoft.
In 2009, we ceased using certain leased facilities and, accordingly, recorded expense for the remaining lease payments, less estimated sublease recoveries, and wrote-off any assets being used in those facilities.
Facility and employee relocation relates to costs associated with relocating certain facilities. Most notably, we consolidated our legacy European distribution centers into a new distribution center in Eschbach, Germany.
Over the past three years we have acquired a number of U.S. and foreign-based distributors. We have incurred various costs related to the acquisition and integration of those businesses.
Certain litigation matters relate to costs recognized during the year for the estimated or actual settlement of various legal matters, including patent litigation matters, commercial litigation matters and matters arising from our acquisitions of certain competitive distributorships in prior years. We recognize expense for the potential settlement of a legal matter when we believe it is probable that a loss has been incurred and we can reasonably estimate the loss. In 2009, we made a concerted effort to settle many of these matters to avoid further litigation costs.
Contract termination costs relate to terminated agreements in connection with the integration of acquired companies. The terminated contracts primarily relate to sales agents and distribution agreements.
Cash and Cash Equivalents – We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. The carrying amounts reported in the balance sheet for cash and cash equivalents are valued at cost, which approximates their fair value. Restricted
Certificates of Deposit – We invest in cash is primarily composeddeposits with original maturities greater than three months and classify these investments as certificates of cash helddeposit on our consolidated balance sheet. The carrying amounts reported in escrow related to certain insurance coverage.the balance sheet for certificates of deposit are valued at cost, which approximates their fair value.
Inventories – Inventories, net of allowances for obsolete and slow-moving goods, are stated at the lower of cost or market, with cost determined on afirst-in first-out basis.
Property, Plant and Equipment – Property, plant and equipment is carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method based on estimated useful lives of ten to forty years for buildings and improvements and three to eight years for machinery and equipment. Maintenance and repairs are expensed as incurred. In accordance with Statement of Financial Accounting Standards (“SFAS”) No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets,” weWe review property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value.
43
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
Software Costs – We capitalize certain computer software and software development costs incurred in connection with developing or obtaining computer software for internal use when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs generally include external direct costs of materials and services utilized in developing or obtaining computer software and compensation and related benefits for employees who are directly associated with the software project. Capitalized software costs are included in property, plant and equipment on our balance sheet and amortized on a straight-line basis when the software is ready for its intended use over the estimated useful lives of the software, which approximate three to seventen years.
Instruments – Instruments are hand-held devices used by orthopaedic surgeons during total joint replacement and other surgical procedures. Instruments are recognized as long-lived assets and are included in property, plant and equipment. Undeployed instruments are carried at cost, net of allowances for excess and obsolete instruments. Instruments in the field are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method based on average estimated useful lives, determined principally in reference to associated product life cycles, primarily five years. We review instruments for impairment whenever events or changes in accordance with SFAS No. 144.circumstances indicate that the carrying value of an instrument may not be recoverable. Depreciation of instruments is recognized as selling, general and administrative expense.
Goodwill – We account for goodwill in accordance with SFAS No. 142, “Goodwill and Other Intangible Assets.” Goodwill is not amortized but is subject to annual impairment tests. Goodwill has been assigned to reporting units. We perform annual impairment tests by comparing each reporting unit’s fair value to its carrying amount to determine if there is potential impairment. The fair value of the reporting unit and the implied fair value of goodwill are determined based upon a discounted cash flow analysis. Significant assumptions are incorporated into to these discounted cash flow analyses such as estimated growth rates and risk-adjusted discount rates. We perform this test in the fourth quarter of the year.year or whenever events or changes in circumstances indicate that the carrying value of the reporting unit’s assets may not be recoverable. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit goodwill is less than the carrying value of the reporting unit goodwill. During the year ended December 31, 2009, we recorded a goodwill impairment charge of $73.0 million related to our U.S. Spine reporting unit. See Note 8 for more information regarding goodwill and goodwill impairment.
Intangible Assets – We account for intangible assets in accordance with SFAS No. 142. Intangible assets are initially measured at their fair value. We have determined the fair value of our intangible assets either by the fair value of the
44
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
consideration exchanged for the intangible asset or the estimated after-tax discounted cash flows expected to be generated from the intangible asset. Intangible assets with an indefinite life, including certain trademarks and trade names, are not amortized. Indefinite life intangible assets are assessed annually to determine whether events and circumstances continue to support an indefinite life. Intangible assets with a finite life, including core and developed technology, certain trademarks and trade names, customer-related intangibles, intellectual property rights and patents and licenses are amortized on a straight-line basis over their estimated useful life, ranging from less than one year to 40 years. Intangible assets with a finite life are tested for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. Intangible assets with an indefinite life are tested for impairment annually or whenever events or circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized if the carrying amount exceeds the estimated fair value of the asset. The amount of the impairment loss to be recorded would be determined based upon the excess of the asset’s carrying value over its fair value. The fair values of indefinite lived intangible assets are determined based upon a discounted cash flow analysis using the relief from royalty method. The relief from royalty method estimates the cost savings associated with owning, rather than licensing, assets. Significant assumptions are incorporated into to these discounted cash flow analyses such as estimated growth rates, royalty rates and risk-adjusted discount rates.
The useful lives of intangible assets range from less than one year to 40 years. In determining the useful lives of intangible assets, we consider the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, we consider the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology. Trademarks and trade names that do not have a wasting characteristic (i.e., there are no legal, regulatory, contractual, competitive, economic or other factors which limit the useful life) are assigned an indefinite life. Trademarks and trade names that are related to products expected to be phased out are assigned lives consistent with the period in which the products bearing each brand are expected to be sold. For customer relationship intangible assets, we assign useful lives based upon historical levels of customer attrition. Intellectual property rights are assigned useful lives that approximate the contractual life of any related patent or the period for which we maintain exclusivity over the intellectual property.
Research and Development – We expense all research and development costs as incurred. Research and development costs include salaries, prototypes, depreciation of equipment used in research and development, consultant fees and service fees paid to collaborative partners.
Income Taxes – We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
44
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
consequences of events that have been included in accordance with SFAS No. 109, “Accounting for Income Taxes” and related interpretations, including FIN 48. Deferredthe financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reportingstatements and tax basesbasis of assets and liabilities and are measured using the enacted tax rates in effect for the yearsyear in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S.
Derivative Financial Instruments – We account for all derivative financial instruments in accordance with SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities,” as amended by SFAS No. 138, “Accounting for Certain Derivative Instruments and Certain Hedging Activities (an amendment of FASB Statement No. 133)” and SFAS No. 149, “Amendment of Statement 133 on Derivative Instruments and Hedging Activities.” SFAS No. 133 requires thatmeasure all derivative instruments be reportedat fair value and report them on our consolidated balance sheet as assets or liabilities on the balance sheet and measured at fair value.liabilities. We maintain written policies and procedures that permit, under appropriate circumstances and subject to proper authorization, the use of derivative financial instruments solely for hedging purposes. The use of derivative financial instruments for trading or speculative purposes is prohibited by our policy. We are exposed to market risk due to changes in currency exchange rates. As a result, we utilize foreign exchange forward contracts and options to offset the effect of exchange rate fluctuations on anticipated foreign currency transactions, generally intercompany sales and purchases expected to occur within the next twelve to thirty months. Derivative instruments that qualify as cash flow hedges are designated as such from inception. We maintain formal documentationSee Note 11 for more information regarding our objectives, the nature of the risk being hedged, identification of the instrument, the hedged transaction, thederivative and hedging relationship and how effectiveness of the hedging instrument will be assessed. Our policy requires that critical terms of a hedging instrument are effectively the same as a hedged forecasted transaction. On this basis, with respect to a cash flow hedge, changes in cash flows attributable to the hedged transaction are generally expected to be completely offset by the cash flows attributable to hedge instruments. We, therefore, perform quarterly assessments of hedge effectiveness by verifying and documenting those critical terms of the hedge instrument and that forecasted transactions have not changed. We also assess on a quarterly basis whether there have been adverse developments regarding the risk of a counterparty default. For derivatives which qualify as hedges of future cash flows, the effective portion of changes in fair value is temporarily recorded in other comprehensive income and then recognized in cost of products sold when the hedged item affects net earnings. The ineffective portion of a derivative’s change in fair value, if any, is reported in cost of products sold immediately. The net amount recognized in earnings duringactivities.
45
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
the years ended December 31, 2008, 2007 and 2006, due to ineffectiveness and amounts excluded from the assessment of hedge effectiveness, was not significant.
For contracts outstanding at December 31, 2008, we have an obligation to purchase U.S. Dollars and sell Euros, Japanese Yen, British Pounds, Canadian Dollars, Australian Dollars and Korean Won and purchase Swiss Francs and sell U.S. Dollars at set maturity dates ranging from January 2009 through June 2011. The notional amounts of outstanding forward contracts entered into with third parties to purchase U.S. Dollars at December 31, 2008 were $1,343.0 million. The notional amounts of outstanding forward contracts entered into with third parties to purchase Swiss Francs at December 31, 2008 were $207.5 million. The fair value of outstanding derivative instruments recorded on the balance sheet at December 31, 2008, together with settled derivatives where the hedged item has not yet affected earnings, was a net unrealized gain of $32.7 million, or $33.0 million net of taxes, which is deferred in other comprehensive income, of which $16.4 million, or $17.9 million, net of taxes, is expected to be reclassified to earnings over the next twelve months.
We also enter into foreign currency forward exchange contracts with terms of one month to manage currency exposures for assets and liabilities denominated in a currency other than an entity’s functional currency. As a result, any foreign currency remeasurement gains/losses recognized in earnings under SFAS No. 52, “Foreign Currency Translation,” are generally offset with gains/losses on the foreign currency forward exchange contracts in the same reporting period.
Other Comprehensive Income – Other comprehensive income refers to revenues, expenses, gains and losses that under generally accepted accounting principles are included in comprehensive income but are excluded from net earnings as these amounts are recorded directly as an adjustment to stockholders’ equity. Other comprehensive income is comprised of foreign currency translation adjustments, unrealized foreign currency hedge gains and losses, unrealized gains and losses onavailable-for-sale securities and amortization of prior service costs and unrecognized gains and losses in actuarial assumptions. In 2006 we adopted SFAS 158, “Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans – an amendment of FASB Statements No. 87, 88, 106 and 132(R).” This statement required recognition of the funded status of our benefit plans in the statement of financial position and recognition of certain deferred gains or losses in other comprehensive income. We recorded an unrealized loss of $35.4 million in other comprehensive income during 2006 related to the adoption of SFAS 158.
The components of accumulated other comprehensive income are as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Balance at
| | Other
| | Balance at
| | | Balance at
| | Other
| | Balance at
| |
| | | December 31,
| | Comprehensive
| | December 31,
| | | December 31,
| | Comprehensive
| | December 31,
| |
| | | 2007 | | Income (Loss) | | 2008 | | | 2008 | | Income (Loss) | | 2009 | |
| | | | | |
| |
| Foreign currency translation | | $ | 368.8 | | | $ | (49.4 | ) | | $ | 319.4 | | | $ | 319.4 | | | $ | 114.0 | | | $ | 433.4 | |
| Foreign currency hedges | | | (45.4 | ) | | | 78.4 | | | | 33.0 | | | | 33.0 | | | | (47.0 | ) | | | (14.0 | ) |
| Unrealized gain/(loss) on securities | | | (1.9 | ) | | | 0.6 | | | | (1.3 | ) | | | (1.3 | ) | | | (0.3 | ) | | | (1.6 | ) |
| Unrecognized prior service cost and unrecognized gain/(loss) in actuarial assumptions | | | (31.2 | ) | | | (79.9 | ) | | | (111.1 | ) | |
| Unrecognized prior service cost and | | | | | | | | | | | | | |
| unrecognized gain/(loss) in actuarial assumptions | | | | (111.1 | ) | | | 51.9 | | | | (59.2 | ) |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Accumulated other comprehensive income | | $ | 290.3 | | | $ | (50.3 | ) | | $ | 240.0 | | | $ | 240.0 | | | $ | 118.6 | | | $ | 358.6 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
During 2008, we reclassified an investment previously accounted for under the equity method to anavailable-for-sale investment as we no longer exercised significant influence over the third-party investee. The investment wasmarked-to-market in accordance with SFAS 115, “Accountingthe FASB’s guidance on accounting for Certain Investmentscertain investments in Debtdebt and Equity Securities,”equity securities, resulting in a net unrealized gain of $23.8 million recorded in other comprehensive income for 2008. This unrealized gain was reclassified to the income statement when we sold this investment in 2008 for total proceeds of $54.9 million and a gross realized gain of $38.8 million included in interest and other income. The basis of these securities was determined based on the consideration paid at the time of acquisition.
Treasury Stock – We account for repurchases of common stock under the cost method and present treasury stock as a reduction of shareholders equity. We may reissue common stock held in treasury only for limited purposes.
Noncontrolling Interest – On January 1, 2009, we adopted the FASB’s newly issued guidance related to noncontrolling interests. This new guidance changes the accounting and reporting for minority interests, which are now recharacterized as noncontrolling interests and classified as a component of equity. This new guidance requires retroactive adoption of the presentation and disclosure requirements for existing noncontrolling interests. This adoption did not have a material impact on our consolidated financial statements or results of operations. During the year ended December 31, 2009, we acquired 100 percent ownership of our only outstanding noncontrolling interest for approximately $8.6 million. This purchase was recorded as an equity transaction and is reflected as a financing activity in our consolidated statement of cash flows. As a result, the carrying balance of the noncontrolling interests of $3.6 million was eliminated, and the remaining $5.0 million, representing the difference between the purchase price and carrying balance, was recorded as a reduction in paid-in capital. Transactions with noncontrolling interests had the following
45
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
effect on equity attributable to Zimmer Holdings, Inc. (in millions):
| | | | | | | | | |
| | | 2009 | | | 2008 | |
| | |
| |
| Net earnings of Zimmer Holdings, Inc. | | $ | 717.4 | | | $ | 848.6 | |
| Transfers to noncontrolling interests: | | | | | | | | |
| Decrease in equity related to the purchase of noncontrolling interests | | | (5.0 | ) | | | – | |
| | | | | |
| | | | | |
| Change from net earnings of Zimmer Holdings, Inc. and transfers to noncontrolling interests | | $ | 712.4 | | | $ | 848.6 | |
| | | | | |
| | | | | |
Accounting Pronouncements – In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements,”guidance related to fair value measurements, which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement doesguidance did not require any new fair value measurements, but providesprovided guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. In February 2008, the FASB issued FASB Staff Position (FSP)No. SFAS 157-2, which delaysdelayed the effective date of certain provisions of SFAS No. 157this fair value guidance relating to non-financial assets and liabilities measured at fair value on a non-recurring basis until fiscal years beginning after November 15, 2008. The fullIn January 2009, we adopted these additional provisions of the FASB’s fair value guidance. This adoption of SFAS No. 157 isdid not expected to have a material impact on our consolidated financial statements or results of operations. See Note 7 for more information on fair value measurements of assets and liabilities.
46
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
NotesOn January 1, 2009, we adopted the FASB’s newly issued guidance related to Consolidated Financial Statements(Continued)
In December 2007, the FASB issued SFAS No. 141(R), “Business Combinations,” which is a revision of SFAS No. 141 “Business Combinations.” SFAS No. 141(R) will change the way in which we account for business combinations. The StatementThis guidance introduces new purchase accounting concepts, expands the use of fair value accounting related to business combinations and changes the subsequent period accounting for certain acquired assets and liabilities, among other things. SFAS No. 141(R) will be applied prospectively on business combinations with acquisition dates in fiscal years beginning on or after December 15, 2008, and therefore this statement will not affect our financial statementsliabilities. Additionally, it changes the accounting for business combinations that preceded the effective date. For deferred tax assets and income tax reserves recorded as part of a business combinations, these assets will be accounted for under SFAS 109 and FIN 48 after the effective date regardless of the acquisition date. Therefore, ifcombination. If a remeasurement of thosethese assets andor liabilities is warranted after the effective date of this statement,January 1, 2009, it maywill affect our income tax expense as opposed to the previous accounting guidance which would have required goodwill to be adjusted. We have applied this guidance to business combinations with acquisition dates occurring in the period in which the remeasurement occurs.
In December 2007, the FASB also issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB 51.” SFAS No. 160 will change the accounting and reporting for minority interests, which will be recharacterized as noncontrolling interests and classified as a component of equity. SFAS No. 160 requires retroactive2009. This adoption of the presentation and disclosure requirements for existing minority interests. SFAS No. 160 is effective for fiscal years beginning on or after December 15, 2008 and interim periods within those fiscal years. We dodid not expect that the adoption of SFAS No. 160 will have a material impact on our consolidated financial statements or results of operations.
In March 2008,On January 1, 2009, we adopted the FASBFASB’s newly issued SFAS No. 161, “Disclosuresguidance related to disclosures about Derivative Instrumentsderivative instruments and Hedging Activities, an amendment of SFAS No. 133.” SFAS No. 161 will requirehedging activities. This guidance requires increased disclosure of our derivative and hedging activities, including how derivative and hedging activities affect our consolidated statement of earnings, balance sheet and cash flows. SFAS No. 161 is effective for fiscal years beginning on or after December 15, 2008 and interim periods within those fiscal years. The adoption of SFAS No. 161 will increase the required disclosure of our derivative and hedging activities,flows, but willdoes not have any impact on our financial position or results of operations. See Note 11 for more information on our derivative instruments and hedging activities.
In May 2009, the FASB issued new guidance related to the accounting for and disclosure of subsequent events, which is effective for interim and annual periods ending after June 15, 2009. This new guidance establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. This guidance introduces new terminology but is based on the same principles that previously existed in the auditing standards. Under this new guidance we are required to provide disclosure of the date through which we have evaluated subsequent events and whether that date represents the date the financial statements were issued or the date the financial statements were available to be issued. For the financial statements related to the years ended December 31, 2009, 2008 and 2007 contained herein, we have evaluated subsequent events through February 25, 2010 representing the date these financial statements were issued.
In July 2006, the FASB issued guidance which clarifies the accounting for uncertainty in income taxes recognized in the financial statements. This guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition threshold at the effective date and in subsequent periods to be recognized. The FASB also provided guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. We adopted the FASB guidance effective January 1, 2007.
| | |
| 3. | | SHARE-BASED COMPENSATION |
Our share-based payments primarily consist of stock options, restricted stock, restricted stock units (RSUs), performance shares and an employee stock purchase plan. For the year ended December 31, 2009, share-based payment expense was $75.3 million or $54.4 million net of the related tax benefits. For the year ended December 31, 2008, share-based payment expense was $69.9 million or $49.5 million net of the related tax benefits. For the year ended December 31, 2007, share-based payment expense was $70.1 million or $48.1 million net of the related tax benefits. For the year ended December 31, 2006, share-based payment expense was $76.0 million or $54.5 million net of the related tax benefits.
Stock Options
We had threetwo equity compensation plans in effect at December 31, 2008:2009: the 2009 Stock Incentive Plan (2009 Plan) and the Stock Plan for Non-Employee Directors. The 2009 Plan succeeds the 2006 Stock Incentive Plan (the “2006 Plan”), and the TeamShare Stock Option Plan and the Stock Plan for Non-Employee Directors. The 2006 Plan replaced the 2001 Stock Incentive Plan (the “2001 Plan”), which by its terms expired in August 2006.(TeamShare Plan). Following stockholder approval of the 20062009 Plan in May 2006,2009, no further awards were granted under the 20012006 Plan or under the TeamShare Plan, and shares remaining available for
46
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
grant under those plans are expected to be merged into the 2009 Plan. However, vestedVested and unvested stock options and unvested restricted stock and RSUs previously granted under the 2006 Plan, the TeamShare Plan and another prior plan, the 2001 Stock Incentive Plan, remained outstanding as of December 31, 2008.2009. We have reserved the maximum number of shares of common stock available for award under the terms of each of these plans andplans. We have registered 52.9 million shares of common stock.stock and expect to register an additional 5 million shares under the Securities Act of 1933, as amended. The 20062009 Plan provides for the grant of nonqualified stock options and incentive stock options, long-term performance awards in the form of performance shares or units, restricted stock, restricted stock unitsRSUs and stock appreciation rights. The Compensation and Management Development Committee of the Board of Directors determines the grant date for annual grants under our equity compensation plans. The date for annual grants under the 20062009 Plan to our executive officers is expected to occur in Februarythe first quarter of each year following the earnings announcements for the previous quarter and full year. The TeamShare Stock Option Plan provides for the grant of non-qualified stock options and, in certain jurisdictions, stock appreciation rights, while the Stock Plan for Non-Employee Directors provides for awards of stock options, restricted stock and restricted stock unitsRSUs to non-employee directors. It has been our practice to issue shares of common stock upon exercise of stock options from previously unissued shares. The total number of awards which may be granted in a given yearand/or over the life of the plan under each of our equity compensation plans is limited. At December 31, 2008,2009, an aggregate of 11.214.2 million shares were available for future grants and awards under these plans.
Stock options granted to date under our plans generally vest over four years and generally have a maximum contractual life of 10 years. As established under our equity compensation plans, vesting may accelerate upon retirement after the first anniversary date of the award if certain criteria are met. We recognize expense related to stock options on a straight-line basis over the vestingrequisite service period, for the entire award, less awards expected to be forfeited using estimated forfeiture rates. Due to the accelerated retirement provisions, the requisite service period of our stock options range from one to four years. Stock options are granted with an exercise price equal to the market price of our common stock on the date of grant, except in limited circumstances where local law may dictate otherwise. In the past, certain options have had price thresholds, which affect exercisability. All such price thresholds have been satisfied. The total number of awards which may be granted in a given yearand/or over the life of the plan under each of our stock option plans is limited to control dilution.
47
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
A summary of stock option activity for the year ended December 31, 20082009 is as follows (options in thousands):
| | | | | | | | | | | | | | | | | |
| | | | | Weighted Average
| | | | | Weighted Average
| |
| | | Stock Options | | Exercise Price | | | Stock Options | | Exercise Price | |
| | | | | |
| |
| Outstanding at December 31, 2007 | | | 14,107 | | | $ | 67.94 | | |
| Outstanding at December 31, 2008 | | | | 15,900 | | | $ | 71.25 | |
| Options granted | | | 3,975 | | | | 76.45 | | | | 2,567 | | | | 40.12 | |
| Options exercised | | | (1,190 | ) | | | 43.68 | | | | (176 | ) | | | 30.32 | |
| Options cancelled | | | (698 | ) | | | 77.87 | | | | (799 | ) | | | 63.61 | |
| Options expired | | | (294 | ) | | | 76.85 | | | | (580 | ) | | | 75.56 | |
| | | | | | | | | | | |
| | | | | | | |
| Outstanding at December 31, 2008 | | | 15,900 | | | $ | 71.25 | | |
| Outstanding at December 31, 2009 | | | | 16,912 | | | | 67.17 | |
| | | | | | | | | | | |
| | | | | | | |
The following table summarizes information about stock options outstanding at December 31, 20082009 (options in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Outstanding | | | | | | | Outstanding | | Exercisable | |
| | | | | Weighted
| | | | Exercisable | | | | | Weighted
| | | | | | | |
| | | | | Average
| | Weighted
| | | | Weighted
| | | | | Average
| | Weighted
| | | | Weighted
| |
| | | | | Remaining
| | Average
| | | | Average
| | | | | Remaining
| | Average
| | | | Average
| |
| Range of Exercise Prices | | Options | | Contractual Life | | Exercise Price | | Options | | Exercise Price | | | Options | | Contractual Life | | Exercise Price | | Options | | Exercise Price | |
| | | | | |
| |
| $22.00 – $27.50 | | | 187 | | | | 1.85 | | | $ | 24.76 | | | | 187 | | | $ | 24.76 | | | | 137 | | | | 1.11 | | | $ | 25.73 | | | | 137 | | | $ | 25.73 | |
| $27.51 – $37.50 | | | 915 | | | | 2.46 | | | | 30.64 | | | | 915 | | | | 30.64 | | | | 858 | | | | 2.10 | | | | 30.84 | | | | 814 | | | | 30.55 | |
| $39.50 – $51.00 | | | 734 | | | | 4.19 | | | | 44.02 | | | | 734 | | | | 44.02 | | |
| $55.00 – $70.50 | | | 2,970 | | | | 6.01 | | | | 68.64 | | | | 2,403 | | | | 69.30 | | |
| $71.00 – $91.00 | | | 11,094 | | | | 7.79 | | | | 77.88 | | | | 3,900 | | | | 77.93 | | |
| $37.51 – $51.00 | | | | 2,928 | | | | 7.69 | | | | 41.08 | | | | 715 | | | | 44.01 | |
| $51.01 – $70.50 | | | | 2,813 | | | | 4.98 | | | | 68.67 | | | | 2,522 | | | | 68.97 | |
| $70.51 – $91.00 | | | | 10,176 | | | | 6.92 | | | | 77.88 | | | | 5,993 | | | | 77.95 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
| | | | 15,900 | | | | 6.91 | | | $ | 71.25 | | | | 8,139 | | | $ | 65.79 | | | | 16,912 | | | | 6.44 | | | | 67.17 | | | | 10,181 | | | | 68.85 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
We use a Black-Scholes option-pricing model to determine the fair value of our stock options. Expected volatility was derived from the implied volatility of our traded options that were actively traded around the grant date of the stock options with exercise prices similar to the stock options and maturities of over one year. The expected term of the stock options has been derived from historical employee exercise behavior. The risk-free interest rate is determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term equal to the expected life of the options. A dividend yield of zero percent has been used as we have not paid a dividend since becoming a public company in 2001.2001 and we do not expect to pay a dividend in the foreseeable future.
47
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
The weighted average fair value of the options granted in the years ended December 31, 2009, 2008 2007 and 20062007 were determined using the following assumptions:
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Dividend Yield | | | – | % | | | – | % | | | – | % | | | – | % | | | – | % | | | – | % |
| Volatility | | | 27.4 | % | | | 23.8 | % | | | 25.7 | % | | | 41.6 | % | | | 27.4 | % | | | 23.8 | % |
| Risk-free interest rate | | | 2.9 | % | | | 4.4 | % | | | 4.5 | % | | | 1.7 | % | | | 2.9 | % | | | 4.4 | % |
| Expected life (years) | | | 5.4 | | | | 5.1 | | | | 5.1 | | | | 5.4 | | | | 5.4 | | | | 5.1 | |
The weighted average fair value for stock options granted during 2009, 2008 and 2007 was $16.02, $23.32 and 2006 was $23.32, $22.60, and $22.32, respectively. The total intrinsic value of stock options exercised during the years ended December 31, 2009, 2008 and 2007 and 2006 was $3.3 million, $31.9 million $124.5 million and $40.5$124.5 million, respectively. For the years ended December 31, 2009, 2008 2007 and 2006,2007, share-based payment expense related to stock options was $61.9 million, $65.4 million $73.4 million and $66.3$73.4 million, respectively, or $44.7 million, $46.3 million $50.4 million and $47.7$50.4 million net of the related tax benefits, respectively.
Summarized information about outstanding stock options as of December 31, 20082009 that are already vested and that we expect to vest, as well as stock options that are currently exercisable, is as follows:
| | | | | | | | | | | | | | | | | |
| | | Outstanding Stock
| | | | | Outstanding Stock
| | | |
| | | Options Already
| | Options
| | | Options Already
| | Options
| |
| | | Vested and Expected
| | that are
| | | Vested and Expected
| | that are
| |
| | | to Vest* | | Exercisable | | | to Vest* | | Exercisable | |
| | | | | |
| |
| Number of outstanding options (in thousands) | | | 15,096 | | | | 8,139 | | | | 16,008 | | | | 10,181 | |
| Weighted average remaining contractual life | | | 6.9 years | | | | 5.6 years | | | | 6.3 years | | | | 5.3 years | |
| Weighted average exercise price per share | | | $70.94 | | | | $65.79 | | | | $67.37 | | | | $68.85 | |
| Intrinsic value (in millions) | | | $12.2 | | | | $12.2 | | | | $75.3 | | | | $38.6 | |
| |
| * | Includes effects of estimated forfeitures |
As of December 31, 2008,2009, there was $117.5$85.1 million of unrecognized share-based payment expense related to nonvested stock options granted under our plans. That expense is expected to be recognized over a weighted average period of 2.72.3 years.
Performance Shares and RSUs
We grantedhave utilized both performance shares and performance-based RSUs in 2006 and 2007, respectively,as share-based payments to our employees. Some of these awards have had service conditions while others have had performance conditions. The terms of the service condition awards have been either two or four years with vesting occurring ratably on the anniversary date of the award. However, based upon meeting certain criteria, as established under our equity compensation plans, these awards may accelerate upon retirement after the first anniversary date of the award. Accordingly, the requisite service period used for share-based payment expense ranges from one to four years.
The vesting of which depended onthe awards with performance conditions was based upon the achievement of objective performance targets over periods endedmultiple year periods. For these performance-based awards, it was determined in 2008 that the performance targets would not be achieved. Accordingly, as of December 31, 2008. The
48
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
performance targets related to these2009 and 2008, no performance-based awards were not met and the related performance shares and RSUs were forfeited. We also granted RSUs in December 2007. These RSUs are not tied to our performance and vest ratably on the first and second anniversaries of the date of grant, provided that the recipient is still our employee. Each of these awards are converted into one share of our common stock upon vesting.outstanding.
A summary of nonvested performance share and RSU activity for the year ended December 31, 20082009 is as follows (Performance Shares and RSUs in(in thousands):
| | | | | | | | | | | | | | | | | |
| | | | | Weighted Average
| | | | | Weighted Average
| |
| | | Performance
| | Grant Date
| | | | | Grant Date Fair
| |
| | | Shares and RSUs | | Fair Value | | | RSUs | | Value | |
| | | | | |
| |
| Outstanding at January 1, 2008 | | | 1,147 | | | $ | 69.35 | | |
| Outstanding at January 1, 2009 | | | | 169 | | | $ | 64.93 | |
| Granted | | | 40 | | | | 53.29 | | | | 573 | | | | 40.33 | |
| Vested | | | (123 | ) | | | 68.29 | | | | (118 | ) | | | 68.27 | |
| Forfeited | | | (895 | ) | | | 69.64 | | | | (189 | ) | | | 41.28 | |
| | | | | | | | | | | |
| | | | | | | |
| Outstanding at December 31, 2008 | | | 169 | | | $ | 64.93 | | |
| Outstanding at December 31, 2009 | | | | 435 | | | | 42.09 | |
| | | | | | | | | | | |
| | | | | | | |
The fair value of the awards was determined based upon the fair market value of our common stock on the date of grant. SFAS 123(R) requires usWe are required to estimate the number of performance shares and RSUs that will vest and recognize share-based payment expense on a straight linestraight-line basis over the requisite service period. As of December 31, 2008,2009, we estimate that all 169,000approximately 404,000 outstanding RSUs will vest. If our estimate were to change in the future, the cumulative effect of the change in estimate will be recorded in that period. Based upon the number of RSUs that we expect to vest, the unrecognized share-based payment expense as of December 31, 20082009 was $10.0$13.2 million and is expected to be recognized over a weighted-average period of 1.43.1 years. For the years ended December 31, 2009, 2008 2007 and 2006,2007, pre-tax expense (income) related to these awards was $13.4 million, $4.5 million $(3.3) million and $9.7$(3.3) million, respectively, or $9.7 million, $3.2 million $(2.3) million and $6.8$(2.3) million net of the related tax benefits, respectively.
Inventories at December 31, 2009 and 2008 consist of the following (in millions):
| | | | | | | | | |
| | | 2009 | | | 2008 | |
| | |
| |
| Finished goods | | $ | 718.6 | | | $ | 731.2 | |
| Work in progress | | | 48.0 | | | | 52.6 | |
| Raw materials | | | 146.6 | | | | 144.5 | |
| | | | | |
| | | | | |
| Inventories, net | | $ | 913.2 | | | $ | 928.3 | |
| | | | | |
| | | | | |
Reserves for excess and obsolete inventory were $255.1 million and $199.6 million at December 31, 2009 and 2008, respectively. Included in finished goods inventory at December 31, 2009 is approximately $1.3 million of inventorystep-up resulting from the Abbott Spine acquisition. Inventorystep-up values are based upon estimated sales prices less distribution costs and a profit allowance. Included in finished goods inventory at December 31, 2009 and 2008 is approximately $9.4 million and $11.3 of capitalized share-based payment expense, respectively.
48
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
| | |
| 5. | | PROPERTY, PLANT AND EQUIPMENT |
Property, plant and equipment at December 31, 2009 and 2008 was as follows (in millions):
| | | | | | | | | |
| | | 2009 | | | 2008 | |
| | |
| |
| Land | | $ | 21.8 | | | $ | 21.7 | |
| Building and equipment | | | 1,147.7 | | | | 992.7 | |
| Capitalized software costs | | | 158.8 | | | | 136.7 | |
| Instruments | | | 1,210.2 | | | | 1,161.7 | |
| Construction in progress | | | 62.0 | | | | 149.0 | |
| | | | | |
| | | | | |
| | | | 2,600.5 | | | | 2,461.8 | |
| Accumulated depreciation | | | (1,378.8 | ) | | | (1,197.7 | ) |
| | | | | |
| | | | | |
| Property, plant and equipment, net | | $ | 1,221.7 | | | $ | 1,264.1 | |
| | | | | |
| | | | | |
Depreciation expense was $244.2 million, $215.8 million and $182.6 million for the years ended December 31, 2009, 2008 and 2007, respectively.
We made acquisitions during the years 2009, 2008 and 2007, and 2006, the moremost significant of which arewas our acquisition of Abbott Spine in 2008, which is described below. These acquisitions were accounted for under the purchase method of accounting pursuant to SFAS No. 141. Accordingly, theThe results of operations of the acquired companies have been included in our consolidated results of operations subsequent to the transaction dates, and the respective assets and liabilities of the acquired companies have been recorded at their estimated fair values in our consolidated statement of financial position as of the transaction dates, with any excess purchase price being allocated to goodwill. Pro forma financial information and other information required by SFAS No. 141the FASB’s guidance on business combinations have not been included as the acquisitions did not have a material impact upon our financial position or results of operations.
Abbott Spine
In October 2008, we acquired Abbott Spine, a former subsidiary of Abbott Laboratories, for an aggregate value of approximately $363.0 million, including a $358.0 million cash purchase price after certain working capital adjustments and $5.0 million of direct acquisition costs. The acquisition was funded by approximately $253 million of cash on-hand and $110 million from new borrowings under our Senior Credit Facility. This investment adds a number of innovative products and builds critical mass in the Spine product category. The acquisition also enhances our research and development capabilities in the Spine product category and strengthens our sales coverage.
WeIn 2009 we completed the preliminary purchase price allocation in accordance with U.S. generally accepted accounting principles. The process included interviews with both Abbott Spine and our management, review of the economic and competitive environment and examination of assets including historical performance and future prospects. The preliminary purchase price allocation was based on information currently available to us, and expectations and assumptions deemed reasonable by us. No assurance can be given, however, that the underlying assumptions used to estimate expected technology-based product revenues, development costs or profitability, or the events associated with such technology will occur as projected. The final purchase price allocation, may vary fromwhich reflects additional contract termination liabilities, changes to the preliminary purchase price allocation. The final valuationfair values assigned to acquired inventory and associated purchase price allocation is expectedchanges to be completed during the first half of 2009. To the extent that the estimates need to be adjusted, we will do so.deferred taxes.
The following table summarizes the preliminary estimateestimates of fair valuesvalue of the assets acquired and liabilities assumed at the date of the Abbott Spine acquisition (in millions):
| | | | | |
| | | As of
| |
| | | October 16, 2008 | |
| | |
| |
| Current assets | | $ | 63.6 | |
| Property, plant and equipment | | | 6.5 | |
| Instruments | | | 17.5 | |
| Intangible assets subject to amortization: | | | | |
| Customer relationships (10 year useful life) | | | 8.6 | |
| Developed technology (10 year useful life) | | | 64.3 | |
| In-process research and development | | | 38.5 | |
| Other assets | | | 10.0 | |
| Goodwill | | | 197.4 | |
| |
| |
| Total assets acquired | | | 406.4 | |
| |
| |
| Current liabilities | | | 14.0 | |
| Deferred taxes | | | 29.4 | |
| |
| |
| Total liabilities assumed | | | 43.4 | |
| |
| |
| Net assets acquired | | $ | 363.0 | |
| |
| |
49
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
| | | | | |
| | | As of October 16,
| |
| | | 2008 | |
| | |
| |
| Current assets | | $ | 61.4 | |
| Property, plant and equipment | | | 6.5 | |
| Instruments | | | 17.5 | |
| Intangible assets subject to amortization: | | | | |
| Customer relationships (10 year useful life) | | | 8.6 | |
| Developed technology (10 year useful life) | | | 64.3 | |
| In-process research and development | | | 38.5 | |
| Other assets | | | 10.0 | |
| Goodwill | | | 203.2 | |
| |
| |
| Total assets acquired | | | 410.0 | |
| |
| |
| Current liabilities | | | 19.5 | |
| Deferred taxes | | | 27.5 | |
| |
| |
| Total liabilities assumed | | | 47.0 | |
| |
| |
| Net assets acquired | | $ | 363.0 | |
| |
| |
Goodwill of $129.3$130.6 million, $65.7$69.9 million and $2.4$2.7 million was assigned to the Americas, Europe and Asia Pacific reporting segments, respectively. None of the goodwill is deductible for tax purposes.
In-process research and development charges relate to acquired technologies for which no alternative future use has been identified at the acquisition date. The values assigned to in-process research and development (IPR&D), are based on valuations that estimate the future cash flows of the related technologies and discounting the net cash flows back to their present values utilizing an appropriate risk-adjusted rate of return (discount rate). These valuations also include consideration of the risk of the project not achieving commercial feasibility and include a factor that takes into account the uncertainty surrounding the successful development of the IPR&D.
At the time of acquisition, we expect all acquired IPR&D will reach technological feasibility, but there can be no assurance that the commercial viability of these products will actually be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, and conducting clinical trials necessary to obtain regulatory approvals. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, and patent issuance, validity and litigation, if any.
The $38.5 million of IPR&D primarily relates to projects in the following spine product categories: 1) Thoracolumbar, 2) Minimally Invasive Surgery, and 3) Cervical. The related products have projected launch dates beginning in 2009 through 2014, with estimated total costs to complete of approximately $8.5 million.
ORTHOsoft Inc.
In November 2007, we acquired ORTHOsoft Inc. (ORTHOsoft), a leader in computer navigation for orthopaedic surgery, in a cash transaction for an aggregate value of approximately $50 million. We recorded $31.3 million in goodwill in connection with the acquisition. The acquisition of ORTHOsoft bolsters our SmartTools strategic initiative to bring innovative tools to the marketplace that will help create better and more reproducible outcomes for surgeons and patients.
Endius Incorporated
In April 2007, we acquired Endius Incorporated (Endius), a privately held spinal products company based in Massachusetts, for an aggregate value of approximately $80 million in cash, before adjustments for debt repayment and other items. We recorded $38.5 million in goodwill in connection with the acquisition. Endius develops and manufactures minimally invasive spine surgery products, implants and techniques to treat spine disease. The acquisition of Endius has expanded our spine product portfolio to include innovative minimally invasive instruments and implants.
| | |
5.7. | | FAIR VALUE MEASUREMENTS OF ASSETS AND LIABILITIES |
On January 1, 2008, we adopted the provisions of SFAS No. 157 “Fair Value Measurements” as it relates to financial assets and liabilities recorded at fair value on a recurring basis. FSPNo. SFAS 157-2 has delayed the effective date of SFAS No. 157 for nonfinancial assets and liabilities, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis. We do not expect that the full adoption of SFAS No. 157 will have a material impact on our consolidated financial statements or results of operations.
The following financial assets and liabilities are recorded at fair value on a recurring basis as of December 31, 20082009 (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | Fair Value Measurements at Reporting Date Using: | | | | Fair Value Measurements at Reporting Date Using: |
| | | | | Quoted Prices in
| | | | Significant
| | | | Quoted Prices
| | | | |
| | | | | Active Markets for
| | Significant Other
| | Unobservable
| | | | in Active
| | | | |
| | | Recorded
| | Identical Assets
| | Observable Inputs
| | Inputs
| | | | Markets for
| | Significant Other
| | Significant
|
| | | Balance | | (Level 1) | | (Level 2) | | (Level 3) | | | | Identical
| | Observable
| | Unobservable
|
| | | | Recorded
| | Assets
| | Inputs
| | Inputs
|
| Description | | | Balance | | (Level 1) | | (Level 2) | | (Level 3) |
| | |
| | | |
Assets | | | | | | | | | | | | | | | | | | | | | | | | |
| | | |
| Available-for-sale securities | | $ | 1.1 | | $ | 1.1 | | $ | – | | $ | – | | $ | 0.9 | | $ | 0.9 | | $ | – | | $ | – |
| | | |
| Derivatives, current and non-current | | | 65.4 | | | – | | | 65.4 | | | – | | | 12.4 | | | – | | | 12.4 | | | – |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | |
| Total assets recorded at fair value | | $ | 66.5 | | $ | 1.1 | | $ | 65.4 | | $ | – | |
| | | | $ | 13.3 | | $ | 0.9 | | $ | 12.4 | | $ | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | |
Liabilities | | | | | | | | | | | | | | | | | | | | | | | | |
| | | |
| Derivatives, current and non-current | | $ | 28.9 | | $ | – | | $ | 28.9 | | $ | – | | $ | 32.7 | | $ | – | | $ | 32.7 | | $ | – |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | |
| Total liabilities recorded at fair value | | $ | 28.9 | | $ | – | | $ | 28.9 | | $ | – | |
| | | | | | | | | | | | | $ | 32.7 | | $ | – | | $ | 32.7 | | $ | – |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
Available-for-sale securities are valued using a market approach, based on quoted prices for the specific security from transactions in active exchange markets. Derivatives relate to foreign currency exchange forward contracts and foreign currency options entered into with various third parties. We value these instruments using a market approach based on foreign currency exchange rates obtained from active markets.
Inventories at December 31, 2008markets and 2007 consistperform an assessment of the following (in millions):
| | | | | | | | | |
| | | 2008 | | | 2007 | |
| | |
| |
| Finished goods | | $ | 731.2 | | | $ | 564.2 | |
| Work in progress | | | 52.6 | | | | 50.3 | |
| Raw materials | | | 144.5 | | | | 113.3 | |
| | | | | |
| | | | | |
| Inventories, net | | $ | 928.3 | | | $ | 727.8 | |
| | | | | |
| | | | | |
Reserves for excess and obsolete inventory were $199.6 million and $143.7 million at December 31, 2008 and 2007, respectively. Included in finished goods inventory atcounterparty credit risk.
5049
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
The following nonfinancial assets were measured at fair value on a nonrecurring basis during the year ended December 31, 2008 is approximately $14.0 million of inventorystep-up resulting primarily from the Abbott Spine acquisition. Inventorystep-up values are based upon estimated sales prices less distribution costs and a profit allowance.
| | |
7. | | PROPERTY, PLANT AND EQUIPMENT |
Property, plant and equipment at December 31, 2008 and 2007 was as follows2009 (in millions):
| | | | | | | | | |
| | | 2008 | | | 2007 | |
| | |
| |
| Land | | $ | 21.7 | | | $ | 19.4 | |
| Building and equipment | | | 992.7 | | | | 855.3 | |
| Capitalized software costs | | | 136.7 | | | | 98.7 | |
| Instruments | | | 1,161.7 | | | | 903.8 | |
| Construction in progress | | | 149.0 | | | | 98.7 | |
| | | | | |
| | | | | |
| | | | 2,461.8 | | | | 1,975.9 | |
| Accumulated depreciation | | | (1,197.7 | ) | | | (1,004.0 | ) |
| | | | | |
| | | | | |
| Property, plant and equipment, net | | $ | 1,264.1 | | | $ | 971.9 | |
| | | | | |
| | | | | |
| | | | | | | | | | | | | | | | |
| | | Fair Value Measurements Using: |
| | | | | Quoted Prices
| | | | | | |
| | | | | in Active
| | | | | | |
| | | | | Markets for
| | Significant Other
| | Significant
| | |
| | | Year Ended
| | Identical
| | Observable
| | Unobservable
| | |
| | | December 31,
| | Assets
| | Inputs
| | Inputs
| | Total
|
| Description | | 2009 | | (Level 1) | | (Level 2) | | (Level 3) | | Losses |
| |
| |
| | | | | | | | | | | | | | | | |
| Goodwill | | $ | 342.9 | | $ | – | | $ | – | | $ | 342.9 | | $ | 73.0 |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | $ | 342.9 | | $ | – | | $ | – | | $ | 342.9 | | $ | 73.0 |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Depreciation expenseIn 2009, goodwill relating to our U.S. Spine reporting unit with a carrying amount of $415.9 million was $215.8written down to its implied fair value of $342.9 million, $182.6 millionresulting in an impairment charge of $73.0 million. The implied fair value of goodwill equals the estimated fair value of a reporting unit minus the fair value of the reporting unit’s net assets. Accordingly, in determining the implied fair value of the U.S. Spine reporting unit goodwill, we used unobservable inputs to estimate the fair value of the reporting unit and $155.0 millionits assets and liabilities. Fair value was determined using an equal weighting of income and market approaches. Fair value under the income approach was determined by discounting to present value the estimated future cash flows of the reporting unit. Fair value under the market approach utilized the comparable transaction methodology, which uses valuation indicators determined from sales of other businesses that are similar to our U.S. Spine reporting unit. In estimating the future cash flows of the reporting unit, we utilized a combination of market and company specific inputs that a market participant would use in assessing the fair value of the reporting unit. The primary market input was revenue growth rates. These rates were based upon historical trends and estimated future growth drivers such as an aging global population, obesity and more active lifestyles. Significant company specific inputs included assumptions regarding how the reporting unit could leverage operating expenses as revenue grows and the impact any new products will have on revenues. Under the comparable transaction methodology, we took into consideration when the comparable transaction occurred and the differences that may exist due to changes in the economic environment. We also took into consideration differences between the comparable companies and our U.S. Spine reporting unit that could affect fair value, such as cash and debt levels.
The fair value of the reporting unit’s assets and liabilities were determined by using the same methods that are used in business combination purchase accounting. See Note 8 for further information regarding this goodwill impairment.
There were no other significant nonfinancial assets that were measured at fair value in the years endedyear ending December 31, 2008, 2007 and 2006, respectively.2009.
| | |
| 8. | | GOODWILL AND OTHER INTANGIBLE ASSETS |
The following table summarizes the changes in the carrying amount of goodwill for the years ended December 31, 20082009 and 20072008 (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Americas | | Europe | | Asia Pacific | | Total | | | Americas | | Europe | | Asia Pacific | | Total | |
| | | | | |
| |
| Balance at January 1, 2007 | | $ | 1,414.1 | | | $ | 993.9 | | | $ | 107.6 | | | $ | 2,515.6 | | |
| Change in fair value estimates of Centerpulse related to: | | | | | | | | | | | | | | | | | |
| Integration liability | | | (0.1 | ) | | | (1.0 | ) | | | (0.1 | ) | | | (1.2 | ) | |
| Income taxes | | | 16.3 | | | | – | | | | – | | | | 16.3 | | |
| Impact of FIN 48 adoption | | | (61.4 | ) | | | – | | | | – | | | | (61.4 | ) | |
| Change in fair value estimates of Musculoskeletal Management Systems related to: | | | | | | | | | | | | | | | | | |
| Earn-out payment liability | | | 0.3 | | | | – | | | | – | | | | 0.3 | | |
| Integration liability | | | 0.6 | | | | – | | | | – | | | | 0.6 | | |
| Purchase of Endius | | | 42.3 | | | | – | | | | – | | | | 42.3 | | |
| Purchase of ORTHOsoft Inc. | | | 31.4 | | | | – | | | | – | | | | 31.4 | | |
| Other | | | – | | | | 9.9 | | | | – | | | | 9.9 | | |
| Currency translation | | | – | | | | 63.5 | | | | 4.1 | | | | 67.6 | | |
| Balance at January 1, 2008 | | | | | | | | | | | | | | | | | |
| Goodwill | | | $ | 1,443.5 | | | $ | 1,066.3 | | | $ | 111.6 | | | $ | 2,621.4 | |
| Accumulated impairment losses | | | | – | | | | – | | | | – | | | | – | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Balance at December 31, 2007 | | | 1,443.5 | | | | 1,066.3 | | | | 111.6 | | | | 2,621.4 | | |
| | | | | 1,443.5 | | | | 1,066.3 | | | | 111.6 | | | | 2,621.4 | |
| Change in fair value estimates of Centerpulse related to: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Integration liability | | | – | | | | (0.1 | ) | | | – | | | | (0.1 | ) | | | – | | | | (0.1 | ) | | | – | | | | (0.1 | ) |
| Income taxes | | | (22.7 | ) | | | (0.9 | ) | | | – | | | | (23.6 | ) | | | (22.7 | ) | | | (0.9 | ) | | | – | | | | (23.6 | ) |
| Change in fair value estimates of Endius related to: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Integration liability | | | 0.2 | | | | – | | | | – | | | | 0.2 | | | | 0.2 | | | | – | | | | – | | | | 0.2 | |
| Income taxes | | | (4.0 | ) | | | – | | | | – | | | | (4.0 | ) | | | (4.0 | ) | | | – | | | | – | | | | (4.0 | ) |
| Change in fair value estimates of ORTHOsoft related to: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Developed technology | | | 0.8 | | | | – | | | | – | | | | 0.8 | | | | 0.8 | | | | – | | | | – | | | | 0.8 | |
| Income taxes | | | (1.0 | ) | | | – | | | | – | | | | (1.0 | ) | | | (1.0 | ) | | | – | | | | – | | | | (1.0 | ) |
| Other | | | 0.1 | | | | – | | | | – | | | | 0.1 | | | | 0.1 | | | | – | | | | – | | | | 0.1 | |
| Purchase of Abbott Spine | | | 129.3 | | | | 65.7 | | | | 2.4 | | | | 197.4 | | | | 129.3 | | | | 65.7 | | | | 2.4 | | | | 197.4 | |
| Other | | | – | | | | (0.5 | ) | | | – | | | | (0.5 | ) | | | – | | | | (0.5 | ) | | | – | | | | (0.5 | ) |
| Currency translation | | | (5.9 | ) | | | (20.4 | ) | | | 10.4 | | | | (15.9 | ) | | | (5.9 | ) | | | (20.4 | ) | | | 10.4 | | | | (15.9 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Balance at December 31, 2008 | | $ | 1,540.3 | | | $ | 1,110.1 | | | $ | 124.4 | | | $ | 2,774.8 | | | | | | | | | | | | | | | | | |
| Goodwill | | | | 1,540.3 | | | | 1,110.1 | | | | 124.4 | | | | 2,774.8 | |
| Accumulated impairment losses | | | | – | | | | – | | | | – | | | | – | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | 1,540.3 | | | | 1,110.1 | | | | 124.4 | | | | 2,774.8 | |
| Change in fair value estimates of Abbott Spine related to: | | | | | | | | | | | | | | | | | |
| Integration liability | | | | 1.0 | | | | 4.2 | | | | 0.3 | | | | 5.5 | |
| Inventory | | | | 2.2 | | | | – | | | | – | | | | 2.2 | |
| Income taxes | | | | (1.9 | ) | | | – | | | | – | | | | (1.9 | ) |
| U.S. Spine reporting unit impairment | | | | (73.0 | ) | | | – | | | | – | | | | (73.0 | ) |
| Other acquisitions | | | | – | | | | 5.0 | | | | – | | | | 5.0 | |
| Currency translation | | | | 6.3 | | | | 53.8 | | | | 10.8 | | | | 70.9 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | |
| Balance at December 31, 2009 | | | | | | | | | | | | | | | | | |
| Goodwill | | | | 1,547.9 | | | | 1,173.1 | | | | 135.5 | | | | 2,856.5 | |
| Accumulated impairment losses | | | | (73.0 | ) | | | – | | | | – | | | | (73.0 | ) |
| | | | | | | | | | | | | | | |
| | | | | | | | | | |
| | | | $ | 1,474.9 | | | $ | 1,173.1 | | | $ | 135.5 | | | $ | 2,783.5 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | |
Goodwill increased by $197.4 million during 2008We conduct our annual impairment test in the fourth quarter of every year or whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. In the fourth quarter of 2009, we determined our U.S. Spine reporting unit’s carrying value was in excess of its estimated fair value. Fair value was determined using an equal weighting of income and market approaches. Factors that contributed to the estimated fair value of the reporting unit to be below its carrying value included a decrease in projected revenues related to the acquisitionDynesysDynamic Stabilization System. This product line experienced increased competition and insurance reimbursement issues in 2009. We have been seeking approval from the FDA to market this product differently in the U.S., which would enhance its position in the market. However, in November 2009 an FDA advisory panel issued a non-approvable recommendation, increasing the uncertainty of Abbott Spine. During the year ended December 31, 2007, goodwill was reduced by $61.4 million related to the adoption of FIN 48 and increased by $83.6 million related to the acquisitions of Endius, ORTHOsoft and a foreign-based distributor.
5150
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
estimated future cash flows. In addition to theDynesysproduct, revenues from other products have been affected as we work through the integration of the sales channel following the Abbott Spine acquisition.
As a result, we recorded a related goodwill impairment charge of approximately $73.0 million during the year ended December 31, 2009. Before the impairment charge, goodwill assigned to this reporting unit was approximately $416 million, of which approximately two-thirds arose from the Centerpulse acquisition in 2003 and the remaining from the Abbott Spine acquisition in 2008.
We have five other reporting units with goodwill assigned to them. We estimate the fair value of those reporting units using the income approach by discounting to present value the estimated future cash flows of the reporting unit. For each of those five reporting units, the estimated fair value substantially exceeds its carrying value.
We will continue to monitor the fair value of our U.S. Spine reporting until as well as our other five reporting units in our interim and annual reporting periods. If our estimated cash flows for these reporting units decrease, we may have to record further impairment charges in the future. Factors that could result in our cash flows being lower than our current estimates include: 1) decreased revenues caused by changes in the healthcare market, or our inability to generate new product revenue from our research and development activities, and 2) if we are not able to achieve the estimated operating margins in our forecasts due to unforeseen factors. Additionally, changes in the broader economic environment could cause changes to our estimated discount rates which will impact our estimated fair values.
The components of identifiable intangible assets are as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Core
| | Developed
| | Intellectual
| | Trademarks and
| | Customer
| | | | | | | | | | | Intellectual
| | Trademarks
| | | | | | | |
| | | Technology | | Technology | | Property Rights | | Trade Names | | Relationships | | Other | | Total | | | Core
| | Developed
| | Property
| | and Trade
| | Customer
| | | | | |
| | | | Technology | | Technology | | Rights | | Names | | Relationships | | Other | | Total | |
| | | | |
| | |
| As of December 31, 2009: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Intangible assets subject to amortization: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross carrying amount | | | $ | 144.1 | | | $ | 499.1 | | | $ | 145.2 | | | $ | 34.7 | | | $ | 129.2 | | | $ | 51.5 | | | $ | 1,003.8 | |
| Accumulated amortization | | | | (44.0 | ) | | | (183.5 | ) | | | (40.3 | ) | | | (20.0 | ) | | | (23.4 | ) | | | (31.1 | ) | | | (342.3 | ) |
| Intangible assets not subject to amortization: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross carrying amount | | | | – | | | | – | | | | – | | | | 196.5 | | | | – | | | | – | | | | 196.5 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| Total identifiable intangible assets | | | $ | 100.1 | | | $ | 315.6 | | | $ | 104.9 | | | $ | 211.2 | | | $ | 105.8 | | | $ | 20.4 | | | $ | 858.0 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| As of December 31, 2008: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Intangible assets subject to amortization: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross carrying amount | | $ | 144.1 | | | $ | 498.8 | | | $ | 109.4 | | | $ | 35.6 | | | $ | 52.9 | | | $ | 83.6 | | | $ | 924.4 | | | $ | 144.1 | | | $ | 498.8 | | | $ | 109.4 | | | $ | 35.6 | | | $ | 93.6 | | | $ | 42.9 | | | $ | 924.4 | |
| Accumulated amortization | | | (36.0 | ) | | | (147.5 | ) | | | (6.7 | ) | | | (16.6 | ) | | | (8.7 | ) | | | (33.8 | ) | | | (249.3 | ) | | | (36.0 | ) | | | (147.5 | ) | | | (6.7 | ) | | | (16.6 | ) | | | (15.6 | ) | | | (26.9 | ) | | | (249.3 | ) |
| Intangible assets not subject to amortization: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross carrying amount | | | – | | | | – | | | | – | | | | 197.0 | | | | – | | | | – | | | | 197.0 | | | | – | | | | – | | | | – | | | | 197.0 | | | | – | | | | – | | | | 197.0 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total identifiable intangible assets | | $ | 108.1 | | | $ | 351.3 | | | $ | 102.7 | | | $ | 216.0 | | | $ | 44.2 | | | $ | 49.8 | | | $ | 872.1 | | | $ | 108.1 | | | $ | 351.3 | | | $ | 102.7 | | | $ | 216.0 | | | $ | 78.0 | | | $ | 16.0 | | | $ | 872.1 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| As of December 31, 2007: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Intangible assets subject to amortization: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross carrying amount | | $ | 144.8 | | | $ | 433.3 | | | $ | – | | | $ | 35.6 | | | $ | 44.5 | | | $ | 75.7 | | | $ | 733.9 | | |
| Accumulated amortization | | | (27.9 | ) | | | (116.4 | ) | | | – | | | | (13.1 | ) | | | (6.2 | ) | | | (26.4 | ) | | | (190.0 | ) | |
| Intangible assets not subject to amortization: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross carrying amount | | | – | | | | – | | | | – | | | | 199.9 | | | | – | | | | – | | | | 199.9 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Total identifiable intangible assets | | $ | 116.9 | | | $ | 316.9 | | | $ | – | | | $ | 222.4 | | | $ | 38.3 | | | $ | 49.3 | | | $ | 743.8 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
During 20082009, we made lump-sum payments of $109.4$35.8 million to certain healthcare professionals and institutions in place of future royalty payments that otherwise would have been due under the terms of existing contractual arrangements. Such payments were based upon a third party fair market valuation of the current net present value of the contractual arrangement.arrangements. Under the terms of these resolutions, we acquired the exclusive rights to any intellectual property, patented and unpatented, provided by the healthcare professional or institution during the course of the original contractual arrangement.arrangements. The weighted average useful life for these assets is 5.6 years, which represents the life of any related patent or the period for which we maintain exclusivity to the intellectual property. Amortization expense for these assets is reported as part of cost of goods sold.
As a result of the acquisition of Abbott Spine, we acquired developed technology-related intangible assets of approximately $64.3 million and customer relationship related intangible assets of approximately $8.6 million, based on the preliminary purchase price allocation as of December 31, 2008. These assets each have a 10 year useful life.
Total amortization expense for finite-lived intangible assets was $93.2 million, $59.3 million $47.4 million and $42.4$47.4 million for the years ended December 31, 2009, 2008 and 2007, respectively. For 2009, $33.6 million of amortization expense was recorded as part of cost of goods sold, with the remaining $59.6 million recorded as part of selling, general and 2006, respectively.administrative expenses. For 2008, $6.7 million of amortization expense was recorded as part of cost of goods sold, with the remaining $52.6 million recorded as part of selling, general and administrative expenses. For 2007, and 2006, all amortization expense was recorded as part of selling, general and administrative expenses. Estimated annual amortization expense for the years ending December 31, 20092010 through 20132014 is $82.2$89.7 million, $79.9$80.9 million, $74.3$73.4 million, $72.2$66.8 million and $67.1$62.6 million, respectively.
51
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
| | |
| 9. | | OTHER CURRENT AND LONG-TERM LIABILITIES |
Other current and long-term liabilities at December 31, 20082009 and 20072008 consist of the following (in millions):
| | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | | 2009 | | 2008 | |
| | | | | |
| |
| Other current liabilities: | | | | | | | | | | | | | | | | |
| License and service agreements | | $ | 169.6 | | | $ | 149.9 | | | $ | 108.0 | | | $ | 169.6 | |
| Certain claims accrual (Note 16) | | | 62.8 | | | | – | | |
| Fair value of derivatives | | | 17.7 | | | | 50.0 | | |
| Certain claims accrual (Note 17) | | | | 42.5 | | | | 62.8 | |
| Salaries, wages and benefits | | | 91.5 | | | | 59.3 | | | | 95.7 | | | | 91.5 | |
| Accrued liabilities | | | 236.5 | | | | 230.2 | | | | 252.4 | | | | 234.2 | |
| | | | | | | | | | | |
| | | | | | | | | |
| Total other current liabilities | | $ | 578.1 | | | $ | 489.4 | | | $ | 498.6 | | | $ | 558.1 | |
| | | | | | | | | | | |
| | | | | | | | | |
| Other long-term liabilities: | | | | | | | | | | | | | | | | |
| Long-term income tax payable | | $ | 116.9 | | | $ | 137.0 | | | $ | 94.3 | | | $ | 116.9 | |
| Accrued retirement and postretirement benefit plans | | | 129.9 | | | | 66.3 | | | | 32.9 | | | | 129.9 | |
| Certain claims accrual (Note 17) | | | | 29.4 | | | | – | |
| Other long-term liabilities | | | 107.1 | | | | 125.1 | | | | 171.9 | | | | 107.1 | |
| | | | | | | | | | | |
| | | | | | | | | |
| Total other long-term liabilities | | $ | 353.9 | | | $ | 328.4 | | | $ | 328.5 | | | $ | 353.9 | |
| | | | | | | | | | | |
| | | | | | | | | |
In November 2009, we sold $500 million aggregate principal amount of our 4.625% Senior Notes due November 30, 2019 and $500 million aggregate principal amount of our 5.75% Senior Notes due November 30, 2039 (Senior Notes) in a public offering. Interest is payable on May 30 and November 30 of each year beginning on May 30, 2010 until maturity. We received net proceeds of approximately $998.8 million, net of an offering discount of $1.2 million. The Senior Notes carry an effective interest rate of 4.634% and 5.762%, respectively. We used the proceeds to repay amounts outstanding under our senior credit facility, to finance our stock repurchase program and for general corporate purposes.
We may redeem the Senior Notes at our election in whole or in part at any time prior to maturity at a redemption price equal to the greater of 1) 100 percent of the principal amount of the notes being redeemed; or 2) the sum of the present values of the remaining scheduled payments of principal and interest (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semi-annual basis at the Treasury Rate (as defined in the debt agreement), plus 20 basis points, in the case of the 2019 notes, and 25 basis points, in the case of the 2039 notes. We will also pay the accrued and unpaid interest on the Senior Notes to the redemption date.
We have a five year $1,350 million senior credit agreement (the “Senior(Senior Credit Facility”)Facility). The Senior Credit Facility is a revolving, multi-currency, senior unsecured credit facility maturing November 30, 2012. Available borrowings under the Senior Credit Facility at December 31, 20082009 were $889.9$1,221.2 million. The Senior Credit Facility contains provisions whereby borrowings may be increased to $1,750 million and the maturity date may be extended for up to two one-year periods.million.
We and certain of our wholly owned foreign subsidiaries are the borrowers under the Senior Credit Facility. Borrowings under the Senior Credit Facility bear interest at a LIBOR-based rate plus an applicable margin determined by reference to our senior unsecured long-term credit rating and the amounts drawn under the Senior Credit Facility, at an alternate base rate, or at a fixed rate determined through a competitive bid process. The Senior Credit Facility contains customary affirmative and negative covenants and events of default for an unsecured financing arrangement, including,
52
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
among other things, limitations on consolidations, mergers and sales of assets. Financial covenants include a maximum leverage ratio of 3.0 to 1.0 and a minimum interest coverage ratio of 3.5 to 1.0. If we fall below an investment grade credit rating, additional restrictions would result, including restrictions on investments, payment of dividends and stock repurchases. We were in compliance with all covenants under the Senior Credit Facility as of December 31, 2008.2009. Commitments under the Senior Credit Facility are subject to certain fees, including a facility and a utilization fee. Borrowings under the Senior Credit Facility were Japanese Yen-based borrowings at December 31, 2009 and U.S. Dollar and Japanese Yen-based borrowings at December 31, 2008.
Outstanding long-term debt as of December 31, 20082009 was $460.1$1,127.6 million, comprised of $998.8 million from our Senior Notes and $104.3 million as$128.8 from our Senior Credit Facility. As of December 31, 2007.2008, $460.1 million was outstanding from our Senior Credit Facility. We had no currentshort-term debt as of December 31, 20082009 or 2007.2008. The estimated fair value of our Senior Notes as of December 31, 2009 was $992.1 million. The carrying value of the Senior Credit Facility approximates fair value, as the underlying instruments have variable interest rates at market value.
We also have available uncommitted credit facilities totaling $71.4$84.1 million.
The weighted average interest rate for all borrowings under the Senior Credit Facility was 3.24.7 percent at December 31, 2008. Borrowings under the Senior Credit Facility were U.S. Dollar and Japanese Yen-based borrowings at December 31, 2008 and Japanese Yen-based borrowings at December 31, 2007.2009. We paid $17.0 million, $14.0 million $8.5 million and $5.8$8.5 million in interest during 2009, 2008 2007 and 2006,2007, respectively.
Debt issuance costs of $22.8 million were incurred to obtain the Senior Credit Facility arrangement.and debt issuance costs of $8.5 million were incurred during the sale of our Senior Notes. These costs were capitalized and are amortized to interest expense over the lives of the related facility.facility and the Senior Notes. At December 31, 2008,2009, total unamortized debt issuance costs were $3.5$11.7 million.
| | |
| 11. | | DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES |
We are exposed to certain market risks relating to our ongoing business operations, including foreign currency risk, commodity price risk, interest rate risk and credit risk. We manage our exposure to these and other market risks through regular operating and financing activities. Currently, the only risk that we manage through the use of derivative instruments is foreign currency risk.
52
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts and options with major financial institutions. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and net assets denominated in Euros, Swiss Francs, Japanese Yen, British Pounds, Canadian Dollars, Australian Dollars, Korean Won and Swedish Krona. We do not use derivative financial instruments for trading or speculative purposes.
We report all derivative instruments as assets or liabilities on the balance sheet at fair value.
Derivatives Designated as Hedging Instruments
Our revenues are generated in various currencies throughout the world. However, a significant amount of our inventory is produced in U.S. Dollars. Therefore, movements in foreign currency exchange rates may have different proportional effects on our revenues compared to our cost of products sold. To minimize the effects of foreign currency exchange rate movements on cash flows, we hedge intercompany sales of inventory expected to occur within the next 30 months with foreign currency exchange forward contracts and options. We designate these derivative instruments as cash flow hedges. We have not entered into any derivative instruments designated as fair value or net investment in foreign operation hedges.
We perform quarterly assessments of hedge effectiveness by verifying and documenting the critical terms of the hedge instrument and that forecasted transactions have not changed significantly. We also assess on a quarterly basis whether there have been adverse developments regarding the risk of a counterparty default. For derivatives which qualify as hedges of future cash flows, the effective portion of changes in fair value is temporarily recorded in other comprehensive income and then recognized in cost of products sold when the hedged item affects net earnings. The ineffective portion of a derivative’s change in fair value, if any, is reported in cost of products sold immediately. The net amount recognized in earnings during 2009 and 2008 due to ineffectiveness and amounts excluded from the assessment of hedge effectiveness was not significant.
For forward contracts and options outstanding at December 31, 2009, we have obligations to purchase U.S. Dollars and sell Euros, Japanese Yen, British Pounds, Canadian Dollars, Australian Dollars, Korean Won and Swedish Krona and purchase Swiss Francs and sell U.S. Dollars at set maturity dates ranging from January 2010 through June 2012. The notional amounts of outstanding forward contracts and options entered into with third parties to purchase U.S. Dollars at December 31, 2009 were $1.1 billion. The notional amounts of outstanding forward contracts entered into with third parties to purchase Swiss Francs at December 31, 2009 were $202 million.
As of December 31, 2009 and 2008, all derivative instruments designated as cash flow hedges are recorded at fair value on the balance sheet. On our consolidated balance sheet, we recognize individual forward contracts and options with the same counterparty on a net asset/liability basis if we have a master netting agreement with the counterparty. The fair value of derivative instruments on a gross basis as of December 31, 2009 and 2008 is as follows (in millions):
| | | | | | | | | | | | | | | |
| | | 2009 | | | 2008 | |
| | | Balance Sheet
| | Fair
| | | Balance Sheet
| | | Fair
| |
| | | Location | | Value | | | Location | | | Value | |
| | |
| |
Asset Derivatives | | | | | | | | | | | | | | |
| Foreign exchange forward contracts | | Other current assets | | $ | 23.3 | | | | Other current assets | | | $ | 53.7 | |
| Foreign exchange options | | Other current assets | | | – | | | | Other current assets | | | | 4.6 | |
| Foreign exchange forward contracts | | Other assets | | | 6.3 | | | | Other assets | | | | 30.3 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total asset derivatives | | | | $ | 29.6 | | | | | | | $ | 88.6 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Liability Derivatives | | | | | | | | | | | | | | |
| Foreign exchange forward contracts | | Other current liabilities | | $ | 35.4 | | | | Other current liabilities | | | $ | 34.4 | |
| Foreign exchange forward contracts | | Other long-term liabilities | | | 14.5 | | | | Other long-term liabilities | | | | 17.7 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total liability derivatives | | | | $ | 49.9 | | | | | | | $ | 52.1 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
The fair value of outstanding derivative instruments recorded on the balance sheet at December 31, 2009, together with settled derivatives where the hedged item has not yet affected earnings, was a net unrealized loss of $24.9 million, or $14.1 million net of taxes, which is deferred in other comprehensive income, of which $11.0 million, or $5.3 million net of taxes, is expected to be reclassified to earnings over the next twelve months.
Derivative instruments had the following effects on other comprehensive income on our consolidated balance sheet and
53
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
our consolidated statement of earnings on a gross basis for the years ended December 31, 2009 and 2008 (in millions):
| | | | | | | | | | | | | | | | | |
| | | Amount of
| | | Amount of
| |
| | | Gain/(Loss)
| | | Gain/(Loss)
| |
| | | Recognized
| | | Reclassified From OCI
| |
| | | in OCI | | | to Cost of Products Sold | |
| | | | | |
| Derivative Instrument | | 2009 | | | 2008 | | | 2009 | | | 2008 | |
| | |
| |
| Foreign exchange forward contracts | | $ | (35.8) | | | $ | 33.1 | | | $ | 16.8 | | | $ | (52.6) | |
| Foreign exchange options | | | (2.0) | | | | 1.2 | | | | 1.2 | | | | – | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | $ | (37.8) | | | $ | 34.3 | | | $ | 18.0 | | | $ | (52.6) | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Derivatives Not Designated as Hedging Instruments
We enter into foreign currency forward exchange contracts with terms of one month to manage currency exposures for monetary assets and liabilities denominated in a currency other than an entity’s functional currency. As a result, any foreign currency remeasurement gains/losses recognized in earnings are generally offset with gains/losses on the foreign currency forward exchange contracts in the same reporting period. These offsetting gains/losses are recorded in cost of products sold as the underlying assets and liabilities exposed to remeasurement include inventory-related transactions. These contracts are settled on the last day of each reporting period. Therefore, there is no outstanding balance related to these contracts recorded on the balance sheet as of the end of the reporting period. The notional amounts of these contracts are typically in a range of $1.2 billion to $1.4 billion per quarter.
The following gains/(losses) from these derivative instruments were recognized in cost of products sold on our consolidated statement of earnings (in millions):
| | | | | | | | | |
| | | Year Ended
| |
| | | December 31, | |
| Derivative Instrument | | 2009 | | | 2008 | |
| | |
| |
| Foreign exchange forward contracts | | $ | (10.3 | ) | | $ | (2.2 | ) |
| | | | | |
| | | | | |
| Total | | $ | (10.3 | ) | | $ | (2.2 | ) |
| | | | | |
| | | | | |
This impact does not include any offsetting gains/losses recognized in earnings as a result of foreign currency remeasurement of monetary assets and liabilities denominated in a currency other than an entity’s functional currency.
| | |
| 12. | | RETIREMENT BENEFIT PLANS |
We have defined benefit pension plans covering certain U.S. and Puerto Rico employees. The employees who are not participating in the defined benefit plans receive additional benefits under our defined contribution plans. Plan benefits are primarily based on years of credited service and the participant’s average eligible compensation. In addition to the U.S. and Puerto Rico defined benefit pension plans, we sponsor variousnon-U.S. pension arrangements, including retirement and termination benefit plans required by local law or coordinated with government sponsored plans.
We use a December 31 measurement date for our benefit plans.
Defined Benefit Plans
The components of net pension expense for the years ended December 31, 2009, 2008 2007 and 20062007 for our defined benefit retirement plans are as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | U.S. and Puerto Rico | | Non-U.S. | | | U.S. and Puerto Rico | | Non-U.S. | |
| | | 2008 | | 2007 | | 2006 | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Service cost | | $ | 11.7 | | | $ | 13.0 | | | $ | 13.1 | | | $ | 12.1 | | | $ | 10.8 | | | $ | 10.2 | | | $ | 12.3 | | | $ | 11.7 | | | $ | 13.0 | | | $ | 13.7 | | | $ | 12.1 | | | $ | 10.8 | |
| Interest cost | | | 9.7 | | | | 8.8 | | | | 7.4 | | | | 7.3 | | | | 5.7 | | | | 4.8 | | | | 10.6 | | | | 9.7 | | | | 8.8 | | | | 6.8 | | | | 7.3 | | | | 5.7 | |
| Expected return on plan assets | | | (13.5 | ) | | | (10.9 | ) | | | (8.2 | ) | | | (9.3 | ) | | | (8.0 | ) | | | (6.6 | ) | | | (16.4 | ) | | | (13.5 | ) | | | (10.9 | ) | | | (8.2 | ) | | | (9.3 | ) | | | (8.0 | ) |
| Curtailment | | | | 0.4 | | | | – | | | | – | | | | – | | | | – | | | | – | |
| Settlement | | | 3.4 | | | | – | | | | – | | | | 0.1 | | | | – | | | | – | | | | – | | | | 3.4 | | | | – | | | | – | | | | 0.1 | | | | – | |
| Amortization of prior service cost | | | 0.1 | | | | – | | | | – | | | | (0.1 | ) | | | – | | | | 0.1 | | | | 0.1 | | | | 0.1 | | | | – | | | | (0.7 | ) | | | (0.1 | ) | | | – | |
| Amortization of unrecognized actuarial loss | | | 2.2 | | | | 2.9 | | | | 3.7 | | | | 0.1 | | | | 0.2 | | | | 0.2 | | | | 4.1 | | | | 2.2 | | | | 2.9 | | | | 1.9 | | | | 0.1 | | | | 0.2 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Net periodic benefit cost | | $ | 13.6 | | | $ | 13.8 | | | $ | 16.0 | | | $ | 10.2 | | | $ | 8.7 | | | $ | 8.7 | | | $ | 11.1 | | | $ | 13.6 | | | $ | 13.8 | | | $ | 13.5 | | | $ | 10.2 | | | $ | 8.7 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
The weighted average actuarial assumptions used to determine net pension expense for our defined benefit retirement plans were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | U.S. and Puerto Rico | | Non-U.S. | | | U.S. and Puerto Rico | | Non-U.S. | |
| | | 2008 | | 2007 | | 2006 | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Discount rate | | | 6.16 | % | | | 6.14 | % | | | 5.84 | % | | | 3.60 | % | | | 3.64 | % | | | 3.20 | % | | | 5.79 | % | | | 6.16 | % | | | 6.14 | % | | | 3.40 | % | | | 3.60 | % | | | 3.64 | % |
| Rate of compensation increase | | | 3.84 | % | | | 3.84 | % | | | 3.84 | % | | | 3.06 | % | | | 3.12 | % | | | 2.27 | % | | | 3.84 | % | | | 3.84 | % | | | 3.84 | % | | | 2.39 | % | | | 3.06 | % | | | 3.12 | % |
| Expected long-term return on plan assets | | | 8.00 | % | | | 8.00 | % | | | 8.25 | % | | | 4.64 | % | | | 4.73 | % | | | 4.70 | % | |
| Expected long-term rate of return on plan assets | | | | 7.75 | % | | | 8.00 | % | | | 8.00 | % | | | 4.16 | % | | | 4.64 | % | | | 4.73 | % |
54
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
The expected long-term ratesrate of return on plan assets is based on the period expected benefits will be paidhistorical and the historicalestimated future rates of return on the different asset classes held in the plans. The expected long-term rate of return is the weighted average of the target asset allocation of each individual asset class. We believe that historical asset results approximate expected market returns applicable to the funding of a long-term benefit obligation.
Discount rates were determined for each of our defined benefit retirement plans at their measurement date to reflect the yield of a portfolio of high quality bonds matched against the timing and amounts of projected future benefit payments.
53
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
Changes in projected benefit obligations and plan assets, for the years ended December 31, 20082009 and 20072008 for our defined benefit retirement plans, were (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | U.S. and Puerto Rico | | Non-U.S. | | | U.S. and Puerto Rico | | Non-U.S. | |
| | | 2008 | | 2007 | | 2008 | | 2007 | | | 2009 | | 2008 | | 2009 | | 2008 | |
| | | | | |
| |
| Projected benefit obligation – beginning of year | | $ | 166.0 | | | $ | 144.2 | | | $ | 181.6 | | | $ | 167.9 | | | $ | 188.4 | | | $ | 166.0 | | | $ | 192.1 | | | $ | 181.6 | |
| Plan amendments | | | – | | | | 0.9 | | | | – | | | | (1.2 | ) | |
| Service cost | | | 11.7 | | | | 13.0 | | | | 12.1 | | | | 10.8 | | | | 12.3 | | | | 11.7 | | | | 13.7 | | | | 12.1 | |
| Interest cost | | | 9.7 | | | | 8.8 | | | | 7.3 | | | | 5.7 | | | | 10.6 | | | | 9.7 | | | | 6.8 | | | | 7.3 | |
| Employee contributions | | | – | | | | – | | | | 14.5 | | | | 12.2 | | | | – | | | | – | | | | 12.0 | | | | 14.5 | |
| Benefits paid | | | (9.7 | ) | | | (2.8 | ) | | | (22.5 | ) | | | (16.4 | ) | | | (2.6 | ) | | | (9.7 | ) | | | (27.0 | ) | | | (22.5 | ) |
| Actuarial (gain) loss | | | 11.8 | | | | 1.9 | | | | (8.5 | ) | | | (5.7 | ) | | | (21.0 | ) | | | 11.8 | | | | (3.0 | ) | | | (8.5 | ) |
| Prior service cost | | | | – | | | | – | | | | (5.0 | ) | | | – | |
| Curtailment | | | | (0.1 | ) | | | – | | | | – | | | | – | |
| Settlement | | | (1.1 | ) | | | – | | | | – | | | | – | | | | – | | | | (1.1 | ) | | | – | | | | – | |
| Translation loss | | | – | | | | – | | | | 7.6 | | | | 8.3 | | | | – | | | | – | | | | 7.7 | | | | 7.6 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Projected benefit obligation – end of year | | $ | 188.4 | | | $ | 166.0 | | | $ | 192.1 | | | $ | 181.6 | | | $ | 187.6 | | | $ | 188.4 | | | $ | 197.3 | | | $ | 192.1 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Plan assets at fair market value – beginning of year | | $ | 147.2 | | | $ | 115.3 | | | $ | 180.4 | | | $ | 159.7 | | | $ | 138.5 | | | $ | 147.2 | | | $ | 163.7 | | | $ | 180.4 | |
| Actual return on plan assets | | | (39.3 | ) | | | 6.7 | | | | (31.4 | ) | | | 3.4 | | | | 25.8 | | | | (39.3 | ) | | | 11.0 | | | | (31.4 | ) |
| Company contributions | | | 40.3 | | | | 28.0 | | | | 15.2 | | | | 13.3 | | |
| Employer contributions | | | | 40.4 | | | | 40.3 | | | | 12.2 | | | | 15.2 | |
| Employee contributions | | | – | | | | – | | | | 14.5 | | | | 12.2 | | | | – | | | | – | | | | 12.0 | | | | 14.5 | |
| Benefits paid | | | (9.7 | ) | | | (2.8 | ) | | | (22.5 | ) | | | (16.4 | ) | | | (2.6 | ) | | | (9.7 | ) | | | (27.0 | ) | | | (22.5 | ) |
| Translation gain | | | – | | | | – | | | | 7.5 | | | | 8.2 | | | | – | | | | – | | | | 7.1 | | | | 7.5 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Plan assets at fair market value – end of year | | $ | 138.5 | | | $ | 147.2 | | | $ | 163.7 | | | $ | 180.4 | | | $ | 202.1 | | | $ | 138.5 | | | $ | 179.0 | | | $ | 163.7 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Funded status | | $ | (49.9 | ) | | $ | (18.8 | ) | | $ | (28.4 | ) | | $ | (1.2 | ) | | $ | 14.5 | | | $ | (49.9 | ) | | $ | (18.3 | ) | | $ | (28.4 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Amounts recognized in consolidated balance sheet: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prepaid pension | | $ | – | | | $ | – | | | $ | 2.5 | | | $ | 7.1 | | | $ | 21.4 | | | $ | – | | | $ | 1.8 | | | $ | 2.5 | |
| Short-term accrued benefit liability | | | (0.5 | ) | | | (5.6 | ) | | | – | | | | – | | | | (0.3 | ) | | | (0.5 | ) | | | – | | | | – | |
| Long-term accrued benefit liability | | | (49.4 | ) | | | (13.2 | ) | | | (30.9 | ) | | | (8.3 | ) | | | (6.6 | ) | | | (49.4 | ) | | | (20.1 | ) | | | (30.9 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Net amount recognized | | $ | (49.9 | ) | | $ | (18.8 | ) | | $ | (28.4 | ) | | $ | (1.2 | ) | | $ | 14.5 | | | $ | (49.9 | ) | | $ | (18.3 | ) | | $ | (28.4 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Amounts recognized in accumulated other comprehensive income: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Unrecognized prior service cost | | $ | 0.9 | | | $ | 1.0 | | | $ | (1.3 | ) | | $ | (1.1 | ) | | $ | 0.5 | | | $ | 0.9 | | | $ | (5.8 | ) | | $ | (1.3 | ) |
| Unrecognized actuarial loss | | | 101.0 | | | | 43.2 | | | | 31.2 | | | | 6.0 | | | | 66.2 | | | | 101.0 | | | | 30.8 | | | | 31.2 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Net amount recognized | | $ | 101.9 | | | $ | 44.2 | | | $ | 29.9 | | | $ | 4.9 | | |
| Total amount recognized | | | $ | 66.7 | | | $ | 101.9 | | | $ | 25.0 | | | $ | 29.9 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
55
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
We estimate the following amounts recorded as part of accumulated other comprehensive income will be recognized as part of our net pension expense during 2009:2010 (in millions):
| | | | | | | | | |
| | | U.S. and
| | | | |
| | | Puerto Rico | | | Non-U.S. | |
| | |
| |
| Unrecognized prior service cost | | $ | 0.1 | | | $ | (0.1 | ) |
| Unrecognized actuarial loss | | | 4.6 | | | | 1.3 | |
| | | | | |
| | | | | |
| | | $ | 4.7 | | | $ | 1.2 | |
| | | | | |
| | | | | |
54
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
| | | | | | | | | |
| | | U.S. and
| | | | |
| | | Puerto Rico | | | Non-U.S. | |
| | |
| |
| Unrecognized prior service cost | | $ | 0.1 | | | $ | (0.6 | ) |
| Unrecognized actuarial loss | | | 2.6 | | | | 1.0 | |
| | | | | |
| | | | | |
| | | $ | 2.7 | | | $ | 0.4 | |
| | | | | |
| | | | | |
The weighted average actuarial assumptions used to determine the projected benefit obligation for our defined benefit retirement plans were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | U.S. and Puerto Rico | | Non-U.S. | | | U.S. and Puerto Rico | | Non-U.S. | |
| | | 2008 | | 2007 | | 2006 | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Discount rate | | | 5.79 | % | | | 6.16 | % | | | 6.14 | % | | | 3.34 | % | | | 3.71 | % | | | 3.23 | % | | | 6.26 | % | | | 5.79 | % | | | 6.16 | % | | | 3.25 | % | | | 3.34 | % | | | 3.71 | % |
| Rate of compensation increase | | | 3.84 | % | | | 3.84 | % | | | 3.84 | % | | | 3.03 | % | | | 3.15 | % | | | 2.28 | % | | | 3.80 | % | | | 3.84 | % | | | 3.84 | % | | | 2.46 | % | | | 3.03 | % | | | 3.15 | % |
Plans with projected benefit obligations in excess of plan assets as of December 31, 20082009 and 20072008 were as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | U.S. and Puerto Rico | | Non-U.S. | | | U.S. and Puerto Rico | | Non-U.S. | |
| | | 2008 | | 2007 | | 2008 | | 2007 | | | 2009 | | 2008 | | 2009 | | 2008 | |
| | | | | |
| |
| Projected benefit obligation | | $ | 188.4 | | | $ | 166.0 | | | $ | 178.3 | | | $ | 163.0 | | | $ | 6.9 | | | $ | 188.4 | | | $ | 157.5 | | | $ | 178.3 | |
| Plan assets at fair market value | | | 138.5 | | | | 147.2 | | | | 147.8 | | | | 155.5 | | | | – | | | | 138.5 | | | | 137.7 | | | | 147.8 | |
Plans with accumulated benefit obligations in excess of plan assets as of December 31, 20082009 and 20072008 were as follows (in millions):
| | | | | | | | | | | | | | | | | |
| | | U.S. and
| | | | | | | | | | | | | | | | | | |
| | | Puerto Rico | | Non-U.S. | | | U.S. and Puerto Rico | | Non-U.S. | |
| | | 2008 | | 2007 | | 2008 | | 2007 | | | 2009 | | 2008 | | 2009 | | 2008 | |
| | | | | |
| |
| Accumulated benefit obligation | | $ | 15.5 | | | $ | 20.5 | | | $ | 140.4 | | | $ | 5.5 | | | $ | 5.0 | | | $ | 15.5 | | | $ | 145.9 | | | $ | 140.4 | |
| Plan assets at fair market value | | | 7.4 | | | | 8.8 | | | | 120.1 | | | | 4.5 | | | | – | | | | 7.4 | | | | 133.8 | | | | 120.1 | |
The accumulated benefit obligation for U.S. and Puerto Rico defined benefit retirement pension plans was $140.6$148.3 million and $116.8$140.6 million as of December 31, 20082009 and 2007,2008, respectively. The accumulated benefit obligation fornon-U.S. defined benefit retirement plans was $178.7$186.6 million and $150.9$178.7 million as of December 31, 20082009 and 2007,2008, respectively.
The benefits expected to be paid out in each of the next five years and for the five years combined thereafter are as follows (in millions):
| | | | | | | | | |
| | | U.S. and
| | | | |
| For the Years Ending December 31, | | Puerto Rico | | | Non-U.S. | |
| | |
| |
| 2009 | | $ | 3.4 | | | $ | 17.6 | |
| 2010 | | | 3.8 | | | | 16.9 | |
| 2011 | | | 5.1 | | | | 15.8 | |
| 2012 | | | 6.4 | | | | 14.0 | |
| 2013 | | | 7.3 | | | | 14.4 | |
| 2014-2018 | | | 57.6 | | | | 72.5 | |
Our weighted-average asset allocations at December 31, 2008 and 2007, by asset category are as follows:
| | | | | | | | | | | | | | | | | |
| | | U.S. and
| | | | |
| | | Puerto Rico | | | Non-U.S. | |
| Asset Category | | 2008 | | | 2007 | | | 2008 | | | 2007 | |
| | |
| |
| Equity Securities | | | 59 | % | | | 65 | % | | | 28 | % | | | 37 | % |
| Debt Securities | | | 31 | | | | 35 | | | | 43 | | | | 38 | |
| Real Estate | | | – | | | | – | | | | 18 | | | | 15 | |
| Cash Funds | | | 10 | | | | – | | | | 3 | | | | 4 | |
| Other | | | – | | | | – | | | | 8 | | | | 6 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | | 100 | % | | | 100 | % | | | 100 | % | | | 100 | % |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | |
| | | U.S. and
| | | | |
| For the Years Ending December 31, | | Puerto Rico | | | Non-U.S. | |
| | |
| |
| 2010 | | $ | 3.7 | | | $ | 16.1 | |
| 2011 | | | 5.1 | | | | 15.4 | |
| 2012 | | | 6.5 | | | | 15.2 | |
| 2013 | | | 7.2 | | | | 14.9 | |
| 2014 | | | 8.5 | | | | 15.0 | |
| 2015-2019 | | | 64.0 | | | | 78.2 | |
The U.S. and Puerto Rico defined benefit retirement plans’ overall investment strategy is to maximize total returns by emphasizing long-term growth of capital while avoiding risk. We have established target ranges of assets held by the plans of 50 to 75 percent for equity securities and 25 to 50 percent for debt securities. The plans strive to have sufficiently diversified assets so that adverse or unexpected results from one asset class will not have an unduly detrimental impact on the entire portfolio. The investments in the plans aremay be rebalanced quarterly based upon the target asset allocation of the plans.
In the U.S. and Puerto Rico, we maintain an investment policy statement that guides the investment allocation in the plans. The investment policy statement describes the target asset allocation positions described above. We have a benefits committee to manage the general philosophy, objectives and process of the plans. The benefits committee meets quarterly to review performance and to ensure that the current investment allocation is within the guidelines set forth in the investment policy statement.
The investment strategies ofnon-U.S. based plans vary according to the plan provisions and local laws. The majority of the assets innon-U.S. based plans are located in Switzerland based plans. These assets are held in trusts and are commingled with the assets of other Swiss companies with representatives of all the companies making the investment decisions. The overall strategy is to maximize total returns while avoiding risk. The trustees of the assets have established target ranges of assets held by the plans of 30 to 50 percent in debt securities, 20 to 37 percent in equity
56
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
securities, 15 to 24 percent in real estate, 3 to 15 percent in cash funds and 0 to 12 percent in other funds.
The fair value of our U.S. and Puerto Rico pension plan assets as of December 31, 2009, by asset category are as follows (in millions):
| | | | | | | | | | | | | |
| | | | | Fair Value Measurements at Reporting Date Using: |
| | | | | Quoted Prices
| | | | |
| | | | | in Active
| | Significant
| | |
| | | | | Markets for
| | Other
| | Significant
|
| | | | | Identical
| | Observable
| | Unobservable
|
| | | | | Assets
| | Inputs
| | Inputs
|
| Asset Category | | Total | | (Level 1) | | (Level 2) | | (Level 3) |
| |
| |
| | | | | | | | | | | | | |
| Cash and cash equivalents | | $ | 12.1 | | $ | 12.1 | | $ | – | | $ | – |
| | | | | | | | | | | | | |
| Equity securities: | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| U.S. large-cap | | | 67.6 | | | – | | | 67.6 | | | – |
| | | | | | | | | | | | | |
| U.S. small-cap | | | 20.8 | | | – | | | 20.8 | | | – |
| | | | | | | | | | | | | |
| International | | | 22.5 | | | – | | | 22.5 | | | – |
| | | | | | | | | | | | | |
| Intermediate fixed income securities | | | 79.1 | | | – | | | 79.1 | | | – |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | $ | 202.1 | | $ | 12.1 | | $ | 190.0 | | $ | – |
| | | | | | | | | | |
| | | | | | | | | | |
The fair value of ournon-U.S. pension plan assets as of December 31, 2009, by asset category are as follows (in millions):
| | | | | | | | | | | | | |
| | | | | Fair Value Measurements at Reporting Date Using: |
| | | | | Quoted Prices
| | | | |
| | | | | in Active
| | Significant
| | |
| | | | | Markets for
| | Other
| | Significant
|
| | | | | Identical
| | Observable
| | Unobservable
|
| | | | | Assets
| | Inputs
| | Inputs
|
| Asset Category | | Total | | (Level 1) | | (Level 2) | | (Level 3) |
| |
| |
| | | | | | | | | | | | | |
| Cash and cash equivalents | | $ | 7.4 | | $ | 7.4 | | $ | – | | $ | – |
| | | | | | | | | | | | | |
| Equity securities: | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Energy | | | 1.6 | | | 1.6 | | | – | | | – |
| | | | | | | | | | | | | |
| Materials | | | 1.3 | | | 1.3 | | | – | | | – |
| | | | | | | | | | | | | |
| Industrials | | | 3.0 | | | 3.0 | | | – | | | – |
| | | | | | | | | | | | | |
| Consumer discretionary | | | 2.2 | | | 2.2 | | | – | | | – |
| | | | | | | | | | | | | |
| Consumer staples | | | 3.5 | | | 3.5 | | | – | | | – |
| | | | | | | | | | | | | |
| Healthcare | | | 6.3 | | | 6.3 | | | – | | | – |
| | | | | | | | | | | | | |
| Financials | | | 5.7 | | | 5.7 | | | – | | | – |
| | | | | | | | | | | | | |
| Information technology | | | 2.7 | | | 2.7 | | | – | | | – |
| | | | | | | | | | | | | |
| Telecommunication services | | | 1.0 | | | 1.0 | | | – | | | – |
| | | | | | | | | | | | | |
| Utilities | | | 1.4 | | | 1.4 | | | – | | | – |
| | | | | | | | | | | | | |
| Other equities | | | 23.2 | | | 20.5 | | | 2.7 | | | – |
| | | | | | | | | | | | | |
| Fixed income securities: | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Government bonds | | | 29.5 | | | – | | | 29.5 | | | – |
| | | | | | | | | | | | | |
| Corporate bonds | | | 36.9 | | | – | | | 36.9 | | | – |
| | | | | | | | | | | | | |
| Asset-backed securities | | | 8.6 | | | – | | | 8.6 | | | – |
| | | | | | | | | | | | | |
| Other debt | | | 0.9 | | | – | | | 0.9 | | | – |
| | | | | | | | | | | | | |
| Other types of investments: | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Mortgage loans | | | 5.0 | | | – | | | 5.0 | | | – |
| | | | | | | | | | | | | |
| Insurance contracts | | | 5.1 | | | – | | | 5.1 | | | – |
| | | | | | | | | | | | | |
| Other investments | | | 5.8 | | | – | | | 5.8 | | | – |
| | | | | | | | | | | | | |
| Real estate | | | 27.9 | | | – | | | – | | | 27.9 |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | $ | 179.0 | | $ | 56.6 | | $ | 94.5 | | $ | 27.9 |
| | | | | | | | | | |
| | | | | | | | | | |
As of December 31, 20082009 and 2007,2008, our defined benefit pension plans’ assets did not hold any direct investment in Zimmer Holdings common stock.
Equity securities are valued using a market approach, based on quoted prices for the specific security from transactions in active exchange markets (Level 1), or in some cases where we are invested in mutual or collective funds, based upon the net asset value per unit of the fund which is determined from quoted market prices of the underlying securities in the fund’s portfolio (Level 2). Fixed income securities are valued using a market approach, based upon quoted prices for the specific security or from institutional bid evaluations. Some fixed income securities are in funds with a net asset value per unit which is determined using similar techniques for the underlying securities in the fund’s portfolio. Real estate is valued by discounting to present value the cash flows expected to be generated by the specific properties.
The value of Level 3 assets has not changed significantly from the prior year. Further information related to Level 3 assets has not been provided as we do not consider the Level 3 assets significant to the consolidated financial statements.
We expect that we will have no minimum funding requirements by law in 20092010 for the qualified U.S. and Puerto Rico defined benefit retirement plans, however, subsequent Congressional action may impact the minimum funding requirement for 2009.2010. We expect to voluntarily contribute between $40$20 million to $50$30 million to these plans during 2009.2010. Contributions tonon-U.S. defined benefit plans are estimated to be approximately $11$14 million in 2009.2010. We do not expect the plan assets in any of our plans to be returned to us in the next year.
55
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
Defined Contribution Plans
We also sponsor defined contribution plans for substantially all of the U.S. and Puerto Rico employees and certain employees in other countries. The benefits of these plans relate to local customs and practices in the countries concerned. We expensed $14.9$21.6 million, $12.8$17.1 million and $12.6$14.0 million related to these plans for the years ended December 31, 2009, 2008 and 2007, respectively.
Postretirement Benefit Plans
During 2009 we amended the postretirement benefit plans for certain U.S. and 2006, respectively.Puerto Rico employees. Participants in the plan between the ages of 55 and 65 that were previously receiving benefits will continue to receive benefits until reaching the age of 65. For all other participants in the plan, no benefits will be paid after January 1, 2010. Additionally, we funded approximately $7 million to a Voluntary Employees’ Beneficiary Association (VEBA) trust to settle any future obligations. We recognized a curtailment gain and settlement loss related to these actions.
57
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
The components of net periodic expense for the year ended December 31, 2009, 2008 and 2007 for our unfunded postretirement benefit plans are as follows (in millions):
| | | | | | | | | | | | | |
| | | 2009 | | | 2008 | | | 2007 | |
| | |
| |
| Service cost | | $ | 0.8 | | | $ | 1.5 | | | $ | 1.6 | |
| Interest cost | | | 1.3 | | | | 2.5 | | | | 2.2 | |
| Amortization of prior service cost | | | (0.2 | ) | | | (0.5 | ) | | | (0.5 | ) |
| Amortization of unrecognized actuarial loss | | | 0.3 | | | | 0.6 | | | | 0.5 | |
| Settlement | | | 3.2 | | | | – | | | | – | |
| Curtailment | | | (35.3 | ) | | | – | | | | – | |
| | | | | | | | | |
| | | | | | | | | |
| Net periodic benefit cost | | $ | (29.9 | ) | | $ | 4.1 | | | $ | 3.8 | |
| | | | | | | | | |
| | | | | | | | | |
We have not provided further disclosures related to these postretirement benefit plans as other than the curtailment gain and settlement loss in 2009 discussed above, these plans are not significant to our results of operations or financial position.
The components of earnings before taxes consist of the following (in millions):
| | | | | | | | | | | | | |
| For the Years Ending December 31, | | 2008 | | | 2007 | | | 2006 | |
| | |
| |
| United States operations | | $ | 618.8 | | | $ | 597.0 | | | $ | 727.3 | |
| Foreign operations | | | 503.0 | | | | 534.6 | | | | 441.7 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 1,121.8 | | | $ | 1,131.6 | | | $ | 1,169.0 | |
| | | | | | | | | |
| | | | | | | | | |
| The provision for income taxes consists of (in millions): | | | | |
| Current: | | | | | | | | | | | | |
| Federal | | $ | 136.0 | | | $ | 173.0 | | | $ | 178.5 | |
| State | | | 27.3 | | | | 25.0 | | | | 22.2 | |
| Foreign | | | 107.0 | | | | 96.0 | | | | 89.5 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | 270.3 | | | | 294.0 | | | | 290.2 | |
| | | | | | | | | |
| | | | | | | | | |
| Deferred: | | | | | | | | | | | | |
| Federal | | | 31.6 | | | | 39.0 | | | | 31.7 | |
| State | | | (2.0 | ) | | | 19.0 | | | | 5.0 | |
| Foreign | | | (27.6 | ) | | | 5.9 | | | | 7.1 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | 2.0 | | | | 63.9 | | | | 43.8 | |
| | | | | | | | | |
| | | | | | | | | |
| Provision for income taxes | | $ | 272.3 | | | $ | 357.9 | | | $ | 334.0 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | | | | | |
| For the Years Ending December 31, | | 2009 | | | 2008 | | | 2007 | |
| | |
| |
| United States operations | | $ | 489.7 | | | $ | 618.8 | | | $ | 597.0 | |
| Foreign operations | | | 508.5 | | | | 503.0 | | | | 534.6 | |
| | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 998.2 | | | $ | 1,121.8 | | | $ | 1,131.6 | |
| | | | | | | | | |
| | | | | | | | | |
The provision for income taxes consists of (in millions):
| | | | | | | | | | | | | |
| Current: | | | | | | | | | | | | |
| Federal | | $ | 204.9 | | | $ | 136.0 | | | $ | 173.0 | |
| State | | | 23.3 | | | | 27.3 | | | | 25.0 | |
| Foreign | | | 72.3 | | | | 107.0 | | | | 96.0 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | 300.5 | | | | 270.3 | | | | 294.0 | |
| | | | | | | | | |
| | | | | | | | | |
| Deferred: | | | | | | | | | | | | |
| Federal | | | (17.4 | ) | | | 31.6 | | | | 39.0 | |
| State | | | (3.1 | ) | | | (2.0 | ) | | | 19.0 | |
| Foreign | | | 0.8 | | | | (27.6 | ) | | | 5.9 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | (19.7 | ) | | | 2.0 | | | | 63.9 | |
| | | | | | | | | |
| | | | | | | | | |
| Provision for income taxes | | $ | 280.8 | | | $ | 272.3 | | | $ | 357.9 | |
| | | | | | | | | |
| | | | | | | | | |
Income taxes paid during 2009, 2008 and 2007 and 2006 were $268.5 million, $332.9 million $255.9 million and $257.6$255.9 million, respectively.
A reconciliation of the U.S. statutory income tax rate to our effective tax rate is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For the Years Ended December 31, | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| U.S. statutory income tax rate | | | 35.0 | % | | | 35.0 | % | | | 35.0 | % | | | 35.0 | % | | | 35.0 | % | | | 35.0 | % |
| State taxes, net of federal deduction | | | 1.6 | | | | 2.7 | | | | 1.3 | | | | 1.4 | | | | 1.6 | | | | 2.7 | |
| Foreign income taxes at rates different from the U.S. statutory rate, net of foreign tax credits | | | (7.3 | ) | | | (7.0 | ) | | | (4.3 | ) | | | (9.9 | ) | | | (9.8 | ) | | | (10.1 | ) |
| Tax benefit relating to operations in Puerto Rico | | | (2.5 | ) | | | (3.1 | ) | | | (2.0 | ) | |
| Tax benefit relating to U.S. manufacturer’s deduction and export sales | | | (1.3 | ) | | | (1.2 | ) | | | (1.2 | ) | | | (1.5 | ) | | | (1.3 | ) | | | (1.2 | ) |
| R&D credit | | | (0.1 | ) | | | (0.4 | ) | | | (0.1 | ) | | | (0.3 | ) | | | (0.1 | ) | | | (0.4 | ) |
| Non-deductible expenses | | | 0.1 | | | | 0.2 | | | | 0.1 | | |
| Department of Justice settlement | | | (2.8 | ) | | | 5.2 | | | | – | | |
| 2007 settlement (tax benefit) | | | | – | | | | (2.8 | ) | | | 5.2 | |
| In-process research and development charges | | | 1.2 | | | | 0.2 | | | | – | | | | – | | | | 1.2 | | | | 0.2 | |
| Goodwill impairment | | | | 2.6 | | | | – | | | | – | |
| Other | | | 0.4 | | | | – | | | | (0.2 | ) | | | 0.8 | | | | 0.5 | | | | 0.2 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Effective income tax rate | | | 24.3 | % | | | 31.6 | % | | | 28.6 | % | | | 28.1 | % | | | 24.3 | % | | | 31.6 | % |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Our operations in Puerto Rico, Switzerland and the State of Indiana benefit from various tax incentive grants. Unless these grants are extended, they will expire between fiscal years 2016 and 2019.
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We have established valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.
The components of deferred taxes consisted of the following (in millions):
| | | | | | | | | |
| | | 2008 | | | 2007 | |
| | |
| |
| Deferred tax assets: | | | | | | | | |
| Inventory | | $ | 165.9 | | | $ | 118.6 | |
| Net operating loss carryover | | | 64.8 | | | | 101.4 | |
| Tax credit carryover | | | 23.7 | | | | 20.7 | |
| Capital loss carryover | | | – | | | | 1.7 | |
| Accrued liabilities | | | 105.4 | | | | 97.3 | |
| Share-based compensation | | | 49.4 | | | | 35.7 | |
| Unremitted earnings of foreign subsidiaries | | | 95.5 | | | | 94.0 | |
| Other | | | 38.4 | | | | 24.4 | |
| | | | | |
| | | | | |
| Total deferred tax assets | | | 543.1 | | | | 493.8 | |
| Less: Valuation allowances | | | (37.1 | ) | | | (55.7 | ) |
| | | | | |
| | | | | |
| Total deferred tax assets after valuation | | | 506.0 | | | | 438.1 | |
| | | | | |
| | | | | |
| Deferred tax liabilities: | | | | | | | | |
| Fixed assets | | $ | (79.1 | ) | | $ | (36.3 | ) |
| Intangible assets | | | (188.1 | ) | | | (174.8 | ) |
| Accrued liabilities | | | (0.4 | ) | | | (1.4 | ) |
| Other | | | (4.4 | ) | | | (3.0 | ) |
| | | | | |
| | | | | |
| Total deferred tax liabilities | | | (272.0 | ) | | | (215.5 | ) |
| | | | | |
| | | | | |
| Total net deferred tax assets | | $ | 234.0 | | | $ | 222.6 | |
| | | | | |
| | | | | |
The net operating loss carryovers are available to reduce future federal, state and foreign taxable earnings. At December 31, 2008, these net operating loss carryovers generally expire within a period of 1 to 20 years. Valuation allowances for net operating loss carryovers have been established in the amount of $18.9 million and $16.3 million at December 31, 2008 and 2007, respectively. The tax credit carryovers are available to offset future federal, state and foreign tax liabilities. At December 31, 2008, these tax credit carryovers generally expire within a period of 1 to 15 years. We have established valuation allowances for certain tax credit carryovers in the amount of $12.9 million and $20.2 million at December 31, 2008 and 2007, respectively. The remaining valuation allowances of $5.3 million and $17.5 million at December 31, 2008 and 2007, respectively, relate primarily to potential capital losses. We have established valuation allowances related to certain business combination transactions through goodwill. These allowances were approximately $19.3 million and $33.9 million at December 31, 2008 and 2007, respectively.
At December 31, 2008, we had an aggregate of approximately $871 million of unremitted earnings of foreign subsidiaries that have been, or are intended to be, indefinitely
56
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
reinvested for continued use in foreign operations. If the total undistributed earnings of foreign subsidiaries were remitted, a significant amount of the additional tax would be offset by the allowable foreign tax credits. It is not practical for us to determine the additional tax of remitting these earnings.
In September 2007, we reached a settlement with the United States Department of Justice to resolve an investigation intoU.S. government concerning our financial relationships between major orthopaedic manufacturers andwith consulting orthopaedic surgeons. Under the terms of the settlement, we paid a civil settlement amount of $169.5 million, and we recorded an expense in that amount. At the time, no tax benefit was recorded related to the settlement expense due to the uncertainty as to the tax treatment. During the third quarter of 2008, we reached an agreement with the U.S. Internal Revenue Service (IRS) confirming the deductibility of a portion of the settlement payment. As a result, during 2008 we recorded a current tax benefit of $31.7 million.
In June 2006,Deferred income taxes reflect the Financial Accounting Standards Board (FASB) issued Interpretation No. 48, Accountingnet tax effects of temporary differences between the carrying amounts of assets and liabilities for Uncertainty in Income Taxes – an interpretationfinancial reporting purposes and the amounts used for income tax purposes. We have established valuation allowances for deferred tax assets when the amount of FASB Statement No. 109, Accounting for Income Taxes (FIN 48). FIN 48 addressesexpected future taxable income is not likely to support the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under FIN 48, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical meritsuse of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. FIN 48 also provides guidance on derecognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.deduction or credit.
We adopted FIN 48 on January 1, 2007. Prior
58
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
The components of deferred taxes consisted of the adoption of FIN 48 we had a long term tax liability for expected settlement of variousfollowing (in millions):
| | | | | | | | | |
| | | 2009 | | | 2008 | |
| | |
| |
| Deferred tax assets: | | | | | | | | |
| Inventory | | $ | 204.1 | | | $ | 165.9 | |
| Net operating loss carryover | | | 37.5 | | | | 64.8 | |
| Tax credit carryover | | | 20.7 | | | | 23.7 | |
| Accrued liabilities | | | 78.3 | | | | 105.4 | |
| Share-based compensation | | | 71.1 | | | | 49.4 | |
| Unremitted earnings of foreign subsidiaries | | | 105.5 | | | | 95.5 | |
| Other | | | 49.9 | | | | 38.4 | |
| | | | | |
| | | | | |
| Total deferred tax assets | | | 567.1 | | | | 543.1 | |
| Less: Valuation allowances | | | (37.3 | ) | | | (37.1 | ) |
| | | | | |
| | | | | |
| Total deferred tax assets after valuation | | | 529.8 | | | | 506.0 | |
| | | | | |
| | | | | |
| Deferred tax liabilities: | | | | | | | | |
| Fixed assets | | $ | (105.0 | ) | | $ | (79.1 | ) |
| Intangible assets | | | (162.7 | ) | | | (188.1 | ) |
| Accrued liabilities | | | (2.4 | ) | | | (0.4 | ) |
| Other | | | (1.5 | ) | | | (4.4 | ) |
| | | | | |
| | | | | |
| Total deferred tax liabilities | | | (271.6 | ) | | | (272.0 | ) |
| | | | | |
| | | | | |
| Total net deferred tax assets | | $ | 258.2 | | | $ | 234.0 | |
| | | | | |
| | | | | |
The net operating loss carryovers are available to reduce future federal, state and foreign income tax liabilities that was reflectedtaxable earnings. At December 31, 2009, these net operating loss carryovers generally expire within a period of the corollary tax impact of these expected settlements of $102.1 million, as well as a separate accrued interest liability of $1.7 million. As a result of the adoption of FIN 48, we are required1 to present the different components of such liability on a gross basis versus the historical20 years. Valuation allowances for net presentation. The adoption resultedoperating loss carryovers have been established in the financial statement liability for unrecognized tax benefits decreasing by $6.4 million as of January 1, 2007. The adoption resulted in this decrease in the liability as well as a reduction to retained earnings of $4.8 million, a reduction in goodwill of $61.4 million, the establishment of a tax receivable of $58.2 million, which was recorded in other current and non-current assets on our consolidated balance sheet, and an increase in an interest/penalty payable of $7.9 million, all as of January 1, 2007. Therefore, after the adoption of FIN 48, the amount of unrecognized tax benefits is $95.7$13.2 million as of January 1, 2007.
As ofand $18.9 million at December 31, 2009 and 2008, respectively. The tax credit carryovers are available to offset future federal, state and foreign tax liabilities. At December 31, 2009, these tax credit carryovers generally expire within a period of 1 to 15 years. We have established valuation allowances for certain tax credit carryovers in the amount of unrecognized tax benefits is $129.5 million. Of this amount, $45.5$17.9 million would impact our effective tax rate if recognized. $38.2and $12.9 million at December 31, 2009 and 2008, respectively. The remaining valuation allowances of $6.2 million and $5.3 million at December 31, 2009 and 2008, respectively, relate primarily to potential capital losses. We have established valuation allowances related to certain business combination transactions through goodwill. These allowances were approximately $14.5 million and $19.3 million at December 31, 2009 and 2008, respectively.
At December 31, 2009, we had an aggregate of approximately $1,835 million of unremitted earnings of foreign subsidiaries that have been, or are intended to be, indefinitely reinvested for continued use in foreign operations. If the $129.5 million liabilitytotal undistributed earnings of foreign subsidiaries were remitted, a significant amount of the additional tax would be offset by the allowable foreign tax credits. It is not practical for unrecognizedus to determine the additional tax benefits relate to tax positions of acquired entities taken prior to their acquisition by us. Under FAS 141(R), ifremitting these liabilities are settled for different amounts, they will affect the income tax expense in the period of reversal or settlement.earnings.
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
| | | | | | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Balance at January 1 | | $ | 135.2 | | | $ | 95.7 | | | $ | 129.5 | | | $ | 135.2 | | | $ | 95.7 | |
| Increases related to prior periods | | | 12.1 | | | | 27.4 | | | | 32.9 | | | | 12.1 | | | | 27.4 | |
| Decreases related to prior periods | | | (32.0 | ) | | | (5.5 | ) | | | (26.7 | ) | | | (32.0 | ) | | | (5.5 | ) |
| Increases related to current period | | | 15.8 | | | | 21.9 | | | | 17.4 | | | | 15.8 | | | | 21.9 | |
| Decreases related to settlements with taxing authorities | | | (1.3 | ) | | | (1.3 | ) | | | (1.1 | ) | | | (1.3 | ) | | | (1.3 | ) |
| Decreases related to lapse of statue of limitations | | | (0.3 | ) | | | (3.0 | ) | |
| Decreases related to lapse of statute of limitations | | | | (1.6 | ) | | | (0.3 | ) | | | (3.0 | ) |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | |
| Balance at December 31 | | $ | 129.5 | | | $ | 135.2 | | | $ | 150.4 | | | $ | 129.5 | | | $ | 135.2 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | |
Included in the balance of unrecognized tax benefits at December 31, 2009 are $100.4 million of tax benefits that, if recognized, would affect the effective tax rate.
We recognize accrued interest and penalties related to unrecognized tax benefits inas income tax expense in the Consolidated Statements of Earnings, which is consistent with the recognition of these items in prior reporting periods. As of December 31, 2007, we recorded a liability of $19.6 million forand accrued interest and penalties of which $14.7$5.7 million would impact our effective tax rate, if recognized. The amount of this liability is $22.9 millionduring 2009, and as of December 31, 2008. Of this amount, $17.12009, had recognized a liability for interest and penalties of $28.6 million. During 2008, we accrued interest and penalties of $3.3 million, would impact our effective tax rate, if recognized.and as of December 31, 2008, had recognized a liability for interest and penalties of $22.9 million. During 2007, we accrued interest and penalties of $10.0 million, and as of December 31, 2007, had recognized a liability for interest and penalties of $19.6 million.
We expect that the net amount of tax liability for unrecognized tax benefits will change in the next twelve months; however,months. We are currently under audit in numerous federal, state and foreign jurisdictions. While it is possible that such matters will be resolved in the next twelve months, we do not expect thesecannot reasonably estimate the amount or the periods in which changes in the unrecognized tax benefits will have a significant impact on our results of operations or financial position.occur.
The U.S. federal statuteDuring the third quarter of limitations remains open2009, we settled various tax matters with the IRS for the year 2003 and onward. Theall years prior to 2005. Our U.S. federal returns for years 2003 and 20042005 through 2007 are currently under examination by the IRS. On July 15, 2008, the IRS issued its examination report. We filed a formal protest on August 15, 2008 and requested a conference with the Appeals Office regarding disputed issues. Although the appeals process could take several years, we do not anticipate resolution of the audit will result in any significant impact on our results of operations, financial position or cash flows. In addition, for the 1999 tax year of Centerpulse, which we acquired in October 2003, one issue remains in dispute.examination.
State income tax returns are generally subject to examination for a period of 3 to 5 years after filing of the respective return. The state impact of any federal changes generally remains subject to examination by various states for a period of up to one year after formal notification to the states. We have various state income tax returns in the process of examination, administrative appeals or litigation. It is
57
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
reasonably possible that such matters will be resolvedOur tax returns are currently under examination in the next twelve months, but we do not anticipate that the resolution of these matters would result in any material impact on our results of operations or financial position.
various foreign jurisdictions. Foreign jurisdictions have statutes of limitations generally ranging from 3 to 5 years. Years still open to examination by foreign tax authorities in major jurisdictions includeinclude: Australia (2004 onward), Canada (2003 onward), Canada (2002 onward), France (2006(2007 onward), Germany (2005 onward), Italy (2005 onward), Japan (2002(2003 onward), Korea (2004 onward), Puerto Rico (2005 onward), Singapore (2003 onward), Switzerland (2006 onward) and the United Kingdom (2006(2008 onward).
Our tax returns are currently under examination in various foreign jurisdictions. The most significant foreign tax jurisdiction under examination is the United Kingdom. It is reasonably possible that such audits will be resolved in the next twelve months, but we do not anticipate that the resolution of these audits would result in any material impact on our results of operations or financial position.
59
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
| | |
13.14. | | CAPITAL STOCK AND EARNINGS PER SHARE |
We are authorized to issue 250 million shares of preferred stock, none of which were issued or outstanding as of December 31, 2008.2009.
The numerator for both basic and diluted earnings per share is net earnings available to common stockholders. The denominator for basic earnings per share is the weighted average number of common shares outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive stock options and other equity awards. The following is a reconciliation of weighted average shares for the basic and diluted share computations for the years ending December 31 (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Weighted average shares outstanding for basic net earnings per share | | | 227.3 | | | | 235.5 | | | | 243.0 | | | | 215.0 | | | | 227.3 | | | | 235.5 | |
| Effect of dilutive stock options and other equity awards | | | 1.0 | | | | 2.0 | | | | 2.4 | | | | 0.8 | | | | 1.0 | | | | 2.0 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Weighted average shares outstanding for diluted net earnings per share | | | 228.3 | | | | 237.5 | | | | 245.4 | | | | 215.8 | | | | 228.3 | | | | 237.5 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
For the year ended December 31, 2008,2009, an average of 11.214.3 million options to purchase shares of common stock were not included in the computation of diluted earnings per share as the exercise prices of these options were greater than the average market price of the common stock. For the years ended December 31, 20072008 and 2006,2007, an average of 3.111.2 million and 7.63.1 million options, respectively, were not included.
During 2008,2009, we repurchased approximately 10.819.8 million shares of our common stock at an average price of $68.72$46.56 per share for a total cash outlay of $737.0$923.7 million, including commissions. In April 2008, we announced that our Board of Directors authorized a $1.25 billion share repurchase program which expireswas originally set to expire on December 31, 2009. In September 2009, the Board of Directors extended this program to December 31, 2010. Approximately $1.13 billion$211.1 million remains authorized for future repurchases under this plan.
We design, develop, manufacture and market orthopaedic andreconstructive implants, dental reconstructive implants, spinal implants, trauma products and related surgical products which include surgical supplies and instruments designed to aid in orthopaedic surgical procedures and post-operation rehabilitation. We also provide other healthcare-related services. Revenue related to these services currently represents less than 1 percent of our total net sales. We manage operations through three major geographic segments – the Americas, which is comprised principally of the United States and includes other North, Central and South American markets; Europe, which is comprised principally of Europe and includes the Middle East and Africa; and Asia Pacific, which is comprised primarily of Japan and includes other Asian and Pacific markets. This structure is the basis for our reportable segment information discussed below. Management evaluates operatingreportable segment performance based upon segment operating profit exclusive of operating expenses pertaining to global operations and corporate expenses, share-based compensation expense, settlement, certain claims, acquisition, integration, realignment and other expenses, net curtailment and settlement, inventorystep-up, in-process research and development write-offs and intangible asset amortization expense. Global operations include research, development engineering, medical education, brand management, corporate legal, finance, and human resource functions and U.S. and Puerto Rico-based manufacturing operations and logistics. Intercompany transactions have been eliminated from segment operating profit. Management reviews accounts receivable, inventory, property, plant and equipment, goodwill and intangible assets by reportable segment exclusive of U.SU.S. and Puerto Rico-based manufacturing operations and logistics and corporate assets.
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
Net sales, segment operating profit and year-end assets are as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Net Sales | | Operating Profit | | Year-End Assets | | | Net Sales | | Operating Profit | | Year-End Assets | |
| | | 2008 | | 2007 | | 2006 | | 2008 | | 2007 | | 2006 | | 2008 | | 2007 | | | 2009 | | 2008 | | 2007 | | 2009 | | 2008 | | 2007 | | 2009 | | 2008 | |
| | | | | |
| |
| Americas | | $ | 2,353.9 | | | $ | 2,277.0 | | | $ | 2,076.5 | | | $ | 1,209.4 | | | $ | 1,184.2 | | | $ | 1,093.7 | | | $ | 2,845.6 | | | $ | 2,552.6 | | | $ | 2,372.4 | | | $ | 2,353.9 | | | $ | 2,277.0 | | | $ | 1,168.7 | | | $ | 1,209.4 | | | $ | 1,184.2 | | | $ | 3,022.4 | | | $ | 2,845.6 | |
| Europe | | | 1,179.1 | | | | 1,081.0 | | | | 931.1 | | | | 470.2 | | | | 429.6 | | | | 385.9 | | | | 2,200.0 | | | | 1,999.2 | | | | 1,119.2 | | | | 1,179.1 | | | | 1,081.0 | | | | 436.8 | | | | 470.2 | | | | 429.6 | | | | 2,273.6 | | | | 2,200.0 | |
| Asia Pacific | | | 588.1 | | | | 539.5 | | | | 487.8 | | | | 257.1 | | | | 259.5 | | | | 231.5 | | | | 395.1 | | | | 348.3 | | | | 603.8 | | | | 588.1 | | | | 539.5 | | | | 257.4 | | | | 257.1 | | | | 259.5 | | | | 443.6 | | | | 395.1 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Net sales | | $ | 4,121.1 | | | $ | 3,897.5 | | | $ | 3,495.4 | | | | | | | | | | | | | | | | | | | | | | | $ | 4,095.4 | | | $ | 4,121.1 | | | $ | 3,897.5 | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Share-based payment expense | | | | | | | | | | | | | | | (69.9 | ) | | | (70.1 | ) | | | (74.8 | ) | | | | | | | | | | | | | | | | | | | | | | | (73.8 | ) | | | (69.9 | ) | | | (70.1 | ) | | | | | | | | |
Inventorystep-up | | | | | | | | | | | | | | | (7.0 | ) | | | (0.5 | ) | | | – | | | | | | | | | | | | | | | | | | | | | | | | (12.5 | ) | | | (7.0 | ) | | | (0.5 | ) | | | | | | | | |
| Settlement | | | | | | | | | | | | | | | – | | | | (169.5 | ) | | | – | | | | | | | | | | | | | | | | | | | | | | | | – | | | | – | | | | (169.5 | ) | | | | | | | | |
| Certain claims | | | | | | | | | | | | | | | (69.0 | ) | | | – | | | | – | | | | | | | | | | | | | | | | | | | | | | | | (35.0 | ) | | | (69.0 | ) | | | – | | | | | | | | | |
| Acquisition, integration and other | | | | | | | | | | | | | | | (68.5 | ) | | | (25.2 | ) | | | (6.1 | ) | | | | | | | | | |
| Global operations and corporate functions | | | | | | | | | | | | | | | (632.3 | ) | | | (480.4 | ) | | | (465.0 | ) | | | 1,798.3 | | | | 1,733.6 | | |
| Goodwill impairment | | | | | | | | | | | | | | | | (73.0 | ) | | | – | | | | – | | | | | | | | | |
| Acquisition, integration, | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| realignment and other | | | | | | | | | | | | | | | | (75.3 | ) | | | (68.5 | ) | | | (25.2 | ) | | | | | | | | |
| Net curtailment and settlement | | | | | | | | | | | | | | | | 32.1 | | | | – | | | | – | | | | | | | | | |
| Global operations and | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| corporate functions | | | | | | | | | | | | | | | | (606.6 | ) | | | (632.3 | ) | | | (480.4 | ) | | | 2,045.9 | | | | 1,798.3 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Operating profit | | | | | | | | | | | | | | $ | 1,090.0 | | | $ | 1,127.6 | | | $ | 1,165.2 | | | | | | | | | | | | | | | | | | | | | | | $ | 1,018.8 | | | $ | 1,090.0 | | | $ | 1,127.6 | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total assets | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 7,239.0 | | | $ | 6,633.7 | | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 7,785.5 | | | $ | 7,239.0 | |
| | | | | | | | | | | |
| | | | | | | | | |
U.S. sales were $2,237.5 million, $2,212.3 million $2,142.2 million and $1,962.5$2,142.2 million for the years ended December 31, 2009, 2008 2007 and 2006,2007, respectively. Sales towithin any other individual country outsidewere less than 10 percent of the U.S. were not significant.our consolidated sales. Sales are attributable to a country based upon the customer’s country of domicile.
Beginning in 2008,2009, we no longer include our HipsDental product category sales no longer include bone cement and accessory sales, which have been reclassified towithin our Orthopaedic Surgical Products and Other (“OSP and other”) productReconstructive products category. Amounts in 2007 and 2006Prior year amounts related to Dental product category sales of bone cement and accessory products have been reclassified to conform to 2008the current year presentation.
Net sales by product category are as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Reconstructive | | | | | | | | | | | | | | | | | | | | | | | | |
| Knees | | $ | 1,763.0 | | | $ | 1,634.6 | | | $ | 1,460.5 | | | $ | 1,760.6 | | | $ | 1,763.1 | | | $ | 1,634.6 | |
| Hips | | | 1,279.5 | | | | 1,221.4 | | | | 1,126.9 | | | | 1,228.5 | | | | 1,279.4 | | | | 1,221.4 | |
| Extremities | | | 121.0 | | | | 104.0 | | | | 77.6 | | | | 135.6 | | | | 121.0 | | | | 104.0 | |
| Dental | | | 227.5 | | | | 221.0 | | | | 179.0 | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | | 3,391.0 | | | | 3,181.0 | | | | 2,844.0 | | | | 3,124.7 | | | | 3,163.5 | | | | 2,960.0 | |
| Dental | | | | 204.7 | | | | 227.5 | | | | 221.0 | |
| Trauma | | | 221.4 | | | | 205.8 | | | | 194.7 | | | | 234.8 | | | | 222.3 | | | | 205.8 | |
| Spine | | | 230.6 | | | | 197.0 | | | | 177.4 | | | | 253.6 | | | | 229.7 | | | | 197.0 | |
| OSP and other | | | 278.1 | | | | 313.7 | | | | 279.3 | | | | 277.6 | | | | 278.1 | | | | 313.7 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | $ | 4,121.1 | | | $ | 3,897.5 | | | $ | 3,495.4 | | | $ | 4,095.4 | | | $ | 4,121.1 | | | $ | 3,897.5 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Long-lived tangible assets as of December 31, 20082009 and 20072008 are as follows (in millions):
| | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | | 2009 | | 2008 | |
| | | | | |
| |
| Americas | | $ | 918.3 | | | $ | 707.3 | | | $ | 851.0 | | | $ | 918.3 | |
| Europe | | | 272.5 | | | | 211.8 | | | | 285.0 | | | | 272.5 | |
| Asia Pacific | | | 73.3 | | | | 52.8 | | | | 85.7 | | | | 73.3 | |
| | | | | | | | | | | |
| | | | | | | | | |
| Total | | $ | 1,264.1 | | | $ | 971.9 | | | $ | 1,221.7 | | | $ | 1,264.1 | |
| | | | | | | | | | | |
| | | | | | | | | |
The Americas long-lived tangible assets are located primarily in the U.S. Approximately $232.7$232.9 million of Europe long-lived tangible assets as of December 31, 20082009 are located in Switzerland.
Capital expenditures by operatingreportable segment for the years ended December 31, 2009, 2008 2007 and 20062007 were as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Americas | | | | | | | | | | | | | | | | | | | | | | | | |
| Additions to other property, plant and equipment | | $ | 1.5 | | | $ | 0.7 | | | $ | 0.7 | | | $ | 0.6 | | | $ | 1.5 | | | $ | 0.7 | |
| Europe | | | | | | | | | | | | | | | | | | | | | | | | |
| Additions to instruments | | | 25.3 | | | | 25.4 | | | | 20.0 | | | | 17.0 | | | | 25.3 | | | | 25.4 | |
| Additions to other property, plant and equipment | | | 59.6 | | | | 24.6 | | | | 25.9 | | | | 28.8 | | | | 59.6 | | | | 24.6 | |
| Asia Pacific | | | | | | | | | | | | | | | | | | | | | | | | |
| Additions to instruments | | | 2.2 | | | | 1.2 | | | | 1.7 | | | | 5.3 | | | | 2.2 | | | | 1.2 | |
| Additions to other property, plant and equipment | | | 9.4 | | | | 2.4 | | | | 2.5 | | | | 5.1 | | | | 9.4 | | | | 2.4 | |
| Global operations and corporate functions | | | | | | | | | | | | | | | | | | | | | | | | |
| Additions to instruments | | | 210.4 | | | | 111.9 | | | | 104.5 | | | | 101.4 | | | | 210.4 | | | | 111.9 | |
| Additions to other property, plant and equipment | | | 179.5 | | | | 165.0 | | | | 113.0 | | | | 70.6 | | | | 179.5 | | | | 165.0 | |
For segment reporting purposes, deployed instruments are included in the measurement of operatingreportable segment assets while undeployed instruments at U.S. and Puerto Rico-based manufacturing operations and logistics are included in global operations and corporate functions. The majority of instruments are purchased by U.S. and Puerto Rico-based manufacturing operations and logistics and are deployed to the operatingreportable segments as needed for the business.
5961
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
Depreciation and amortization included in operatingreportable segment profit for the years ended December 31, 2009, 2008 2007 and 20062007 was as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2008 | | 2007 | | 2006 | | | 2009 | | 2008 | | 2007 | |
| | | | | |
| |
| Americas | | $ | 78.5 | | | $ | 66.9 | | | $ | 56.7 | | | $ | 86.4 | | | $ | 78.5 | | | $ | 66.9 | |
| Europe | | | 57.0 | | | | 60.7 | | | | 46.5 | | | | 64.8 | | | | 57.0 | | | | 60.7 | |
| Asia Pacific | | | 25.6 | | | | 22.7 | | | | 18.7 | | | | 26.7 | | | | 25.6 | | | | 22.7 | |
| Global operations and corporate functions | | | 114.0 | | | | 79.7 | | | | 75.5 | | | | 159.5 | | | | 114.0 | | | | 79.7 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Total | | $ | 275.1 | | | $ | 230.0 | | | $ | 197.4 | | |
| | | | | | | | | | | | $ | 337.4 | | | $ | 275.1 | | | $ | 230.0 | |
| | | | | | | | | | | | | | | | |
| | | | | | | | |
Future minimum rental commitments under non-cancelable operating leases in effect as of December 31, 20082009 were $38.2 million for 2009, $30.1$37.3 million for 2010, $26.7 million for 2011, $20.9 million for 2011, $15.9 million for 2012, $14.3$15.8 million for 2013, $10.8 million for 2014 and $29.9$23.1 million thereafter. Total rent expense for the years ended December 31, 2009, 2008 and 2007 and 2006 aggregated $43.5 million, $41.4 million $37.1 million and $31.1$37.1 million, respectively.
| | |
16.17. | | COMMITMENTS AND CONTINGENCIES |
Intellectual Property and Product Liability-Related Litigation
In July 2008, we temporarily suspended marketing and distribution of theDurom® Acetabular Component ((DuromDuromCup)in the U.S. to allow us to update product labeling to provide more detailed surgical technique instructions to surgeons and implement a surgical training programCup) in the U.S. Following our announcement, product liability lawsuits and other claims have been asserted against us, some of which we have settled. There are a number of claims still pending, and we expect additional claims willmay be submitted. We recorded a provision of $47.5$69.0 million in the third quarter of 2008, representing management’s estimate of theseDuromCup-related claims. WeIn the third quarter of 2009, based on claims information we received after we made our initial estimate, we increased thatour estimate of the number of claims we may receive and increased the provision by $21.5$35.0 million. The current reserve is $71.9 million inas of December 31, 2009. We expect to pay the fourth quartermajority of 2008.these claims within the next three years. The provision is limited to revisions within two years of an original surgery that occurred prior to July 2008. These parameters are consistent with our data which indicates that cup loosenings associated with surgical technique are most likely to occur within that time period. Any claims received outside of these defined parameters will be managed in the normal course and reflected in our standard product liability accruals.
On February 15, 2005, Howmedica Osteonics Corp. filed an action against us and an unrelated party in the United States District Court for the District of New Jersey alleging infringement of U.S. Patent Nos. 6,174,934; 6,372,814; 6,664,308; and 6,818,020. On June 13, 2007, the Court granted our motion for summary judgment on the invalidity of the asserted claims of U.S. Patent Nos. 6,174,934; 6,372,814; and 6,664,308 by ruling that all of the asserted claims are invalid for indefiniteness. On August 19, 2008, the Court granted our motion for summary judgment of non-infringement of certain claims of U.S. Patent No. 6,818,020, reducing the number of claims at issue in the suit to five. On April 9, 2009, in response to our earlier petition, the U.S. Patent and Trademark Office instituted re-examination proceedings against U.S. Patent No. 6,818,020. The U.S. Patent and Trademark Office rejected all previously issued claims of U.S. Patent No. 6,818,020 as being unpatentable in light of one or more prior art references. On September 30, 2009, the Court issued an order staying proceedings in the litigation pending the outcome of the re-examination process. Subsequent to that stay order, Howmedica filed a motion seeking to certify an appeal of the summary judgment ruling on the ’934, ’814 and ’308 patents. That motion was granted on January 13, 2010. We expect that the U.S. Court of Appeals for the Federal Circuit will hear the appeal of that ruling in 2010. We continue to believe that our defenses against infringement of the remaining claims are valid and meritorious, and we intend to continue to defend this lawsuit vigorously.
In addition to certain claims related to theDuromCup within the parameters discussed above, we are also subject to product liability and other claims and lawsuits arising in the ordinary course of business, for which we maintain insurance, subject to self-insured retention limits. We establish accruals for product liability and other claims in conjunction with outside counsel based on current information and historical settlement information for open claims, related legal fees and claims incurred but not reported. While it is not possible to predict with certainty the outcome of these cases, it is the opinion of management that, upon ultimate resolution, liabilities from these cases in excess of those recorded, if any, will not have a material adverse effect on our consolidated financial position, results of operations or cash flows.
Government Investigations
In March 2005, the U.S. Department of Justice through the U.S. Attorney’s Office in Newark, New Jersey commenced an investigation of usSeptember 2007, we and four other orthopaedic companies settled a U.S. government investigation pertaining to consulting contracts, professional serviceservices agreements and other agreements by which remuneration is provided to orthopaedic surgeons. On September 27, 2007, we reached a settlement with the government to resolve all claims related to this investigation. As part of the settlement, we entered into a settlement agreementCorporate Integrity Agreement (CIA) with the U.S. through the U.S. Department of Justice and the Office of Inspector General of the Department of Health and Human Services (the “OIG-HHS”)(OIG-HHS). In addition, we entered into a Deferred Prosecution Agreement (the “DPA”) with the U.S. Attorney’s Office for the District of New Jersey (the “U.S. Attorney”) and a Corporate Integrity Agreement (the “CIA”) with the OIG-HHS. We did not admit any wrongdoing, plead guilty to any criminal charges or pay any criminal fines as part of the settlement.
We settled all civil and administrative claims related to the federal investigation by making a settlement payment to the U.S. government of $169.5 million.
Under the terms of the DPA, the U.S. Attorney filed a criminal complaint in the U.S. District Court for the District of New Jersey charging us with conspiracy to commit violations of the Anti-Kickback Statute (42 U.S.C.§ 1320a-7b) during the years 2002 through 2006. The court deferred prosecution of the criminal complaint during the18-month term of the DPA. The U.S. Attorney will seek dismissal of the criminal complaint after the18-month period if we comply with the provisions of the DPA. The DPA provides for oversight by a federally-appointed monitor.
Under the CIA, which has a term of five years,expiring in 2012, we agreed, among other provisions, to continue the operation of our enhanced Corporate Compliance Program, designed to promote compliance with federal healthcare program
60
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
requirements, in accordance with the terms set forth in the CIA. We also agreed to retain an independent review organization (“IRO”) to perform annual reviews to assist us in assessing our compliance with the obligations set forth in the CIA to ensure that arrangements we enter into do not violate the Anti-Kickback Statute. Our obligation to retain an IRO is suspended during theStatute (42 U.S.C.18-month§ 1320a-7b). term of the DPA. A material breach of the DPA or the CIA may subject us to further criminal or civil actionand/or to exclusion by OIG-HHS from participation in all federal healthcare programs, which would have a material adverse effect on our financial position, results of operations and cash flows.
In November 2007, we received a civil investigative demand from the Massachusetts Attorney General’s office
62
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
seeking additional information regarding theour financial relationships we publicly disclosed pursuant to the DPA with a number of Massachusetts healthcare providers. We received a similar inquiry from the Oregon Attorney General’s office in October 2008. We are cooperating fully with the investigators with regard to these matters.
In September 2007, the Staff of the U.S. Securities and Exchange Commission (“SEC”)(SEC) informed us that it was conducting an informal investigation regarding potential violations of the Foreign Corrupt Practices Act (FCPA) in the sale of medical devices in a number of foreign countries by companies in the medical device industry. We understandIn November 2007, we received a letter from the U.S. Department of Justice (DOJ) requesting that at least four other medical device companies received similar letters.any information provided to the SEC also be provided to the DOJ on a voluntary basis. We are continuing to provide information and cooperate fully cooperating with the SEC and the U.S. Department of JusticeDOJ with regard to this informalpending investigation. In addition, as part of our global compliance program, we have been conducting our own proactive reviews regarding FCPA compliance in jurisdictions that have not been involved in the pending investigation. These reviews have yielded information indicating that certain third-party, independent distributors of our products in two South American countries made certain payments that may have potential FCPA implications. In the course of continuing dialogues with the agencies, we voluntarily disclosed information relating to these matters to the SEC and the DOJ, and the reviews are ongoing. We cannot currently predict the outcome of the investigation or the impact of our voluntary disclosures to the authorities.
Derivative Actions andPutative Class Actions
On April 24, 2008, a complaint was filed in the U.S. District Court for the Southern District of New York, Thorpe v. Zimmer, Inc., et al., naming us and two of our subsidiaries as defendants. The complaint relates to a putative class action on behalf of certain residents of New York who had hip or knee implant surgery involving Zimmer products during an unspecified period. The complaint alleges that our relationships with orthopaedic surgeons and others violated the New York deceptive practices statute and unjustly enriched us. The plaintiff requests actual damages or $50.00, whichever is greater, on behalf of each class member, a permanent injunction from our engaging in allegedly improper practices in the future and restitution in an unspecified amount. We believe this lawsuit is without merit, and we intend to defend it vigorously.
On August 5, 2008, a complaint was filed in the U.S. District Court for the Southern District of Indiana, Plumbers and Pipefitters Local Union 719 Pension Fund v. Zimmer Holdings, Inc., et al., naming us and two of our executive officers as defendants. The complaint relatesrelated to a putative class action on behalf of persons who purchased our common stock between January 29, 2008 and July 22, 2008. The complaint allegesalleged that we and two of our executive officers engaged in violations ofthe defendants violated the federal securities lawslaw by allegedly failing to disclose developments relating to our OSPorthopaedic surgical products manufacturing operations in Dover, Ohio and problems relating to theDuromCup. The plaintiff seekssought unspecified damages and interest, attorneys’ fees, costs and other relief. On December 24, 2008, the lead plaintiff filed a consolidated complaint that allegesalleged the same claims and relatesrelated to the same time period. The defendants filed a motion to dismiss the consolidated complaint on February 23, 2009. TheOn December 1, 2009, the Court granted defendants’ motion to dismiss, without prejudice. On January 15, 2010, the plaintiff filed a motion for leave to amend the consolidated complaint. That motion is pending with the court.pending. We believe this lawsuit is without merit, and we and the individual defendants intend to defend it vigorously.
On August 15, 2008, a shareholder derivative action, Hays v. Dvorak et al., was filed in the U.S. District Court for the Southern District of Indiana. The plaintiff seeks to maintain the action purportedly on our behalf against certain of our current and former directors and twonon-director executive officers. The plaintiff alleges, among other things, breaches of fiduciary duties, abuse of control, unjust enrichment and gross mismanagement by the named defendants based on substantially the same factual allegations as the putative federal securities class action referenced above brought by the Plumbers and Pipefitters Local Union 719 Pension Fund. The plaintiff does not seek damages from us, but instead requests damages of an unspecified amount on our behalf. The plaintiff also seeks equitable relief to remedy the individual defendants’ alleged misconduct, attorneys’ fees, costs and other relief. The court has entered a scheduling order that permits the plaintiff to file an amended complaint on or before March 11, 2009. Under that same court order, the defendants are not required to respond to any complaint until May 11, 2009.
On November 20, 2008, a complaint was filed in the U.S. District Court for the Northern District of Indiana, Dewald v. Zimmer Holdings, Inc., et al., naming us and certain of our current and former directors and employees as defendants. The complaint relates to a putative class action on behalf of all persons who were participants in or beneficiaries of our U.S. or Puerto Rico Savings and Investment Programs (“plans”)(plans) between October 5, 2007 and the date of filing and whose accounts included investments in our common stock. The complaint alleges, among other things, that the defendants breached their fiduciary duties in violation of the Employee Retirement Income Security Act of 1974, as amended, by continuing to offer Zimmer stock as an investment option in the plans when the stock purportedly was no longer a prudent investment and that defendants failed to provide plan participants with complete and accurate information sufficient to advise them of the risks of investing their retirement savings in Zimmer stock. The plaintiff seeks an unspecified monetary payment to the plans, injunctive and equitable relief, attorneys’ fees, costs and other relief. On January 23, 2009, the plaintiff filed an amended complaint that alleges the same claims and clarifies that the class period is October 5, 2007 through September 2, 2008. The
61
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Notes defendants filed a motion to Consolidated Financial Statements(Continued)
defendants are not required to respond todismiss the amended complaint untilon March 23, 2009. The motion to dismiss is pending with the court. On June 12, 2009, the U.S. Judicial Panel on Multidistrict Litigation entered an order transferring the Dewald case to the U.S. District Court for the Southern District of Indiana for coordinated or consolidated pretrial proceedings with the Plumbers & Pipefitters Local Union 719 Pension Fund case referenced above. We believe this lawsuit is without merit, and we and the individual defendants intend to defend it vigorously.
63
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Notes to Consolidated Financial Statements(Continued)
| | |
17.18. | | QUARTERLY FINANCIAL INFORMATION (UNAUDITED) |
(in millions, except per share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2008 Quarter Ended | | 2007 Quarter Ended | | | 2009 Quarter Ended | | 2008 Quarter Ended | |
| | | Mar | | Jun | | Sep | | Dec | | Mar | | Jun | | Sep | | Dec | | | Mar | | Jun | | Sep | | Dec | | Mar | | Jun | | Sep | | Dec | |
| | | | | |
| |
| Net sales | | $ | 1,059.2 | | | $ | 1,079.5 | | | $ | 952.2 | | | $ | 1,030.2 | | | $ | 950.2 | | | $ | 970.6 | | | $ | 903.2 | | | $ | 1,073.5 | | | $ | 992.6 | | | $ | 1,019.9 | | | $ | 975.6 | | | $ | 1,107.3 | | | $ | 1,059.2 | | | $ | 1,079.5 | | | $ | 952.2 | | | $ | 1,030.2 | |
| Gross profit | | | 804.5 | | | | 817.2 | | | | 715.0 | | | | 787.1 | | | | 743.8 | | | | 754.2 | | | | 704.0 | | | | 819.6 | | | | 762.3 | | | | 783.1 | | | | 726.3 | | | | 832.9 | | | | 804.5 | | | | 817.2 | | | | 715.0 | | | | 787.1 | |
| Net earnings | | | 239.3 | | | | 227.1 | | | | 214.7 | | | | 167.5 | | | | 233.4 | | | | 231.5 | | | | 44.5 | | | | 263.8 | | |
| Net earnings per common share | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net earnings of Zimmer Holdings, Inc. | | | | 202.2 | | | | 210.1 | | | | 149.9 | | | | 155.2 | | | | 239.3 | | | | 227.1 | | | | 214.7 | | | | 167.5 | |
| Earnings per common share | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Basic | | | 1.03 | | | | 0.99 | | | | 0.96 | | | | 0.75 | | | | 0.99 | | | | 0.98 | | | | 0.19 | | | | 1.13 | | | | 0.91 | | | | 0.98 | | | | 0.70 | | | | 0.74 | | | | 1.03 | | | | 0.99 | | | | 0.96 | | | | 0.75 | |
| Diluted | | | 1.02 | | | | 0.99 | | | | 0.95 | | | | 0.75 | | | | 0.98 | | | | 0.97 | | | | 0.19 | | | | 1.12 | | | | 0.91 | | | | 0.98 | | | | 0.70 | | | | 0.74 | | | | 1.02 | | | | 0.99 | | | | 0.95 | | | | 0.75 | |
6264
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 9. | | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure |
None
| | |
| ITEM 9A. | | Controls and Procedures |
We have established disclosure controls and procedures and internal controls over financial reporting to provide reasonable assurance that material information relating to us, including our consolidated subsidiaries, is made known on a timely basis to management and the Board of Directors. However, no control system, no matter how well designed and operated, can provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined inRule 13a-15(e) of the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective.
There was no change in our internal control over financial reporting (as defined inRule 13a-15(f) of the Securities Exchange Act of 1934) that occurred during the quarter ended December 31, 20082009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Management’s report on internal control over financial reporting appears in this report at the conclusion of Part II, Item 7A.
| | |
| ITEM 9B. | | Other Information |
During the fourth quarter of 2008,2009, the Audit Committee of the Board of Directors was not asked to and did not approve the engagement of PricewaterhouseCoopers LLP, our independent registered public accounting firm, to perform any non-audit services. This disclosure is made pursuant to Section 10A(i)(2) of the Securities Exchange Act of 1934, as added by Section 202 of the Sarbanes-Oxley Act of 2002.
We submitted the Annual CEO Certification for 2008 required by the New York Stock Exchange to the exchange on June 3, 2008.
6365
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 10. | | Directors, Executive Officers and Corporate Governance |
The information required by this Item concerning our directors and executive officers is incorporated herein by reference from our definitive Proxy Statement for our 20092010 Annual Meeting of Stockholders which will be filed with the Commission pursuant to Regulation 14A within 120 days after the end of our most recent fiscal year and the information included under the caption “Executive Officers” in Part I of this report.
| | |
| ITEM 11. | | Executive Compensation |
The information required by this Item concerning remuneration of our officers and directors and information concerning material transactions involving such officers and directors is incorporated herein by reference from our definitive Proxy Statement for our 20092010 Annual Meeting of Stockholders which will be filed with the Commission pursuant to Regulation 14A within 120 days after the end of our most recent fiscal year.
| | |
| ITEM 12. | | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
The information required by this Item concerning the stock ownership of management and five percent beneficial owners and related stockholder matters, including equity compensation plan information, is incorporated herein by reference from our definitive Proxy Statement for our 20092010 Annual Meeting of Stockholders which will be filed with the Commission pursuant to Regulation 14A within 120 days after the end of our most recent fiscal year.
| | |
| ITEM 13. | | Certain Relationships and Related Transactions and Director Independence |
The information required by this Item concerning certain relationships and related transactions and director independence is incorporated herein by reference from our definitive Proxy Statement for our 20092010 Annual Meeting of Stockholders which will be filed with the Commission pursuant to Regulation 14A within 120 days after the end of our most recent fiscal year.
| | |
| ITEM 14. | | Principal Accounting Fees and Services |
The information required by this Item concerning principal accounting fees and services is incorporated herein by reference from our definitive Proxy Statement for our 20092010 Annual Meeting of Stockholders which will be filed with the Commission pursuant to Regulation 14A within 120 days after the end of our most recent fiscal year.
6466
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
| | |
| ITEM 15. | | Exhibits, Financial Statement Schedules |
(a) 1. Financial Statements
The following consolidated financial statements of Zimmer Holdings, Inc. and its subsidiaries are set forth in Part II, Item 8.
Report of Independent Registered Public Accounting Firm
Consolidated Statements of Earnings for the Years Ended December 31, 2009, 2008 2007 and 20062007
Consolidated Balance Sheets as of December 31, 20082009 and 20072008
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2009, 2008 2007 and 20062007
Consolidated Statements of Cash Flows for the Years Ended December 31, 2009, 2008 2007 and 20062007
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2009, 2008 2007 and 20062007
Notes to Consolidated Financial Statements
2. Financial Statement Schedules
Schedule II. Valuation and Qualifying Accounts
Other financial statement schedules are omitted because they are not applicable or the required information is shown in the financial statements or the notes thereto.
3. Exhibits
A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which immediately precedes such exhibits and is incorporated herein by reference.
6567
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Zimmer Holdings, Inc.
David C. Dvorak
President and Chief Executive Officer
Dated: February 27, 200925, 2010
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | | |
| Signature | | Title | | Date |
| |
| |
| | | | | |
/s/ David C. Dvorak
David C. Dvorak | | President, Chief Executive Officer and Director
(Principal Executive Officer) | | February 27, 200925, 2010 |
| | | | | |
/s/ James T. Crines
James T. Crines | | Executive Vice President, Finance
and Chief Financial Officer
(Principal Financial Officer) | | February 27, 200925, 2010 |
| | | | | |
/s/ Derek M. Davis
Derek M. Davis | | Vice President, Finance, and Corporate Controller
and Chief Accounting Officer
(Principal Accounting Officer) | | February 27, 200925, 2010 |
| | | | | |
/s/ Betsy J. Bernard
Betsy J. Bernard | | Director | | February 27, 200925, 2010 |
| | | | | |
/s/ Marc N. Casper
Marc N. Casper | | Director | | February 27, 200925, 2010 |
| | | | | |
/s/ Larry C. Glasscock
Larry C. Glasscock | | Director | | February 27, 200925, 2010 |
| | | | | |
/s/ Robert A. Hagemann
Robert A. Hagemann | | Director | | February 27, 200925, 2010 |
| | | | | |
/s/ Arthur J. Higgins
Arthur J. Higgins | | Director | | February 27, 200925, 2010 |
| | | | | |
/s/ John L. McGoldrick
John L. McGoldrick | | Director | | February 27, 200925, 2010 |
| | | | | |
/s/ Cecil B. Pickett, Ph.D.
Cecil B. Pickett, Ph.D. | | Director | | February 27, 200925, 2010 |
| | | | | |
/s/ Augustus A. White, III, M.D., Ph.D.
Augustus A. White, III, M.D., Ph.D. | | Director | | February 27, 200925, 2010 |
6668
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Index to Exhibits
| | | | | |
| Exhibit No | | Description |
| |
| | 3 | .1 | | Restated Certificate of Incorporation of Zimmer Holdings, Inc. dated May 13, 2008 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed August 5, 2008) |
| | 3 | .2 | | Restated By-Laws of Zimmer Holdings, Inc. effective May 6, 2008 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed May 9, 2008) |
| | 4 | .1 | | Specimen Common Stock certificate (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-8 filed January 20, 2006) |
| | 4 | .2 | | Indenture dated as of November 17, 2009 between Zimmer Holdings, Inc. and Wells Fargo Bank, National Association, as Trustee (incorporated by reference to the form filed as Exhibit 4.8 to the Registrant’s Registration Statement on Form S-3 filed November 12, 2009) |
| | 4 | .3 | | First Supplemental Indenture to the Indenture dated as of November 17, 2009 between Zimmer Holdings, Inc. and Wells Fargo Bank, National Association, as Trustee (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 17, 2009) |
| | 4 | .4 | | Form of 4.625% Note due 2019 (incorporated by reference to Exhibit 4.3 above) |
| | 4 | .5 | | Form of 5.750% Note due 2039 (incorporated by reference to Exhibit 4.3 above) |
| | 10 | .1* | | Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Appendix B to the Registrant’s definitive Proxy Statement on Schedule 14A filed March 24, 2003) |
| | 10 | .2* | | First Amendment to the Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed December 15, 2005) |
| | 10 | .3* | | Zimmer Holdings, Inc. 2006 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
| | 10 | .4* | | Zimmer Holdings, Inc. Executive Performance Incentive Plan, as amended (incorporated by reference to Appendix B to the Registrant’s definitive Proxy Statement on Schedule 14A filed March 20, 2008) |
| | 10 | .5* | | Restated Zimmer, Inc. Long-Term Disability Income Plan for Highly Compensated Employees (incorporated by reference to Exhibit 10.9 to the Registrant’s Annual Report on Form 10-K filed February 28, 2007) |
| | 10 | .6* | | Change in Control Severance Agreement with David C. Dvorak (incorporated by reference to Exhibit 10.10 to the Registrant’s Annual Report on Form 10-K filed February 27, 2009) |
| | 10 | .7* | | Form of Change in Control Severance Agreement with Bruno A. Melzi (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q filed May 8, 2002) |
| | 10 | .8* | | Form of Change in Control Severance Agreement with James T. Crines and Cheryl R. Blanchard (incorporated by reference to Exhibit 10.12 to the Registrant’s Annual Report on Form 10-K filed February 27, 2009) |
| | 10 | .9* | | Form of Change in Control Severance Agreement with Jeffery A. McCaulley and Chad F. Phipps (incorporated by reference to Exhibit 10.13 to the Registrant’s Annual Report on Form 10-K filed February 27, 2009) |
| | 10 | .10* | | Change in Control Severance Agreement with Derek M. Davis (incorporated by reference to Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K filed February 27, 2009) |
| | 10 | .11* | | Change in Control Severance Agreement with Stephen Hong Liang, Ooi (incorporated by reference to Exhibit 10.21 to the Registrant’s Annual Report on Form 10-K filed March 12, 2003) |
| | 10 | .12* | | Restated Benefit Equalization Plan of Zimmer Holdings, Inc. and Its Subsidiary or Affiliated Corporations Participating in the Zimmer Holdings, Inc. Savings and Investment Program (incorporated by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K filed February 27, 2009) |
| | 10 | .13* | | Restated Benefit Equalization Plan of Zimmer Holdings, Inc. and Its Subsidiary or Affiliated Corporations Participating in the Zimmer Holdings, Inc. Retirement Income Plan or the Zimmer Puerto Rico Retirement Income Plan (incorporated by reference to Exhibit 10.17 to the Registrant’s Annual Report on Form 10-K filed February 27, 2009) |
| | 10 | .14* | | Form of Confidentiality, Non-Competition and Non-Solicitation Employment Agreement with U.S.-Based Executive Officers (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed August 7, 2009) |
| | 10 | .15* | | Non-Disclosure, Non-Competition and Non-Solicitation Employment Agreement with Stephen Hong Liang, Ooi (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed March 27, 2006) |
| | 10 | .16* | | Confidentiality, Non-Competition and Non-Solicitation Agreement with Bruno A. Melzi (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed March 27, 2006) |
69
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Index to Exhibits(Continued)
| | | | | |
| Exhibit No | | Description |
| |
| | 10 | .17* | | Form of Nonqualified Stock Option Award Letter under the Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed January 11, 2006) |
| | 10 | .18* | | Form of Nonqualified Performance-Conditioned Stock Option Grant Award Letter under the Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed January 21, 2005) |
| | 10 | .19* | | Zimmer Holdings, Inc. Stock Plan for Non-Employee Directors, as amended (incorporated by reference to Appendix C to the Registrant’s Definitive Proxy Statement filed on March 20, 2009) |
| | 10 | .20* | | Form of Nonqualified Stock Option Award Letter under the Zimmer Holdings, Inc. Stock Plan for Non-Employee Directors (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed April 5, 2005) |
| | 10 | .21* | | Form of Restricted Stock Unit Award Letter under the Zimmer Holdings, Inc. Stock Plan for Non-Employee Directors (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed February 21, 2006) |
| | 10 | .22* | | Form of Nonqualified Stock Option Award Letter under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
| | 10 | .23* | | Form of Nonqualified Stock Option Award Letter for Non-U.S. Employees under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
| | 10 | .24* | | Form of Restricted Stock Award Letter under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (five-year vesting) (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
| | 10 | .25* | | Form of Performance-Based Restricted Stock Unit Award Letter under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed February 17, 2009) |
| | 10 | .26* | | Restated Zimmer Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors (incorporated by reference to Appendix D to the Registrant’s Definitive Proxy Statement filed on March 20, 2009) |
| | 10 | .27* | | Zimmer Holdings, Inc. 2009 Stock Incentive Plan (incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement filed on March 20, 2009) |
| | 10 | .28* | | Form of Nonqualified Stock Option Award Letter under the Zimmer Holdings, Inc. 2009 Stock Incentive Plan |
| | 10 | .29* | | Form of Nonqualified Stock Option Award Letter for Non-U.S. Employees under the Zimmer Holdings, Inc. 2009 Stock Incentive Plan |
| | 10 | .30* | | Form of Performance-Based Restricted Stock Unit Award Letter under the Zimmer Holdings, Inc. 2009 Stock Incentive Plan |
| | 10 | .31* | | Form of Performance-Based Restricted Stock Unit Award Letter for Non-U.S. Employees under the Zimmer Holdings, Inc. 2009 Stock Incentive Plan |
| | 10 | .32* | | Form of Restricted Stock Unit Award Letter (five-year vesting) under the Zimmer Holdings, Inc. 2009 Stock Incentive Plan |
| | 10 | .33* | | Summary Compensation Sheet |
| | 10 | .34 | | $1,350,000,000 Amended and Restated Credit Agreement dated as of November 30, 2007 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed December 6, 2007) |
| | 10 | .35 | | Corporate Integrity Agreement dated September 27, 2007, among Zimmer Holdings, Inc., Zimmer, Inc. and the Office of Inspector General of the Department of Health and Human Services (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed November 9, 2007) |
| | 10 | .36 | | Form of Indemnification Agreement with Non-Employee Directors and Officers (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed July 31, 2008) |
| | 21 | | | List of Subsidiaries of Zimmer Holdings, Inc. |
| | 23 | | | Consent of PricewaterhouseCoopers LLP |
| | 31 | .1 | | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | 31 | .2 | | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
70
| |
| ZIMMER HOLDINGS, INC. | 2009FORM 10-K ANNUAL REPORT |
Index to Exhibits(Continued)
| | | | |
| Exhibit No | | Description |
| |
2.1 | 32 | | Stock Purchase Agreement dated as of September 4, 2008 (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed September 4, 2008) |
3.1 | | Restated Certificate of Incorporation of Zimmer Holdings, Inc. dated May 13, 2008 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed August 5, 2008) |
3.2 | | Restated By-Laws of Zimmer Holdings, Inc. effective May 6, 2008 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed May 9, 2008) |
4.1 | | Specimen Common Stock certificate (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-8 filed January 20, 2006) |
10.1* | | Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Appendix B to the Registrant’s definitive Proxy Statement on Schedule 14A filed March 24, 2003) |
10.2* | | First Amendment to the Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed December 15, 2005) |
10.3* | | Zimmer Holdings, Inc. 2006 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
10.4* | | Zimmer Holdings, Inc. Executive Performance Incentive Plan, as amended (incorporated by reference to Appendix B to the Registrant’s definitive Proxy Statement on Schedule 14A filed March 20, 2008) |
10.5* | | Zimmer Holdings, Inc. Stock Plan for Non-Employee Directors, effective August 6, 2001 (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed August 6, 2001) |
10.6* | | First Amendment to the Zimmer Holdings, Inc. Stock Plan for Non-Employee Directors (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed December 15, 2005) |
10.7* | | Restated Zimmer Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, effective January 1, 2005 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed December 15, 2005) |
10.8* | | First Amendment to the Restated Zimmer Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors |
10.9* | | Restated Zimmer, Inc. Long-Term Disability Income Plan for Highly Compensated Employees (incorporated by reference to Exhibit 10.9 to the Registrant’s Annual Report on form 10-K filed February 28, 2007) |
10.10* | | Change in Control Severance Agreement with David C. Dvorak |
10.11* | | Form of Change in Control Severance Agreement with Bruno A. Melzi (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q filed May 8, 2002) |
10.12* | | Form of Change in Control Severance Agreement with James T. Crines and Cheryl R. Blanchard |
10.13* | | Form of Change in Control Severance Agreement with Jeffery A. McCaulley, Mark C. Throdahl and Chad F. Phipps |
10.14* | | Change in Control Severance Agreement with Derek M. Davis |
10.15* | | Change in Control Severance Agreement with Stephen Hong Liang, Ooi (incorporated by reference to Exhibit 10.21 to the Registrant’s Annual Report on Form 10-K filed March 12, 2003) |
10.16* | | Restated Benefit Equalization Plan of Zimmer Holdings, Inc. and Its Subsidiary or Affiliated Corporations Participating in the Zimmer Holdings, Inc. Savings and Investment Program |
10.17* | | Restated Benefit Equalization Plan of Zimmer Holdings, Inc. and Its Subsidiary or Affiliated Corporations Participating in the Zimmer Holdings, Inc. Retirement Income Plan or the Zimmer Puerto Rico Retirement Income Plan |
10.18* | | Form of Non-Disclosure, Non-Competition and Non-Solicitation Employment Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed March 27, 2006) |
10.19* | | Non-Disclosure, Non-Competition and Non-Solicitation Employment Agreement with Stephen Hong Liang, Ooi (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed March 27, 2006) |
10.20* | | Confidentiality, Non-Competition and Non-Solicitation Agreement with Bruno A. Melzi (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed March 27, 2006) |
10.21* | | Form of Nonqualified Stock Option Award Letter under the Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed January 11, 2006) |
10.22* | | Form of Restricted Stock Award Letter under the Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed January 12, 2005) |
10.23* | | Form of Nonqualified Performance-Conditioned Stock Option Grant Award Letter under the Zimmer Holdings, Inc. 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed January 21, 2005) |
67
| |
ZIMMER HOLDINGS, INC. | 2008FORM 10-K ANNUAL REPORT |
Index to Exhibits(Continued)
| | |
Exhibit No | | Description |
|
10.24* | | Form of Nonqualified Stock Option Award Letter under the Zimmer Holdings, Inc. Stock Plan for Non-Employee Directors (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed April 5, 2005) |
10.25* | | Form of Restricted Stock Unit Award Letter under the Zimmer Holdings, Inc. Stock Plan for Non-Employee Directors (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed February 21, 2006) |
10.26* | | Form of Nonqualified Stock Option Award Letter under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
10.27* | | Form of Nonqualified Stock Option Award Letter for Non-U.S. Employees under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
10.28* | | Form of Restricted Stock Award Letter under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (five-year vesting) (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
10.29* | | Form of Restricted Stock Unit Award Letter for Non-U.S. Employees under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (five-year vesting) (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed December 13, 2006) |
10.30* | | Form of Restricted Stock Unit Award Letter under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (two-year vesting) (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed December 11, 2007) |
10.31* | | Form of Restricted Stock Unit Award Letter for Non-US Employees under the Zimmer Holdings, Inc. 2006 Stock Incentive Plan (two-year vesting) (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed December 11, 2007) |
10.32* | | Summary Compensation Sheet |
10.33 | | $1,350,000,000 Amended and Restated Credit Agreement dated as of November 30, 2007 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed December 6, 2007) |
10.34 | | Settlement Agreement dated September 27, 2007, among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services, and Zimmer Holdings, Inc. on behalf of its wholly owned subsidiary Zimmer, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed November 9, 2007) |
10.35 | | Corporate Integrity Agreement dated September 27, 2007, among Zimmer Holdings, Inc., Zimmer, Inc. and the Office of Inspector General of the Department of Health and Human Services (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed November 9, 2007) |
10.36 | | Deferred Prosecution Agreement dated September 27, 2007, between Zimmer, Inc. and the United States Attorney’s Office for the District of New Jersey (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q filed November 9, 2007) |
10.37 | | Zimmer, Inc. Monitor Agreement and Agreement Regarding Fees and Reimbursements, dated October 25, 2007 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed October 31, 2007) |
10.38 | | Form of Indemnification Agreement with Non-Employee Directors and Officers (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed July 31, 2008) |
21 | | List of Subsidiaries of Zimmer Holdings, Inc. |
23 | | Consent of PricewaterhouseCoopers LLP |
31.1 | | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 | | Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 of the Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32 | | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101 | | | The following materials from Zimmer Holdings, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2009, formatted in XBRL (Extensible Business Reporting Language): (1) the Consolidated Statements of Earnings, (2) the Consolidated Balance Sheets, (3) the Consolidated Statements of Stockholders’ Equity, (4) the Consolidated Statements of Cash Flows, (5) the Consolidated Statements of Comprehensive Income and (6) Notes to Consolidated Financial Statements, tagged as blocks of text. |
| |
| * | indicates management contracts or compensatory plans or arrangements |
6871
| |
| ZIMMER HOLDINGS, INC. | 20082009FORM 10-K ANNUAL REPORT |
Schedule of valuation and qualifying accounts disclosure
| |
| Valuation and Qualifying Accounts | Schedule II |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | (In millions) | | | (In millions) | |
| | | | | |
| | | | | Additions
| | | | | | | | | | | | | Additions
| | | | | | | | | |
| | | Balance at
| | Charged
| | | | Effects of
| | Acquired
| | Balance at
| | | Balance at
| | Charged
| | | | Effects of
| | Acquired
| | Balance at
| |
| | | Beginning
| | (Credited)
| | Deductions
| | Foreign
| | Abbott Spine
| | End of
| | | Beginning
| | (Credited)
| | Deductions
| | Foreign
| | Abbott Spine
| | End of
| |
| Description | | of Period | | to Expense | | to Reserve | | Currency | | Allowances | | Period | | | of Period | | to Expense | | to Reserve | | Currency | | Allowances | | Period | |
| | | | | |
| Doubtful Accounts: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Year Ended December 31, 2006 | | $ | 23.3 | | | $ | (3.2 | ) | | $ | (1.0 | ) | | $ | 1.3 | | | $ | – | | | $ | 20.4 | | |
| Year Ended December 31, 2007 | | | 20.4 | | | | 1.4 | | | | (1.2 | ) | | | 1.1 | | | | – | | | | 21.7 | | | $ | 20.4 | | | $ | 1.4 | | | $ | (1.2 | ) | | $ | 1.1 | | | $ | – | | | $ | 21.7 | |
| Year Ended December 31, 2008 | | | 21.7 | | | | (0.5 | ) | | | (1.9 | ) | | | (1.2 | ) | | | 1.9 | | | | 20.0 | | | | 21.7 | | | | (0.5 | ) | | | (1.9 | ) | | | (1.2 | ) | | | 1.9 | | | | 20.0 | |
| Year Ended December 31, 2009 | | | | 20.0 | | | | 0.1 | | | | (1.8 | ) | | | 0.5 | | | | – | | | | 18.8 | |
| | | |
| Excess and Obsolete Inventory: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Year Ended December 31, 2006 | | $ | 121.0 | | | $ | 32.6 | | | $ | (26.0 | ) | | $ | 1.9 | | | $ | – | | | $ | 129.5 | | |
| Year Ended December 31, 2007 | | | 129.5 | | | | 38.6 | | | | (26.9 | ) | | | 2.5 | | | | – | | | | 143.7 | | | $ | 129.5 | | | $ | 38.6 | | | $ | (26.9 | ) | | $ | 2.5 | | | $ | – | | | $ | 143.7 | |
| Year Ended December 31, 2008 | | | 143.7 | | | | 66.5 | | | | (23.1 | ) | | | (2.6 | ) | | | 15.1 | | | | 199.6 | | | | 143.7 | | | | 66.5 | | | | (23.1 | ) | | | (2.6 | ) | | | 15.1 | | | | 199.6 | |
| Year Ended December 31, 2009 | | | | 199.6 | | | | 81.7 | | | | (33.5 | ) | | | 7.3 | | | | – | | | | 255.1 | |
| | | |
| Excess and Obsolete Instruments: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | �� | | | | | | | | |
| Year Ended December 31, 2006 | | $ | 37.7 | | | $ | 8.3 | | | $ | (5.4 | ) | | $ | 0.1 | | | $ | – | | | $ | 40.7 | | |
| Year Ended December 31, 2007 | | | 40.7 | | | | 3.1 | | | | (12.5 | ) | | | 0.4 | | | | – | | | | 31.7 | | | $ | 40.7 | | | $ | 3.1 | | | $ | (12.5 | ) | | $ | 0.4 | | | $ | – | | | $ | 31.7 | |
| Year Ended December 31, 2008 | | | 31.7 | | | | 5.6 | | | | (2.9 | ) | | | 0.3 | | | | 2.4 | | | | 37.1 | | | | 31.7 | | | | 5.6 | | | | (2.9 | ) | | | 0.3 | | | | 2.4 | | | | 37.1 | |
| Year Ended December 31, 2009 | | | | 37.1 | | | | 22.7 | | | | (6.5 | ) | | | 0.5 | | | | – | | | | 53.8 | |
6972
